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ABSTRACT
 
Genetic auto-inflammatory inflammatory skin disorders (GAISDs) are a group of inherited disorders 
which are characterized by seemingly unprovoked recurrent episodes of fever and severe localised 
inflammation. GAISDs are associated with abnormal activation of the innate immune system, leading 
to clinical inflammation and high levels of acute-phase reactants. The most common disorder is 
Familial Mediterranean Fever (FMF), followed by Tumor Necrosis Factor Receptor-Associated 
Periodic Syndrome (TRAPS). TRAPS episodes generally last longer than FMF and FMF patients 
tend to respond well with colchicine while TRAPS management seems to be challenging. Hence this 
work is directed towards improving TRAPS diseases management. A definitive treatment for TRAPS 
has yet to be identified, and current corticosteroid treatment is mainly limited by the long-term side-
effects due to high systemic drug exposure, and the poor availability of drugs at the site of action.  
 
A number of measures were taken in order to overcome the limitations of corticosteroids.Herein a 
novel stimuli responsive nanocolloidal gel system was developed. A nanoliposomal gel was the 
stimuli responsive gel system of choice due to its advantages of skin penetration enhancement in 
transdermal drug delivery system. In this research, a phospholipid based system with Eudragit® 
E100 (EuE100) chemically modified into EuE100-cystamine derivative for dual pH/redox responsive 
delivery of [Copper-glycylglycine-prednisolone succinate] ([Cu(glygly)(PS)]) was developed. The 
rationale of using [Cu(glygly)(PS)] complex instead of the pure PS corticosteroid was supported by 
comparing the biological activities of these two compounds. Results indicated a high 
inflammatory/oxidant inhibitory activity of [Cu(glygly)(PS)] in comparison to the free PS drug. The 
[Cu(glygly)(PS)] complex exhibited a significant free radical-scavenging activity (60.1±1.2%) and 
lipoxygenase (LOX-5) inhibitory activity (36.6±1.3%) in comparison to PS which gave activity of  
4.4±1.4% and inhibition of 6.1±2.6% respectively. The [Cu(glygly)(PS)] loaded NLs showed a low 
level of [Cu(glygly)(PS)] release of 22.9±5.4% in 6h at pH 7.4, in comparison to a significant 
accelerated release at pH 5 in a reducing environment of 75.9±3.7%in 6h. Thereafter optimized 
[Cu(glygly)(PS)]-loaded NLs were dispersed in hydroxypropyl methylcellulose (HPMC)/Polyvinyl 
alcohol(PVA) gel resulting in a [Cu(glygly)(PS)]-loaded nanoliposomal gel termed asdermal sludge.A 
dermal sludge is defined as a viscous gel suspended with solid particles ([Cu(glygly)(PS)]-loaded 
nanoliposomes). The sludge was characterized using ex vivo permeation, in vitro release, 
cytotoxicity and in vivo studies, and compared to the conventional PS formulations. The results 
indicated that the novel dual redox/pH responsive nanoliposomal dermal sludge holds great potential 
for targeted bioactive delivery in TRAPS through the transdermal route, hence improving the 
therapeutic outcome.  
. 
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CHAPTER 1 
BACKGROUND ON GENETIC AUTO-INFLAMMATORY SKIN DISORDERS – THE 
POTENTIAL BENEFITS OF THE NOVEL TARGETED DERMAL SLUDGE
 
 
1.1. Introduction 
Genetic auto-inflammatory inflammatory skin disorders (GAISDs) are a group of inherited 
disorders which are characterized by seemingly unprovoked recurrent episodes of fever and 
severe localised inflammation (McDermott et al., 1999; Kastner and O'Shea, 2001; Meiorin et 
al., 2013; Vitaleet al., 2013). Most GAISDs are monogenic diseases caused by mutatedprotein-
coding genes and these genes are critical for regulating inflammation. These disorders include 
familial Mediterranean fever (FMF), hyper immunoglobulin D syndrome with periodic fever 
(HIDS), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), cryopyrin-
associated periodic syndrome (CAPS) familial cold autoinflammatory syndrome (FCAS), 
pyogenic arthritis, pyoderma gangrenosum and acne (PAPA), Muckle–Wells syndrome (MWS), 
mevalonate kinase deficiency/hyperimmunoglobulin D syndrome(MKD/HIDS), and chronic 
infantile neurological cutaneous articular syndrome (CINCA) (Kanazawa and Furukawa, 2007; 
Dainichi et al., 2014; Ozen and Bilginer, 2014). 
 
In general, all these GAIDS follow different specific characteristic patterns each time they occur, 
a summary of these patterns is shown in Figure 1.1. In caseof TRAPS, mutant TNFR1 
(misfolded protein) leads to an abnormal inflammatory response through NFκB activation; in 
Blau syndrome, mutant NOD2 is activated after stimulation with MDP leading to NFκB 
activation; in FMF, mutant pyrin is suggested to be associated with the inflammasome adaptor 
protein ASC and increase IL-1β processing; in CAPS, activated NLRP3 oligomerizes interacts 
with the adaptor protein ASC and caspase 1 to form macromolecular complexes 
(inflammasomes) that process IL-1β into its active form; in PAPA syndrome, proline-serine-
threonine phosphatase interacting protein 1 (PTSPIP1) has been implicated through its binding 
to pyrin; and in MKD/HIDS, a shortage of nonsterol isoprenoid end products results in increased 
IL-1β production (Meiorin et al., 2013; Dainichi et al., 2014; Ozen and Bilginer, 2014). 
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Figure 1.1: Mutated proteins are denoted by stars, and the terms in green circles denote the 
diseases with which they are associated (Adapted from Ozen and Bilginer, 2014). 
 
These GAIDs are associated with abnormal activation of the innate immune system, leading to 
clinical inflammation and high levels of acute-phase reactants. The innate system reacts even 
though there are no notable autoantibodies or antigen-specific T cells (Touitou, 2008; Kastner et 
al., 2010; Dainichi et al., 2014) and normal inflammation pathway is followed after the abnormal 
activation of the innate system. The most common periodic fever disease is FMF followed by 
TRAPS (Jesus et al., 2008; Standing et al., 2013). TRAPS episodes generally last longer than 
FMF and FMF patients tend to respond well with colchicine while TRAPS treatment is 
problematic, thus this work is mostly directed towards improving TRAPS disease treatment.  
 
The first description of TRAPS illness dates back to 1982, when a large Irish family came to light 
with several of its members affected by a hereditary periodic fever syndrome (Aróstegu, 2011). 
This condition was initially among the Irish-Scottish population, it has been reported in nearly all 
population groups, including Black Americans, Japanese and persons of Mediterranean 
ancestry (Kanazawa and Furukawa 2007; Ozen and Bilginer, 2014). TRAPS is an inherited 
autosomal dominant disorder caused by mutations in the TNF receptor, coded by the 
TNFRSF1A gene (Meiorin et al., 2013; Standing et al., 2013). In normal conditions, TNF 
receptor activation by TNF leads to the activation of a protease that favors the shedding of the 
receptor from the cell surface. This process produces a reduction in TNF cell signaling, and the 
shed receptor is able to bind a free TNF and limit the inflammatory response. Patients affected 
by this syndrome have a defect in receptor shedding that results in a continuous TNF signaling, 
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leading to an inflammatory response (Meiorin et al., 2013). Periods of inflammation are 
predominantly triggered following unnoticed pro-inflammatory signals. The levels of serum 
markers of inflammation such as C-reactive protein are always increased during attacks, 
however autoantibodies remain mostly undetectable (Touitou et al., 2013). 
 
Normally TRAPS begin in the early childhood with prolonged symptomatic episodes lasting 1-3 
weeks and symptom free intervals varying within individual patients, these episodes may be 
triggered by factors such as stress and infections (Meiorin et al., 2013). During symptom free 
intervals, when the physical state and inflammatory variables are normalized, the patients may 
retain their normal way of living. Clinically, TRAPS is characterized by recurrent episodes of 
fever, rash, arthralgia, abdominal pain and conjunctivitis that usually last relatively longer, from 5 
to 21 days. The most common TRAPS manifestation is cutaneous, including symptoms such as 
a centrifugal migratory, erythematous patch overlying the area with urticaria-like plaques and 
generalized serpiginous patches and plaques occur. Figure 1.2 and 1.3 shows the photographic 
images reported by Kanazawa and Furukawa (2007) and Yao and co-workers (2012), 
respectively. These lesions are painful and hot, and when they involve the limbs, they are 
associated with secondary conditions such as myalgias (Kanazawa and Furukawa, 2007; Yao 
et al., 2012; Meiorin et al., 2013).  
 
Figure 1.2: (a) Casting of tumor necrosis factor receptor (TNFR) and atypical signaling in 
TRAPS. (b) Edematous erythema noticed in cheeks and periorbital area of a TRAPS patient. (c) 
Multiple serpiginous patches and plaques in lower extremities (Adapted from Kanazawa and 
Furukawa, 2007). 
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Figure 1.3: (a) Vesicles on the abdomen. (b) Linearly arranged papules on the neck. (c) Diffuse 
erythema on the nose. (d) Serpiginous rash (Adapted from Yao et al., 2012). 
 
A definitive treatment for TRAPS has yet to be identified (Ozen and Bilginer, 2014). The main 
treatment for TRAPS has been steroids until 1999 when the big search for alternative 
treatments began, as steroidal treatment resulted in many side effects including dependency 
syndrome especially in younger patients (Aróstegu, 2011). Currently TRAPS treatment depends 
on the severity and frequency of the disease attacks. Patients with moderate disease and less 
frequent episodes use corticosteroids when necessary during the attacks only, and patients with 
severe condition and high frequency of attacks require prolonged high doses of steroids, 
therefore patients become prone to steroid withdrawal symptoms (Ozen and Bilginer, 2014). 
Non-steroidal anti-inflammatory drugs and TNF-α inhibitors have been reported to relieve 
symptoms in some cases. Presently used TNF-α inhibitors are not effective in all patients, they 
involve invasive administration procedures (i.e. subcutaneous treatment twice a week using 
etanercept) and patient compliance is a major problem (Grateau, 2004; Bulua et al., 2012; 
Dermz 2013). Therefore corticosteroids remain the main and most effective treatment in this 
condition, as they are the almost only anti-inflammatory class that inhibits all the major 
components of inflammation (Greaves, 1976). 
 
Corticosteroids are hormonal based substances, with sturdier anti-inflammatory effects than 
non-steroidal medicines (Congradyova and Jomova, 2012). In dermatological disorders their 
clinical significance is associated with their anti-inflammatory, vasoconstrictive, anti-proliferative 
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and immunosuppressive effects (Senyigit and Ozer, 2012). Besides their major anti-
inflammatory benefits, this class of drugs is associated with a variety of serious side effects 
such as: immune system suppression (prone to infections), bone loss, cataract, mood changes, 
high blood pressure and bone marrow suppression (Rabe et al 2005; Congradyova and 
Jomova, 2012). The severity of these side effects depend on the dosage, duration of use, 
dosing regime and the highest risk factor being prolonged use of the corticosteroids along with 
individual patient variability (Senyigit and Ozer, 2012). 
 
Over the years, research has focused on approaches to improve the potency of steroids while 
diminishing adverse effects, such that different types of corticosteroids have been developed. 
However, “ideal” drug delivery of corticosteroids especially for chronic treatment has not yet 
been produced. Hence the current research is directed towards improving the delivery of the 
corticosteroids drugs, thus increasing the safety of these agents in chronic treatment of 
conditions such as TRAPS (Senyigit and Ozer, 2012). Ideal corticosteroids for TDDS should be 
able to permeate the stratum corneum (SC) and reach adequate concentrations in the 
epidermis without reaching high systemic concentrations (Brazzin and Pimpinelli, 2003). Such 
characteristics can be obtained by optimizing a stimuli responsive nanocolloidal gel system. The 
aim of this project is to develop a new formulation that would improve the risk/benefit ratio of 
corticosteroids delivered through the transdermal route. This system would be formulated into a 
dermal sludge that is more likely to suit the patient’s needs.A dermal sludge being a viscous gel 
suspended with solid particles (nanocolloidal gel system).  
 
1.2. Rationale and Motivation for the Study 
This study relates to a dermally applied sludge for transdermal drug delivery system (TDDS) 
and this route of drug delivery was chosen due to its unique properties such as avoiding first 
pass metabolism, and increased patients’ compliance as they more acceptable compared to 
other forms of drug delivery e.g. injections. This will consist of three synergistic components, 
resulting in a metal-drug complex loaded into a stimuli responsive nanocolloidal gel system. 
Firstly the drug will be complexed by coordinating the drug into the centre of the metal and then 
loaded into the nanocolloidal gel system. The proposed structure for the drug-metal complex is 
shown Figure 1.4, where one of the corticosteroids, hydrocortisone succinate sodium salt is 
demonstrated chelated to a metal (ratio of metal to drug is 1:1). This complex alone is expected 
to improve the anti-inflammatory/ anti-oxidants properties of the parent drug, while the stimuli 
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responsive nanocolloidal gel systemis expected to release the complex in a controlled manner 
at the specific sites of inflammation in TRAPS. 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Hydrocortisone succinate is shown coordinated on the metal (M), M may be Fe, Cu, 
Co, Mn, or Zn. 
 
The ultimate goal of this research is to design a metal-drug loaded stimuli responsive 
nanocolloidal gel system termed a dermal sludge that will dramatically improve the management 
of TRAPS. The factors contributing to this enhancement may include one or more of the 
following:  
 The synergistic effect of the corticosteroid drug-metal complex and the coordination 
residue once the complex is degraded in the biological environment. 
 The protection from any degradations and sustained release of the complex once it is 
loaded into the stimuli responsive nanocolloidal gel system. 
 Improved skin permeability due to the modification of the hydrophobicity/hydrophilicity of 
the complex and polymeric system. 
 
The novelty of this study involves the delivery of a corticosteroid drug-metal complex in a 
stimuli responsive nanocolloidal gel system using an optimized combination of polymer(s) 
and phospholipids to yield the desired release properties for TRAPS management. This 
study was motivated by a number of social and scientific factors including:  
 The possibility of re-activating an old drug into new a superior bioactive by coordinating 
the drug with a transition metal hence improving its properties. This may be of an 
economic advantage over designing new drugs.  
 The ability of a transition metal to enhance the anti-inflammatory/anti-oxidant activities of 
drugs when coordinated to them.   
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 The possibility of making a convenient easily acceptable TDDS for TRAPS management 
as it is a lifelong condition. 
 The generation of logical data to be published in high-impact peer reviewed/accredited 
journals for further progression in the science of medicine.   
 
1.3. The Dermal Sludge for Targeted Drug Delivery in TRAPS: Concept and Outline 
Several drug delivery systems are currently being investigated to bypass the limitations of 
conventional dosage forms and enhance the potential of the respective drug. Based on the 
findings of Lee and co-workers (2010), with a nanotechnology designed drug delivery  system, it 
is possible to tailor drug deposition, disposition, and permeation kinetics through formulation 
engineering (altered composition, drug loading, droplet size, etc.) thus this design is expected to 
circumvent most of the limitations associated with current corticosteroid treatment. This new 
drug delivery system being considered here is expected to have: 
 Improved antioxidant/anti-inflammatory properties. 
 Improved bio-distribution such that more drug molecules reach the target site. 
 Improved local bioavailability of the drug 
 Minimal systemic side effects.  
  
A liposomal nanogel was the stimuli responsive nanocolloidal gel system of choice in this study 
as it has been established that it enhances drug permeation through the skin in TDD system 
(Pierre and Costa, 2011;  Zhao et al., 2013). The superiority of this system would be achieved 
by combining the advantages of the nanoliposomes and a gel-based matrix. This system is 
expected to target the oxidative and low pH occuring during TRAPS inflammatory episodes.  
This would overcome the dose-limiting systemic toxicity of the currently used corticosteroid 
drugs, while increasing the concentration of the drug at the site of action. With the drug-metal 
complex loaded into the liposomal nanogel, the pharmaceutical efficacy of the drug will be 
potentiated and side effects associated with the drug will be reduced as well (Hostynek, Dreher, 
Maibach, 2011; Congradyova and Jomova, 2012; Feng et al., 2014).  
 
The metal-drug loaded liposomal nanogel is expected to release the complex in a controlled 
manner as seen in Figure 1.5. During TRAPS disorder, reactive oxygen species (ROS) are 
formed when oxygen undergoes a partial electron reduction to super oxide anion, and 
subsequently forms hydrogen peroxide (H2O2), and other oxidants (Mahmoud et al., 2012). 
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Hence the formulated sludge would be triggered by both ROS molecules and low pH which are 
typical in inflamed tissue, this design would lead to a better targeted drug delivery.  
 
Figure 1.5: Schematic diagram representing the proposed metal-drug complex loaded 
nanoliposome, and briefly its mechanism of release. The nanoliposome formulation would 
detect the inflammatory mediators through the stimuli responsive nanocolloidal gel system 
chemical groups, and then it would swell, erode, and release the coordinated metal-drug 
complex. 
 
1.4. Potential Benefits of this Study 
Although the complexation of metal centers to drugs is not an entirely new area, the application 
towards and its development in drug delivery systems is relatively new and full of further 
research opportunities. The reactivation of drugs into novel metal-drug complexes with 
improved properties may result in complexes that may not only be used for the traditional parent 
ligand (free drug) function but for treatment of other inflammatory related conditions, for instance 
Cu(II) complexes of NSAIDs have shown anti-cancer propertiesthrough pharmaceutical 
modification (Roy, Banerjee and Sarkar, 2006). This could be a less costly process of obtaining 
bioactives for other diseases. Generally the effects of metal coordinations are expected to 
improve treatment options, therefore creating unique research expansion, diagnostic and 
therapeutic opportunities. 
 
Loading the metal-drug complex into the stimuli responsive nanocolloidal gel system further 
enhances the overall therapeutic outcome of the complex by releasing the complex in a 
controlled manner. As one of the major limitations associated with long-term therapy in 
conditions such as TRAPS are side effects associated with the anti-inflammatory drugs and with 
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this design these limitations may be circumvented. Thestimuli responsive nanocolloidal gel 
system could also be applied in the treatment of other inflammatory diseases such as acne, 
where inflammation is involved. Overall the data obtained from this study could be used to build 
on information for further development in the science of drug delivery systems.  
Possible drug applications of this delivery system include: 
 The complex may be used to treat other conditions, as a number of complexes possess 
other functions such as anti-parasitic, anti-cancer and anti-microbial agent i.e. Gold 
complexes are used in malaria and as a chemotherapeutic agent against other tropical 
diseases such as Trypanosomiasis and Leishmaniasis. 
 Site-specific sustained release of metal-antibiotic drugs to improve the design of compounds 
and reduce toxic drug side effects. 
 Controlled drug delivery for treatment of other skin inflammatory conditions such as acne. 
 
1.5. Aim and Objectives 
The aim of this study was to design and prepare a synergistic metal-drug complex-loaded 
stimuli responsive nanocolloidal gel system, termed adermal sludge, which possesses superior 
permeation, anti-inflammatory and anti-oxidant properties compared to the free ligand (active 
drug). The objectives for the study are: 
1. Preparation of a metal-drug complex and evaluation of its physicochemical (i.e. Fourier 
transform infrared spectroscopy (FTIR)), and biological (i.e. 1,1-diphenyl-2-picrylhydrazyl 
(DPPH)  free radical scavenging assay) profiles 
2. The design and synthesis of the polymer and the initial nanocolloidal preparation, as well as 
manipulation of the parameters to achieve an optimum control of particle size and surface 
properties. 
3. Loading of the metal-drug complex into the designed nanocolloidal and evaluation of the 
nanocarrier produced in order to determine the efficiency of preparation methods used in 
terms of drug encapsulation efficiency, particle size, zeta potential, and morphology. 
4. Formulation of the TDDS, termed the nonosludge, using the designed nanocolloidal system 
5. Determination of further physicochemical and physicomechanical profiles such as thermal 
and rheological properties of the dermal sludge. 
6. Evaluation of the drug release properties of the dermal sludgein vitro and ex vivo. 
7. In vivo animal studies for the preclinical assessment of the dermal sludge. 
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1.6. Overview of this Dissertation 
Chapter one: this chapter introduces and outlines the background to the study. Description of 
the genetic disorder, its currents treatment options and limiting factors is provided. The chapter 
also discusses how the use of the metal-drug complex loaded stimuli responsive polymeric 
colloidal nanogel system (stimuli responsive nanocolloidal gel system) (dermal sludge) for 
transdermal drug delivery systems (TDDS) would enhance the treatment of TRAPS. It outlines 
the rationale, motivation, aim and objectives of the study and the potential benefits of the study. 
 
Chapter two: this chapterpresents a literature review focusing on the application of drug-loaded 
polymeric colloidal nanogels (DPCNs) in transdermal drug delivery systems (TDDS). It entails 
the limitations of conventional TDDS, fabrication techniques of DPCNs networks, ideal 
properties of DPCNs, and therapeutic significance of polymeric nanogels in TDDS. It further 
details how DPCNs have recently advanced with drug delivery systems in order to manage 
chronic diseases such as TRAPS. 
 
Chapter three: this chapter a [copper(glyglycine)(prednisolone succinate)] complex for 
application in transdermal drug delivery was synthesized. The formulatedcomplex was 
confirmed by X-ray diffraction, Nuclear magnetic resonance (NMR), FTIR and UV–visible 
absorption spectroscopy. Furthermore the complex was differentiated from parent drug 
(prednisolone) by Differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), 
antioxidant activity assay, mass spectrometry and in vitro permeation studies. Additionally in 
vitro cytotoxicity studies were undertaken. 
 
Chapter four:this chapter describes the development and characterization of Eudragit ® E100-
cystamine (EuE100-cyst) and dual pH/redox responsive nanoliposomes. The EuE100-Cyst was 
conjugated with the phospholipid film to form the a dual pH/redox responsive nanoliposomes 
and the [copper(glycylglycine)(prednisolone succinate)] complex was loaded into the EuE100-
Cyst for controlled release. The drug loading into the NLs was confirmed using FTIR and the 
actual drug entrapment efficacy was measured. The morphology and size of the NLs was 
confirmed using TEM and Zetasizer analysis, respectively. The pH/redox sensitivity of the NLs 
was established by the change in particle size using the zeta sizer and drug release studies. 
Furthermore cytotoxicity studies were performed on both the loaded and non-loaded 
nanoliposomes. 
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Chapter five:this chapter describes the formulation and optimisation of the stimuli responsive 
nanocolloidal gel system(dermal sludge) for transdermal delivery of 
[copper(glycylglycine)(prednisolone succinate)] complex. A 3-factor, 3-level Box-Behnken 
design was used to derive a second-order polynomial equation to construct contour plots for 
prediction of responses. Independent variables studied were the two different lipids ratios, 
cholesterol ratio and sonication time. The dependent variables studied were the Z-average 
particle size , polydispersity Index (PdI) , zeta potential, entrapment efficiency (% EE) and 
amount of complex released per hour in the presence of pH(5) and 10mM GSH. Response 
surface plots were drawn and statistical validity of the polynomials was established to find the 
compositions of optimized formulations which were evaluated using a Franz-type diffusion cell 
and drug release studies. 
 
Chapter six: this chapter describes the in vivo studies performed which involved dermal 
application of the sludge for transdermal delivery of the [Copper(glycylglycine)(prednisolone 
succinate)] complex in Sprague–Dawley rats. At predetermined time points blood samples were 
taken and the rats were euthanized. On completion of in vivo experimentation, the euthanized 
rats were excised for skin samples to be used for further histopathological examination. In the 
chapter, detection and quantification of the drug from withdrawn plasma samples, and in tissues 
were performed using Ultra-performance liquid chromatography (UPLC). 
 
Chapter seven:this chapter presents the concluding remarks and recommendations for further 
research on transdermal drug delivery system of advanced polymeric nanocolloidal systems 
with a focus on the recommendations for further work. 
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CHAPTER 2 
A REVIEW OF POLYMERIC COLLOIDAL NANOGELS IN TRANSDERMAL DRUG 
DELIVERY
 
 
2.1. Introduction 
Nanogels are colloidal, cross-linked particles with a size that is ideally less than 200 nanometres 
(nm). Generally, they are made from synthetic or natural polymers, (Vinogradov, 2010; Binions, 
2012; Sultana et al., 2013; Zan et al., 2014; Pedrosa et al., 2014) which are chemically or 
physically crosslinked polymer networks depending on the gel applications (Samah and Heard, 
2013; Sultana et al., 2013; Chen et al., 2014). When these colloidal nanogels are loaded with 
active compounds, they are referred to as Drug-loaded polymeric colloidal nanogels (DPCNs).  
Much interest has been directed towards the potential use of DPCNs to deliver a variety of 
drugs to diverse parts of the body system for either controlled or sustained drug delivery 
systems (Huppertz and de Kruif, 2008; Singka et al., 2010). Additionally, they may change their 
size (swell and de-swell) in response to environmental incentives such as ionic strength, pH, 
type of solvent in contact with the gel and surrounding temperature (Murray and Snowden, 
1995; Gonçalves et al., 2010;Singka et al., 2010; Samah and Heard, 2013). These 
environmentally responsive properties depend on the chemical nature of the monomers, 
polymers and cross-linkers used to synthesize the DPCNs (Zhang and Granick, 2006; Kim et 
al., 2013). The overall rational design of DPCNs takes into account the efficient synthesis and 
functionalization of DPCNs, while maintaining good stability and control of nano- particle size. 
To this end these applications have led to the development of innovative DDS that has been 
coined as smart drug delivery systems (Yan and Tsujii, 2005; Almeida et al., 2012; Lu et al., 
2013; Mura et al., 2013; Meléndez-Ortiz et al., 2014).   
 
Moreover, DPCNs employed for TDDs applications have shown that DPCNs  have the ability to 
reach the smallest capillary vessels, which facilitates penetration through the skin tissues and 
they remain in the skin longer promoting more drug absorption (Gonçalves et al., 2010). A 
number of  recent studies have indicated that DPCNs are successful in treating skin cancer 
through the TDDS route, of which this application may be extended to other chronic skin 
conditions treatment such as genetic auto-inflammatory skin disorders (Mangalathillam et al., 
2012; Sabitha et al., 2013; Zhang et al., 2013b). Polymeric nanogels have been successfully 
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formulated for TDDS using a number of polymers including chitosan, chitin, poly(N-isopropyl 
acrylamide-co-acrylic) acid (poly(NIPAM-co-AAc)) and poly (lactic-co-glycolic acid) (PLGA) ( 
Mangalathillam et al., 2012; Shah et al., 2012; Sabitha et al., 2013;Samah and Heard, 2013). 
Despite all these encouraging research reports, there are still some shortcomings that need to 
be circumvented in order to improve the therapeutic effectiveness of the current DPCNs in 
TDDS.  
 
TDDS is defined as the non-invasive application of a drug containing formulation to the skin for 
direct delivery of the drug through the skin into system (Bajaj et al., 2011; Shingade, 2012). This 
system releases the drug at predetermined rates through the dermis for either systemic or 
localised tissues underlying the skin (Bajaj et al., 2011). TDDS have attracted much interest as 
a route of drug administration for both systemic and local effects due to their advantageous 
properties compared to other conventional dosage forms, such as parenteral and oral. Bio-
actives from DPCNs can penetrate deeper into the skin and give better absorption (Shingade, 
2012). Additionally, TDDS are non-invasive, generally cost effective, and they can be self-
administered and easily accepted by patients (Shingade, 2012). Further they are capable of 
providing a prolonged therapeutic drug release, releasing for up to a week or longer periods of 
time (Phatak and Chaudhari, 2012;Shingade, 2012; Chen et al., 2014). Overall these properties 
lead to improved patient compliance and better therapeutic outcomes. However one of the main 
drawbacks of TDDS is the low penetration rates of most active drug molecules through the skin. 
 
Most TDDS present with an occlusive effect, they are highly concentrated and drug release is 
driven by concentration gradient between the skin and patch, diffusing from formulation to the 
skin (Bajaj et al., 2011). For the drug to pass through the skin it has to bypass the stratum 
corneous (SC) limitation barrier. SC is the outermost layer of the skin layer and acts as skin 
barrier resulting into low penetration rates of the drug (Prausnitz and Langer, 2008). The skin’s 
structure and its function as a barrier have been widely reported in the literature (Barry, 1987; 
Williams, 2003; Bharadwaj and Gwalior, 2012; Zhang et al., 2013b). Human skin encompasses 
a number of layers with hair shafts and gland ducts penetrating through the layers, the hair 
follicles and sweat ducts open directly into the skin surface, hence they are appendage for drug 
delivery through the skin Figure 2.1 (Scheuplein, 1965; Kabanov and Vinogradov, 2009). The 
main skin layers starting from outside to inside are: the cellular epidermis, stratified avascular, 
dermis of connective tissue, and fatty subcutaneous layer (hypodermis) (Bissett et al., 1987; 
Maghraby et al., 2006; Kabanov and Vinogradov, 2009). Despite the skin acting as a barrier, it 
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is also used as a special delivery pathway that may be used for therapeutic agents and any 
other molecules applied to the skin. There are two main routes (Figure 2.1) that are used by the 
colloidal molecules to permeate across the SC the intracellular and intercellular pathways, and 
the other being the follicular (appendageal) pathway (Scheuplein, 1965; Maghraby et al., 2006; 
Alexander et al., 2012). The nanometer particulate size of the DPCNs allows them to bypass the 
skin barrier limitation for drug delivery, hence they may be the potential solution for a low drug 
penetration rate. 
 
Figure 2.1: Representation of drug penetration pathways through the skin with the two major 
routes shown on the upper right corner. (Adapted with the permission from Alexander et al. 
(2012). Copyright (2012) Elsevier). 
 
2.2. Limitations of Conventional Transdermal Drug Delivery Systems 
Conventional drug formulations that are currently being used for TDDS include formulations 
such as creams, gels and ointments, and some new formulations such as sprays, foams, and 
patches (Lee et al., 2010). These formulations have shown notable limitations leading to sub-
therapeutic outcomes mostly due to permeation and specificity issues. Presently most of these 
transdermal therapies are associated with poor skin permeation, insufficient reach to disease 
tissue (lack of specificity), low retention at target site, poor intracellular/intercellular penetration 
and skin irritation potential (pain, itching, burning, hypersensitivity reactions and inflammation) 
and low therapeutic index (high toxicity) (Donnelly et al., 2012; Isaac and Holvey, 2012; 
Shingade, 2012). Lack of dosing precision is one of the major limitations associated with gels 
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and creams, as the systemic bioavailability is dependent on the total dose applied on the skin 
(Thomas and Finnin, 2004). Even though dose precision is not an issue with patches the 
flexibility of dosing is restricted (Thomas and Finnin, 2004). These shortcomings may lead to the 
development of several undesirable therapeutic outcomes such as nonspecific cytotoxicity to 
critical normal tissues, sub-therapeutic outcomes, development of resistance and other drug 
associated adverse effects.  
 
Several drug delivery systems are currently being investigated to overcome the limitations of 
conventional dosage forms and enhance the potential of the respective drug. These new drug 
delivery systems being considered are expected to have: a) improved properties; b)improved 
bio-distribution such that more drug molecules reach the target site; c) improved local 
bioavailability of the drug; and c) minimal or no systemic side effects (Kala and Sundeep, 2012). 
Based on the findings of Lee and co-workers (Lee et al., 2010) with a nanotechnology designed 
drug delivery  system it is possible to tailor drug deposition, disposition, and permeation kinetics 
through formulation engineering (altered composition, drug loading, droplet size, etc.) thus 
overcoming most of the limitations associated with current transdermal treatment.  
 
According to various findings that have been reported on nanogels it can be concluded that 
DPCNs deserve a special consideration for use in TDDS because of their favorable 
physicochemical properties, such as their narrow size distribution capable of penetrating 
through the skin barrier (Escobar-Chávez, 2012). Nanogels have the tendency to absorb water 
when placed in an aqueous environment and their affinity to aqueous solutions, superior 
colloidal stability, inertness in the blood stream and the internal aqueous environment, and 
suitability for bulky drugs incorporation, renders them ideal candidates for TDDS. Hence the use 
of more specific, superior DPCNs aids the TDDS by improving the drug permeation through the 
skin, drug bioavailability and reduces severe side effects i.e. toxicity associated with 
conventional therapeutic agents. 
 
2.3. Fabrication Techniques of Polymeric Nanogel Networks in DPCNs 
Generally there are two basic goals that should be satisfied in the design of a TDDS namely: (i) 
efficient drug entrapment and loading to the polymeric matrix accompanied by the release of the 
drugs in a controlled fashion and (ii) ability to release through a local or externally applied trigger 
by changing the binding affinity between the drug and the polymeric matrix. Therefore, a clear 
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understanding on the interaction of the nanogel networks is important for the development of an 
efficient drug delivery system (Tian et al., 2007). 
 
Biodegradable and biocompatible polymeric nanogels used for drug delivery purposes in 
pharmaceutics are formulated from a number of natural and synthetic polymers (Nagarwal et al., 
2009). Synthetic polymers are mostly preferred because their physical and chemical properties 
can be easily manipulated compared to the natural polymers which are hard to work with 
(Sanson and Rieger, 2010). These  polymers enhance the aqueous properties of the delivery 
systems by modifying the viscosity, emulsification, stabilization and gellation of the nanogel 
(Kadajji and Betageri, 2011). Examples of synthetic polymers that have been used for 
transdermal formulations are poly (ethylene glycol) (PEG), polyvinyl pyrrolidine (PVP) 
polyacrylic acid (PAA) and polyacrylamides (PAAm). Examples of natural polymers are xanthan 
gum, pectins, chitosan derivatives and dextran (Kadajji and Betageri, 2011; Ferreira et al., 2013; 
Zhang et al., 2013a). A brief discussion on the techniques employed for nanogels preparations 
using polymers are presented below, considering that there are several methods for the 
preparation of nanogels, four commonly used techniques will be highlighted (Kabanov and 
Vinogradov, 2009; Ferreira et al., 2013).   
 
2.3.1. Physical self-assembly of interactive polymers 
This method is the most utilized procedure in nanogel production due to its simplicity which 
involves mixing of the polymer as a carrier and the drug that has to be loaded. The driving and 
/or limiting forces of the physical interaction of the polymer networks include hydrophobicity, 
hydrogen bonding, van der Waal forces of interaction and electrostatic interaction within the 
polymer networks (Akiyoshi et al., 1993; Chacko et al., 2012; Sultana et al., 2013). The number 
of functional groups in the polymer chemical structure also affect the physical assembly of the 
nanogel (Binions, 2012). Hydrophilic polymers are the most favoured polymers in this method of 
nanogel formulation as they produce the most stable crosslinked nanogels due to the strong 
hydrophilic interactions involved. The degree of crosslinking determines the nanogel properties 
i.e. the nanoparticle size of the nanogel and the degree of swelling and thus drug release profile 
and the overall therapeutic outcome. A number of studies on physical self-assembly of polymers 
in nanogel formulations have been reported and an example is the cholesterol-bearing pullulan 
(CHP) nanogel which has the potential to form complexes with various proteins, drugs, and 
DNA (Akiyoshi et al., 1993; Nishikawa et al., 1996; Akiyoshi et al., 1999; Akiyoshi et al., 2000; 
Kuroda et al., 2002; Chacko et al., 2012).  
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2.3.2. Monomer polymerization in a homogeneous or heterogeneous microscale or 
nanoscale environment 
This technique describes the polymerization of monomers using preformed polymers in 
heterogeneous colloidal environments, mostly in water-in-oil inverse microemulsions (Sanson 
and Rieger, 2010; McAllister et al., 2002). In this method the biomacromolecules and 
micromolecules of the drug are entangled within the nanogel networks (Khmelnitsky et al., 1992; 
Mitra et al., 2001). It is a relatively intense method and involves a purification step to remove the 
unreacted monomer(s) and some of impurities such as the surfactants used for formulation 
stability (Ryu et al., 2010; Chacko et al., 2012). Figure 2.2. shows a nanogel formulated using 
this method. This technique provides control over the nanogel composition, size, and swelling 
behavior by varying the crosslinker and charged monomer concentrations in the polymerization 
step (McAllister et al., 2002). Yuan et al. (2012) reported the efficiency of the polymerization 
technique in the production of polyphosphate nanogels using a moisture sensitive cyclic 
phosphoester monomer and cyclohexane as the microemulsion liquid. The nanogel 
demonstrated controlled protein adsorption, and offers an emerging route for use as 
functionalized carriers to the blood circulation. 
 
2.3.3. Chemical cross-linking of preformed polymers 
Generally this technique includes core crosslinking or shell crosslinking of the preformed linear 
polymers to obtain nanogels. The crosslinking mostly occurs through the covalent bond 
crosslinking method (Cheng and Mahato, 2013).  Figure 2.2shows the preparation of nanogels 
from polymer precursors and crosslinking. This approach is of particular importance in the 
preparation of functionalized drug delivery carriers (Cheng and Mahato, 2013).  A number of 
nanogels have been formulated and used in drug- loaded polymer carriers (Cheng et al., 2013). 
Work by Kabanov and Vinogradov (2009) and Vinogradov et al. (2002) have presented 
examples of cross-linked, functionalized polymers. It has been demonstrated that chemically 
crosslinked nanogels can generally provide opportunities to vary the structure and properties of 
nanogels and due to their covalently crosslinked structures they show no dissociation and 
destabilisation in aqueous media and in the blood stream (Cheng and Mahato, 2013).  
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2.3.4. Template-assisted nanofabrication of nanogels particles (imprint photolithographic 
techniques) 
In this method polymer nanogel particulates are fabricated according to their sizes, hence 
controlling the particle composition, shape, size, and surface properties (Kabanov and 
Vinogradov, 2009). According to Band and Bronich (2014) this may take place in a two-step 
process, which is the condensation of block ionomers into spherical self-assembled block 
ionomer complexes (BIC) and cross-linking reaction of BIC templates by bifunctional agents. 
Although this is not one of the commonly applied fabrication methods, Maggi et al. (2011) 
reported that chitosan covalent nanogels were cross-linked with genipin using template 
chemical cross-linking of chitosan in polyion complex micelle (PIC) nanoreactors. This method 
yielded chitosan nanogels from solely biocompatible materials avoiding the use of organic 
solvents, and thus offers an ideal method for synthesis of moisture sensitive polymers. 
 
 
Figure 2.2: Schematic representation of the synthesis of nanogels via the polymer precursor 
method and the emulsion method respectively. (Adapted with the permission from Chacko et al. 
(2012). Copyright (2012) Elsevier). 
 
2.4. Polymeric Colloidal Nanogel Properties 
2.4.1. Swelling and de-swelling properties 
The swelling/de-swelling characteristic of nanogels allows the colloidal particles to take the form 
of microsponges. Swelling promotes the diffusion of the liquid phase into the DPCNs bulk and 
de-swelling (shrinking) causes the release of the drug with the flow of liquid into the target site, 
this is called the “volume transition” of the DPCNs (Alvarez-Lorenzo and Concheiro, 2008; 
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Maggi et al., 2011; Farag and Mohamed, 2012; Yao et al., 2013; Band and Bronich, 2014). 
DPCNs are capability of rapidly swelling and de-swelling depending on the surrounding 
environment (Sultana et al., 2013; Kettel et al., 2014). This allows them to be responsive to the 
surrounding environment; they may respond to stimuli such as pH, and temperature changes 
and this ensures a targeted controlled drug delivery from the DPCNs (Oh et al., 2007; du Toit et 
al., 2014). The swelling property of the DPCNs is controlled by the chemical structures of 
polymeric precursors used to formulate the gel (polymer networks) and external environments 
(pH, ionic strength, and temperature) (Kabanov and Vinogradov, 2009; Farag and Mohamed, 
2012; Yao et al., 2013). These properties are of vital importance for drug loading and release 
optimisation , and therefore the drug release profile is dependent on the degree of swelling/de-
swelling of the nanogel particles (Kabanov and Vinogradov, 2009; Messager et al., 2013). 
Generally, nanogels have displayed improved drug loading capacities compared to other 
nanosized drug carriers such as micelles due to the increased space for incorporation of 
bioactives  when the particles are swollen (Kabanov and Vinogradov, 2009). Farag and 
Mohamed (2012)  developed  nanogels comprising  of a binary system of carboxymethyl 
chitosan (CMCh) and poly- (vinyl alcohol) PVA which  reached up to 500%  swelling in the 
presence of acidic pH within two hours. The swelling was dependent on the crosslinking 
behavior of the polymers and environmental stimuli as the more crosslinker was added the more 
polar the polymer became and the more acidic the pH was the more swollen the 
nanoparticulates were, respectively enhancing the drug delivery. Another exemplary study was 
done by  Samah and Heard (2013)where a high loading drug capacity increased with the 
degree of swelling due to the network behavior of polymers (polyNIPAM)- co-AAc) in response 
to both temperatures and pH, and thus showing an improved transdermal drug delivery. 
 
2.4.2. Biocompatibility and biodegradability 
Carriers used for drug/gene delivery (polymers) to the intracellular compartments are required to 
deposit the drugs/genes inside the cells. These polymers are expected to remain intact in the 
extracellular environment and disintegrate intracellular releasing the drugs/genes without any 
toxicity inside the body and for this purpose the polymers used have to be biocompatible and 
biodegradable (Behl et al., 2012; Urakami et al., 2013). Polymeric based nanogels are highly 
biodegradable and biocompatible, due to the high water content. The biodegradability of 
nanogels allows them to be responsive to stimuli such pH and oxidants which  promotes 
selective drug delivery carriers (Oh et al., 2007). This property also reduces the DPCNs toxicity 
(Vinogradov et al., 2002) as they are easily excreted from the body. A variety of polymers have 
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been studied and proven to be bio-compatible and degradable (Behl et al., 2012; Singh et al., 
2013; Medeiros et al., 2010; Pujana et al., 2014; Steinhilber et al., 2013), thus making them 
excellent candidates for encapsulation into nanogels for biomedical applications (Rancan et al., 
2014). In a study reported by Urakami et al. (2013)disulfide-based tetralysine and 
oligoethylenimine based prepolymers were formulated and the polymer precursors and nanogel 
particles were determined to be biodegradable, biocompatible, and stimuli-responsive 
nanocarriers for the delivery of drugs and genes. Figure 2.2shows the structure of a 
biodegradable and compatible nanogel. However, to confirm the biodegradability and 
compatibility of any polymeric nanogel in drug delivery in vitro studies are required, which is 
another platform for research.  
 
2.4.3. Morphology 
The particle size and shape composition may be co-designed to enhance the utility of the 
DPCNs.  DPCNs are colloidal, cross-linked particles with smaller particles which degrade into 
even smaller particles that are easily eliminated through the renal clearance (Hans and 
Lowman, 2002; Klinger and Landfester, 2012; Sultana et al., 2013). It has been determined that 
the smaller the size of the nanoparticles the slower is the elimination of the residuals by renal 
clearance (Kadam et al., 2012; Zhang et al., 2013b). It is vital for particle size to be controlled 
for sustained drug delivery, as smaller particles (20-200nm) avoid rapid renal clearance 
(Sultana et al., 2013). This improves the pharmacokinetics of the drug by extending the serum 
half-life. Considering the fact that DPCNs have significantly more particles in situ compared to 
other nanocomposites, they have the ability to exhibit an improved porosity. This high degree of 
porosity allows for efficient encapsulation of therapeutic molecules (Liang and Kiick, 2014). 
 
2.4.4. The drug loading capacity 
Nanogels have the potential of incorporating therapeutics of diverse nature using simple 
techniques (Soni and Yadav, 2014) and the loading capacity of a polymeric nanogel depends on 
the properties of the polymer used to formulate the gel. DPCNs may be loaded with drugs using 
controlled self-assembly, physical entrapment and covalent conjugation methods (Oh et al., 
2007). The chemical structural relationship (the functional groups present) of the polymer 
determines the sites available for the binding of the drug to the polymer, hence drug loading 
capacity. More functional groups increase the capability of drug binding to the polymer. The 
structure of the nanogel should ensure efficient encapsulation stability such that the 
encapsulated drug will not leak ahead of time and this will ensure uttermost therapeutic efficacy 
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with negligible side effects (Nishikawa et al., 1996). Ideally a high loading capacity of drug is 
desired in drug delivery, and if the loading capacity of the drug on the polymer is high, then  less  
of the nanocarrier is required to deliver the therapeutic treatment (Chacko et al., 2012). Hence it 
is important to optimize the loading capacity of the nanocarrier(s) used in order to minimize any 
polymer inherent side effects. The measured loading capacity on its own is not a sufficient 
indicator for a stable nanocarrier.  Moreover encapsulation stability studies are necessary and 
also it is important that drug loading does not affect the ability of targeted nanogels to interact 
with the receptors (Nukolova et al., 2011) therefore further studies directed to this specific 
application may be beneficial.  
 
2.4.5. Sustained and controlled drug release 
The ability of nanogels to swell/deswell in an appropriate environment allows them to be likely 
candidates for the development of controlled/sustained drug delivery systems (Behl et al., 
2012). A number of biodegradable, biocompatible and non-toxic polymeric nanoparticle gel-
based drug delivery studies have been reported using a variety of polymers.   Some 
mentionable examples include, poly(D,L-lactide) and poly(D,L-lactide-co-glycolide)  where they 
were successfullyinvestigated for releasing the drug from a PDCN in a sustained and controlled 
manner ( Vinogradov et al., 2002; Binions, 2012). The use of nanogels to bring about controlled 
and or sustained drug delivery release has been extensively studied (Vinogradov et al., 2002; 
Shah et al., 2012;Khurana et al., 2013a; Khurana et al., 2013b; Samah and Heard, 2013; Singh 
et al., 2013) and the following advantages were noted: a) improved  drug pharmacokinetics, b) 
lower side effects and c) safe degradation.  Based on these reported advantages, renewed 
interest in TDDS is evident in both pharmaceutical and medical fields like  dermatology 
(Medeiros et al., 2010). According to Singh and co-workers (2013) it is established that the 
release kinetics of DPCNs follow a diffusion predominant drug delivery mechanism. The gels 
behaved as homogeneous-planar matrices, coupled with maintenance of structural integrity, 
and the drug was released in a sustained manner. Although most studies have proved that 
nanogels can be effective systems for controlled and sustained drug release, these properties 
are highly dependent on the type of polymers used and their concentrations, and therefore 
these results allow for further optimisation  studies and may be used as a benchmark for new 
research. Controlled TDD can be successfully attained using various pathways including: 
 
I. Physical stimuli induced volume phase transition (Sultana  et al., 2013) 
II. Diffusion – drug diffuses throughout the network (Sultana et al., 2013) 
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III. Erosion – drug molecules erode from the crosslinked nanogel network through the 
disruption of intermolecular bonds or intramolecular degradation (Maggi et al., 2011, 
2013) 
 
Controlled drug release is said to be dependent on the nature of the polymer structure such as 
the solubility, length, crystallinity and its hydrophobicity. Additionally the rate of polymer 
degradation is affected by the diffusion of the drug through the nanogel particles, extent of 
swelling of nanogels in aqueous media and the technique of nanogel fabrication. Controlled 
degradation is essential for an ideal nanocarrier for sustained release applications (Asadi et al., 
2011).  
 
2.4.6. Site specific targeting 
Generally, DPCNs display a smaller particulate diameter promoting drug delivery to the target 
sites in TDDS (Escobar-Chávez, 2012). Furthermore nanogel particles have the ability to 
penetrate through the transcellular and paracelluar pathways into the targeted tissues 
(Gonçalves et al., 2010) hence there is potential use of  these nanoparticles for the design  of 
site specific TDDS.The ability of nanogels to respond to stimuli allows them to turn on/off in 
response to surrounding signals and release the drug in a controlled manner only to the affected 
cells. Specific targeted nanogels play a major role in the drug delivery platform: (i) they have the 
ability to incorporate a variety of drugs including steroidal agents with severe side effects and 
chemotherapies; (ii)  they may coat the surface of the drug and  exhibit ligands targeting 
properties; (iii) they allow for long storage after lyophilization, prolonging the therapeutic activity; 
(iv) due to the crosslinking property they enhance the retention time of the drug  within the 
nanogel core (Murphy et al., 2011);  and  (v) they avoid accumulating in non-target tissues 
thereby lower the therapeutic dosage and minimize harmful side effects (Soni and Yadav, 
2014). Additionally nanogels can be effectively functionalized to attain any desired stimuli 
responsive characteristic such as temperature, pH, ionic and mechanical changes, and these 
modifications are mostly due to the nanogel large specific surface area (small particle size), 
colloidal stability and easily tunable size (Brunel et al., 2009; Richtering and Pich, 2012;Pan et 
al., 2013). Through integration of these specific nanogel functions, targeted drug delivery 
systems are achieved and they hold a great promise in a number of biomedical applications 
including dermatological therapeutical treatments.  
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2.4.7. Penetration enhancing property 
The use of DPCNs can also significantly enhance the penetration of the drug through the skin 
(Phatak and Chaudhari, 2012; Shingade, 2012) without the use of chemical additives. They are 
effective carriers for transdermal preparations and the improved penetration of the formulated 
nanogel may be due to the elongated contact between the drug and the skin, more surface area 
of the nanoparticulates and improved skin hydration due to the gel occlusive property. Hence 
polymeric nanogels have great potential for use in transdermal drug delivery systems. A new 
proposed method of improving skin penetration with the use of colloids was reported 
(Steinhilber et al., 2013; Urakami et al., 2013). Figure 2.3 shows the new method where a 
nanogel with improved skin penetration effects was formulated without the use of penetration 
enhancers i.e. surfactant. 
 
 
Figure 2.3: Representation of a novel surfactant-free route for the preparation of a 
biocompatible, biodegradable and stimuli responsive nanogel for potential targeted gene 
delivery. (Adapted with the permission from Urakami et al. (2013). Copyright (2013) American 
Chemical Society). 
 
2.4.8. Miscellaneous nanogel properties 
2.4.8.1. Superior colloidal stability 
With the application of nanogels principles it is possible to produce more stable DPCNs for 
transdermal administration with or without the use of surfactants ( Brunel et al., 2009; Rigogliuso 
et al., 2012).  
 
25 
 
2.4.8.2. No immunological responses stimulated 
DPCNs do not stimulate any immune response such as skin reaction when applied on the skin 
and they may also protect the skin from any reaction that may result due to the drug as the drug 
is coated inside the crosslinked polymeric networks. Although, when desired, nanogels may be 
used to stimulate immune responses (Nochi et al., 2010; Vinogradov, 2010) and this allows for 
the use of nanogels for immune response controlling vaccine delivery. 
 
2.4.8.3. Can be used as a carrier for both hydrophobic and hydrophilic drugs 
DPCNs may be chemically altered to encapsulate a variety of ligands i.e. both hydrophobic and 
hydrophilic drug molecules (Soni and Yadav, 2014).  
 
2.4.8.4. Solubility 
Nanogels are very soluble in biological fluids, and the core or networks of the gel further 
enhance the solubility of hydrophobic drugs (Soni and Yadav, 2014).  
 
2.5. Therapeutic significance of polymeric nanogels in transdermal drug delivery 
systems 
Although oral drug therapy is the most customary form of drug delivery, it may not be the best 
option for all disease treatment and it has a number of undesirable side effects such as erratic 
absorption. TDD provides an alternative delivery route and may be preferred in the treatment of 
skin related disorders such as skin inflammatory disorders. Effective application of transdermal 
drugs relies on the delivery of an efficient drug concentration at the target site (Sahoo et al., 
2008).  Consequently the development of a TDD is of optimum significance in systemic delivery 
of drug molecules, to attenuate adverse effects associated with absorption, by pass the first 
pass metabolism and be easily accepted by patients hence facilitate drug efficacy. Various 
DPCNs have been reported to be effective nanogels in the field of TDD and their utilization and 
therapeutic effects were also exploited (Sahoo et al., 2008). For instance a DPCNs delivery 
system was formulated to deliver methotrexate drug which is one of the problematic drugs to 
deliver, the drug was efficiently delivered through the skin and  in vivo studies were also done to 
prove the effect (Singka et al., 2010).  
 
According to studies done so far it may be established that DPCN formulations may be an 
effective delivery system for the treatment of skin diseases, as they have the capacity to deliver 
a sufficient concentration of drug into the deeper tissue to treat the skin symptomology (Egbaria 
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and Weiner, 1990), however it can also be used for systemic treatment as sufficient drug 
penetrates through the skin. Generally, the penetration of nanoparticle-mediated drug delivery 
into the epidermis and dermis without barrier modification is usually less successful, and 
PDCNs drug delivery systems makes it possible to encapsulate penetration enhancers for 
molecule permeation through the skin to the target site (Egbaria and Weiner, 1990; Prow et al., 
2010), also with relevant functionalization the DPCNs may also be used as penetration 
enhancers without any additional chemical enhancer (Barry, 1987). They may release drugs in a 
sustained or stimuli-triggered fashion and the nanoscale particles passively accumulate in 
specific tissues (e.g., tumors) through the enhanced permeability and retention effect (Shi et al., 
2010) and translate into even fewer side effects related to the drug. Due to targeted drug 
therapy the overall biopharmaceutical (pharmacokinetics and pharmacodynamics) properties 
are improved, while toxicity, biological recognition of particular stimuli and immunogenicity of the 
delivery system are also enhanced which ultimately gives better therapeutic outcome (Sahoo et 
al., 2008; Lee et al., 2010; Shi et al., 2010). 
 
In a study done by Sultana et al. (2013)it was resolved that nanogel-based drug delivery 
formulations may improve the safety and effectiveness of particular anti-cancer drugs such as 
doxorubicin, due to their chemical composition. Although these studies have also been 
evaluated using the in vivo animal studies, more studies still have to be conducted before these 
products enter clinical trials (Oh et al., 2010; Sultana et al., 2013). In this system the silver ions 
were released in a controlled and sustained rate and the nanoparticles remained on the skin 
surface for longer thus high efficacy is obtained coupled with reduced dosing frequency. 
 
The TDD route of drug administration exhibits a number of advantages over the oral or 
parenteral drug administration including the reduction of side effects, elimination of first-pass 
metabolism, less frequent drug administration, sustained (controlled) drug delivery, and better 
patient compliance (Sahoo et al., 2008; Kala and Sundeep, 2012). The use of polymeric 
colloidal drug delivery systems improves solubility of drugs including hydrophobic drugs like 
steroids in inflammatory skin disorders (Kayser et al., 2005; Shi et al., 2010). The potential use 
a nanocarrier system was further proved to be effective in TDDS without using any chemical 
penetration enhancers by Phatak and Chaudhari (2012) . Despite these advantages some 
drugs may not be suitable for the TDD route because the skin normally allows for the 
permeation of particles less than 500 Da.  This limits the number of likely drug  candidates that 
can be employed (Phatak and Chaudhari, 2012). Furthermore there is a lack of empirical 
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evidence regarding the mechanism of release (Samah and Heard, 2013), therefore more 
investigations considering this form of drug delivery is necessary to overcome these limitations 
in TDD.  
 
There is a growing interest in the development of efficient drug delivery systems targeted to the 
physiological sites of the body system. Several attempts have been investigated and ongoing 
research strives to develop the transdermal formulations of nanoparticles for the treatment of 
various skin diseases. In dermatology, nanosized particles have been widely studied resulting in 
many formulations entering clinical trials and some are still awaiting for approval (Onoue et al., 
2014). A number of biodegradable, biocompatible and non-toxic synthetic and semi-synthetic 
polymers have been investigated for their efficiencies as TDD systems. Examples of 
successfully studied polymers are highlighted (Table2.1). 
 
Table 2.1: Specialized polymeric nanogel systems in transdermal drug delivery. 
A. Improved drug permeation studies 
Polymer Loaded 
drug/protein/gene 
Reference 
 
Poly(lactic-co-glycolic acid) (PLGA)-Chitosanz 
 
Spantide II and Ketoprofen 
 
(Shah et al., 
2012) 
Poly(N-isopropylacrylamide-copolymerized-
acrylic acid)  (polyNIPAM) 
Methotraxate (MTX) (Warheit et al., 
2008) 
Tyrosine-derivative (PEG5K-b-
oligo(desaminotyrosyl-tyrosine octyl ester 
suberate)-b-PEG5K triblock copolymer) 
Sodium diclofenac 
 
(Batheja et al., 
2011) 
Chitosan Fluconazole (Mohammed et 
al., 2013) 
Eudragit RL 100 and Eudragit RS 100  Aceclofenac (Barry, 1987) 
Chitin Curcumin (Sabitha et al., 
2013) 
 
B. Improved drug efficacy with reduced side effects studies 
   
Celullose [hydroxypropylmethylcellulose] 
(HPMC), sodium carboxymethylcellulose 
Chlorpheniramine maleate 
(CPM) 
(Tas et al., 2003) 
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(NaCMC) and methyl cellulose (MC)  
N-isopropylacrylamide (NIPAM) and 
butylacrylate   (BA)                     
MTX (Murphy et al., 
2011) 
 
C. Optimisation  of polymeric nanogel properties studies 
   
Polymethacrylic acid (PMA) and polyglutamic 
acid (PGA) 
Doxorubicin (Band and 
Bronich, 2014) 
 
Chitosan Bovine serum albumin 
(protein) 
(Brunel et al., 
2009, Schütz et 
al., 2011) 
Poly [2-(dimethylamino) ethyl 
methacrylate],PDMAEMA, 
No drug/protein/gene (Meléndez-Ortiz 
et al., 2014) 
 
D. Stimuli responsive studies 
   
Polyacrylic acid Temozolodine (Wu et al., 2010) 
Poly(N-isopropylacrylamide) 
 
Indomethacin drug 
 
5-fluorouracil  
(Shi et al., 2010) 
(Wang et al., 
2008) 
poly(N-isopropylacrylamide-co-acrylamide) 
(poly (NIPAM-co-AAc)) 
Curcumin (Wang et al., 
2014) 
Chitosan 
 
Bovine serum albumin 
(protein) 
Doxorubicin 
(Yu et al., 2006) 
 
(Oh et al., 2010) 
Poly[2-(N,N-diethylamino)methacrylate] core 
and PEG 
Procaine hydrochloride (Oishi et al., 
2007) 
Poly(N-isopropylacrylamide- co-acrylic acid Caffeine (Samah and 
Heard, 2013) 
 
From the work highlighted (Table 2.1) research has shown that nanogels have the ability to 
potentiate drug penetration through all the skin layers as well as the blood circulation. Based on 
both in vivo and in vitro skin penetration, drug loading and entrapment of the nanogel 
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formulations was significantly enhanced, hence nanogels are considered safe and effective for 
TDD especially in dermatological conditions treatment. Also the pharmacokinetics of the drugs 
was improved and according to the in vitro cytotoxicity tests of the nanogels very low cytotoxicity 
resulted from these gel preparations. The prepared nanogel formulation showed better skin 
penetration mostly due to the enhanced contact between the drug and the skin resulting from 
more surface area and hydration. The formulation showed stability over the study period and 
showed substantial increase in the efficacy in animal studies. DPCNs formulations proved to be 
the better alternative for TDD of most drugs especially for chronic conditions treatment and 
eliminate the limitations of the TDDS. Although in most of these formulations chemical 
enhancers were used some of them had better skin penetration without the use of the 
enhancers, but by utilizing the occlusive and nano-carrier properties.During in vivo drug delivery 
covalently crosslinked nanogels present improved stability compared to the non-crosslinked 
nanogels, ensuring better controlled drug release (Liu and An, 2014). Nonetheless, the chemical 
crosslinking also raises safety concerns regarding its potential for toxicity due to either the 
covalent crosslinking remnants or the unpredicted side effects associated with drugs loaded 
during the chemical crosslinking procedure (Liu and An, 2014). Thus more studies are still 
required to assess the effect of nanogels in evaluating the gel’s in vitro stability, in vivo fate and 
cellular toxicity.  
 
2.6. Recent Advances in Polymeric Colloidal Nanogels 
Although the synthesis of nanogels has been extensively studied a number of challenges exist 
with the development of advanced colloidal nanogels where novel applications in various 
medical fields are being developed. This is evident from recent work of Raemdonck et al. (2009) 
which focused on new technologies for the formulation of nanogels with superior molecular 
structures which is a necessity for in vivo optimized drug delivery systems (Raemdonck et al., 
2009). Furthermore examples of the advancements are described below and they include 
application of liposomal nanogel, enzymatically crosslinked colloidal nanogels and stimuli 
sensitive (dual/multiple responsiveness) (Liu and An, 2014).  
 
2.6.1. Stimuli responsive polymeric colloidal nanogels / Targeted polymeric colloidal 
nanogels 
Stimuli sensitive nanogels may be termed as ‘intelligent nanogels’ or ‘smart nanogels’. The 
design of these nanogels is in such a way that they recognize their microenvironment, process 
and transmit a stimulus, and respond by producing a useful effect, and in doing so they mimic 
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living organisms’ responsiveness (Yan and Tsujii, 2005; Lu et al., 2013; Mura et al., 2013; 
Meléndez-Ortiz et al., 2014). Figure 2.4 shows how a stimuli sensitive nanogel behaves. 
Nanogels respond to the environment by changing their chemical or/and physical behavior, 
hence release of the drug encapsulated in the polymeric matrix in a controlled fashion (Oh et al., 
2007; du Toit et al., 2014). 
 
 
Figure 2.4: Proposed drug release from a nanogel in response to a stimulus applied. The model 
shows that the stimulus triggers physical changes in structure of the nanogel, resulting in 
swelling, erosion and ultimately releases the drug. (Adapted with the permission fromChacko et 
al. (2012). Copyright (2012) Elsevier). 
 
Intelligent drug delivery occurs either through exogenous stimuli i.e. light, ultrasound, electric 
fields and temperature or endogenous stimuli i.e. redox potential, pH, and enzymes 
concentration. The various types of stimuli with the ability to activate drug release at the desired 
time and location, allows for the flexibility of designing intelligent systems, therefore much 
research is directed towards the design of more sensitive specific stimuli with discrete 
variations. A specific sensitivity can be achieved by the incorporation of functional groups into 
the gels, enabling a response of the network structure to external triggers (Klinger and 
Landfester, 2012)] and so far a number of “smart” polymeric nanoparticle based drug delivery 
systems have been extensively studied and proved to significantly enhance the overall 
therapeutic outcome in various conditions (Oishi et al., 2007; Oh et al., 2010; Singka et al., 
2010; Murphy et al., 2011;Shah et al., 2012; Samah and Heard, 2013; Shang et al., 2013). 
These studies have shown that this type of TDDS may be applied to a variety of drugs including 
chemotherapeutics which are cytotoxic, as the polymeric film provides protection from the drug 
toxic effects and also targets only the affected tissues. Stimuli responsive polymeric nanogels 
are different from the other drug delivery systems and they possess a high application potential 
specifically due to the following reasons (Zha et al., 2011):  
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I. They have higher stability for prolonged drug release once they are absorbed into the 
skin because of the hydrophillic polymer and their chemically crosslinked structure. 
II. They have the ability to selectively enhance the uptake of the therapeutic drug into the 
pathological site. 
III. As drug release is modulated by stimuli, the drug loading capacity and bioavailability of 
the drug may be greatly enhanced as the therapy is targeted towards specific sites and 
also few side effects are expected from drug loaded stimuli responsive nanogels. 
IV. As nanogels are flexible carriers, they are capable of retaining any shape, they may 
enter the vascular surface and be attached to multiple places, they may also be 
applicable in different shapes of bone cavities, and hence they have a better chance of 
specific retention in the targeted disease site. 
 
Cumulative permeation profiles for caffeine loaded-poly (NIPAM-co-AAc) nanogels at 2–4 °C 
(Figure 2.5a), and room temperature (RT) (Figure 2.5b), with and without the addition of citric 
acid (CA) which is a pH modulator were investigated (Samah and Heard, 2013). This system 
comprised of NIPAM which is a temperature responsive monomer and AAc which is a pH 
(change in charges) responsive co-monomer. The in vitro TDDS permeation data of the 
caffeine-loaded poly (NIPAM-co-AAc) confirmed that, the nanogel significantly improved the 
delivery of caffeine across the epidermal membrane, compared to the saturated solution of the 
caffeine (Samah and Heard, 2013). The highest TDDS permeation was exhibited by the 
nanogel prepared at lower temperatures, hence, the thermal stimulus was the main factor 
determining the release of the drug (Samah and Heard, 2013). This is therapeutically significant 
in TDDS because nanogels prepared at lower temperatures can easily be delivered through the 
skin due to the greater pressure (change in gel conformity) as the temperature increases from 
2-4 to 32°C which is the temperature of the skin. The acidic environment of the skin (pH 4-7) 
would not be as strong as in the presence of the pH modulator, CA, thus, the pH change had no 
significant impact in this study (Samah and Heard, 2013). 
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Figure 2.5:Cumulative permeation profiles of a caffeine-loaded nanogel at (a) 2–4 °C, and (b) 
room temperature (RT). A loaded polyNIPAM nanogel and a saturated caffeine solution was 
used as a control (Adapted with the permission from Samah and Heard (2013). Copyright 
(2013) Elsevier). 
 
According to Mura et al. (2013)recent advances are geared towards the design of superior 
smart nanotechnological drug delivery systems. However only a few have been tested using in 
vivo preclinical models, very few have reached the clinical stage and a number of in vitro studies 
have been done to confirm their efficacy .These stimuli-responsive drug release strategies rely 
on the changes in specific physical or chemical properties of the environmental medium which 
are sometimes limited for in vivo applications, hence there are inadequate in vivo studies 
(Dorwal, 2012: Wang et al., 2014). This poses a challenge in the whole chain of the study of 
stimuli responsive DPCNs in TDDS; hereafter strategies on how to effectively characterize 
these systems are among the issues deserving a more comprehensive research attention. 
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2.6.2. Multiple (dual) stimuli responsive polymeric colloidal nanogels 
Multi-stmuli responsive polymeric nanogels are nanoparticulate based drug delivery platforms 
releasing a drug in response to two or more external/internal signals, these signals may either 
occur concurrently or sequentially from gel preparation to its delivery into the targeted cells 
(Chiang et al., 2012; Cheng et al., 2013). These nanogels may be formulated from two or more 
polymers (copolymers) grafted together ( Mahmoud et al., 2011;Chiang et al., 2012). Currently 
mutli-stimuli-responsive nanoparticles have indicated significant in vitro and/or in vivo drug 
release profiles improvements (Pasparakis and Vamvakaki, 2011; Cui et al., 2012; Cheng et al., 
2013) these nanoparticulate based drug formulations may have tremendous potential for 
targeted TDDS. Recently a polymer backbone of poly thioether ketal’s has been functionalized 
with dual stimuli responsive counterparts and has been employed by Mahmoud and co-workers 
(Mahmoud et al., 2011) for the delivery of proteins. The results obtained with this polymer 
showed an enhanced delivery system directed towards inflammation responsiveness. This 
polymer consists of a pH and oxidative sensitive components that undergoes programmed 
degradation in the presence of inflammatory reactions (H2O2 and acidic pH). Since the skin is 
one of the organs prone to inflammation due to a number of causes from genetic disorders to 
general hypersensitivity reactions, this approach may be modified and applied in TDDS either 
for local or systemic effects. Figure 2.6 demonstrates a nanogel complex with a dual stimuli 
response, in response to low pH this complex changes its features i.e. charge changes from 
negative to positive (Zhuang et al., 2014). The nanogel has the ability of sequentially releasing 
the hydrophobic guest molecules i.e. drug molecules in response to redox stimuli. The 
polyelectrolyte detaches from the nanogel, allowing reduction occurrence, which is followed by 
concomitant targeted release of the guest molecules from the nanogel (Zhuang et al., 2014). 
This dual sensitivity ensures that both stimulus are concurrently present for drug release to 
occur, ensuring further improved site specific drug delivery (Zhuang et al., 2014). 
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Figure 2.6: This nanogel-polyelectrolyte complexis modified with two stimuli responsive 
functionalities. (Adapted with the permission fromZhuang et a. (2014). Copyright (2014) 
American Chemical Society). 
 
Although various multiple intelligent nanogels have been successful in showing the predictions 
of these systems for various TDD applications, detailed research on the functional aspects of 
these systems is still required. Full details on how to maximize their potential, how they are 
affected by the presence of other compounds (i.e. preservatives) and the working formulas for 
their preparation using diverse stimuli responsive groups in TDDS are also required.  
 
2.6.3. Nanogels as carriers for liposomes / liposomal nanogels 
Liposomes are drug carriers that are used to enhance drug permeation through the skin in 
TDDS. By combining the advantages of both liposomes and nanoparticle-based gel vehicle 
(Kermany, 2010; Murphy et al., 2011) a liposomal nanogel with superior properties is 
formulated. A liposomal nanogel may be described as lipid-coated drug loaded nanoparticles 
dispersed in a gel system (Murphy et al., 2011). The liposomes are formed by the self-assembly 
of amphiphiliclipid molecules into a lipid bilayer membrane surrounding the aqueous media 
(Zhang et al., 2013a) amphiphilic substances such as phospholipids and cholesterol are 
incorporated in the liposomes (Zhang et al., 2013a). These carriers may be used for both 
hydrophilic and lipophilic drugs molecules (Cevc, 2004; Honeywell-Nguyen and Bouwstra, 
2005), therefore the synergistic effect of the gels and liposomes may be applicable in the drug 
delivery for a variety of drugs in TDDS. In TDDS the use of chemical enhancers may be avoided 
as the lipid coating enhances penetration of sufficient amount of drug molecules through the 
skin. A number of studies where nanogels have been used with liposomes, have been reported 
for delivery of drugs in the treatment conditions such of microbials and wounds (Fang, 2006). 
The release and entrapment efficacy of an antimicrobial drug chloramphenicol from a liposomal 
gel was studied and the penetration of the drug through the mucous membrane was greatly 
improved. The gel-liposomes (GLs) were prepared using a thermo-responsive gel as the 
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aqueous inner core of the liposome. The lipid bilayer of the delivery system was destroyed to 
confirm the stimuli responsiveness and sustainaibility of the gel (Zhang et al., 2013a). Moreover 
an example of a lipid coated nanogel was investigated and proved to be superior to the use of 
either liposome or nanogel on their own in TDDS (Murphy et al., 2011). Figure 7 shows a 
liposome formulation with a high bilayer melting temperature (Tm) and sodium alginate is 
encapsulated in the liposomal core. To prove their hypothesis the liposomes were placed in an 
aqueous buffer containing calcium chloride, and the temperature was raised up to Tm, allowing 
the permeation of Ca2+ ions through the bilayer and into the core, whereupon these ions 
resulted into the gelation of the encapsulated alginate. The GL showed an improved trans-
bilayer permeability near the Tm (Zhang et al., 2013a). The lipid bilayer is expected to enhance 
the nanogel penetration, after passing through the skin the gelled alginate is unrestricted by the 
lipid layer, it may release the drug in a controlled manner as expected (Zhang et al., 2013a). 
From this study it is established that employing both a stimuli sensitive polymer/monomer and 
lipid bilayer in a single system has the potential of drastically improving TDD of drug loaded 
colloids. 
 
 
Figure 2.7:Route to the preparation of alginate nanogel liposomal templates. Reaction involves 
treating liposomes encapsulating sodium alginate to a 10 mmol/L CaCl2 solution at 
temperatures near the Tm of the lipid. The increased transmembrane permeability permits Ca2+ 
to diffuse into the liposomes and ionically cross-link the alginate to form a nanogel. Upon 
removal of the lipid shell, alginate nanogels are isolated (Adapted with the permission from 
Hong et al. (2008). Copyright (2008) American Chemical Society). 
 
According to Kermany (2010) the liposome mechanism of action as a penetration enhancer in 
TDDS through the skin is not clearly defined, but some researchers propose that liposomes 
disrupt the skin resulting in drug absorption into the skin (Fang, 2006). The composition of the 
lipid in liposomes and the concentration of the liposomes used to formulate the GLs  are critical 
factors in determining the rheological gel properties, thus the drug release from the delivery 
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system, such as the release of a lipophilic drug, is greatly affected by lipid concentration  
(Mourtas et al., 2008).  However, research on liposomal nanogel is still at its early stages of 
growth, hence fundamental studies on interactions between nanogels and liposomes, as well as 
their interaction with the skin layers in TDDS are yet to be discovered. 
 
2.6.4. Enzymatically crosslinked nanogels 
In this application enzymes are used as biological catalysts to mediate the formation of the 
nanogel by utilizing a few advantages such as the reduced need to use toxic polymers as 
crosslinkers, as they have a high selectivity and achieve crosslinking under mild conditions 
(Singh et al., 2013; Klinger and Landfester, 2012). Very few research advances have been 
reported on enzyme-mediated hydrogelation, especially in TDDS. One example is natural 
gelation process of fibrin, where they replaced a chemical crosslinker with a naturally occurring 
protein (fibrin) in the body to improve the gel characteristic of a DPCN (Singh et al., 2013). An 
ongoing study was carried out by utilizing dextran as a polysaccharide that is cleaved with 
dextranase upon incubation (Klinger and Landfester, 2012). Nanogels consisting of 
polyacrylamide (PAAm), crosslinked with dextran methacrylate (Dex-MA), were designed to be 
partially biodegradable by enzymatic cleavage of the methacryl-functionalized polysaccharide 
chains. It was established that the sensitivity of nanogels towards enzymes is of great 
advantage for release applications and it gives a chance for the development of more dual 
sensitive nanogels, hence improving the efficacy of DPCNs (Klinger and Landfester, 2012). 
Even though dextran nanogels are presently used for slow intracellular delivery of proteins, 
future research may explore the potential of increasing their application for other therapeutics. 
Although this nanogel advancement is not yet fully investigated it seems to be a better 
intervention, releasing the drug at site specific enzymatic responses. It allows the reduction of 
the toxicity of chemical crosslinkers while releasing the drug in a controlled manner. It also 
creates more research in drug delivery field for generating further specialized nanogels in TDDS 
biomedical application. 
 
2.7. Concluding Remarks 
It has been elucidated that physicochemical modifications of DPCNs in drug delivery systems 
have provided various advantages to TDD technology. The most common limitations associated 
with conventional transdermal based drug delivery systems are skin irritations, toxicities and 
unfavorable pharmacokinetics, whereas with the application of modified DPCNs the therapeutic 
outcomes of various drug molecules could be drastically improved. Even though various 
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investigations have been done to prove the effectiveness of DPCNs there are still some gaps in 
the explanation of the nanogels and their advanced developments as there are less preclinical 
development studies involving their application in TDDS. Hence there is still some necessity for 
research directed towards the improvement of thein vitro, ex vivo and in vivostudies of drugs 
delivered using the DPCNs via the transdermal route of drug administration. These 
advantageous properties associated with DPCNs have created a unique research expansion, 
diagnostic and pharmaceutical science research and development opportunities in transdermal 
application. 
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CHAPTER 3 
A NOVEL BIOACTIVE COPPER COMPLEX WITH PREDNISOLONE SUCCINATE AND 
GLYCYLGLYCINE: SYNTHESIS, CHARACTERIZATION AND BIOLOGICAL EVALUATION 
FOR TRAPS MANAGEMENT 
 
 
3.1. Introduction 
Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS)is among inherited 
genetic auto-inflammatory disorders caused by mutations in the TNF receptor, coded by the 
TNFRSF1A gene (Meiorin et al., 2013; Standing et al., 2013). TRAPS disorder is characterized 
by seemingly unprovoked recurrent episodes of fever and severe localised skin inflammation 
(McDermott et al., 1999; Kastner and O'Shea, 2001; Vitale et al., 2013; Meiorin et al., 2013). It 
is a lifelong condition and usually begins in early childhood with symptomatic episodes lasting 
between 1-3 weeks (Meiorin et al., 2013). Therefore the efficacy and the overall therapeutic 
outcome of the current agents are the basic concern in the treatment of TRAPS. There is still no 
proven treatment for this disorder and oral corticosteroids are being used as first line treatment 
to relieve the inflammatory symptoms. However with long-term use of the present 
corticosteroids may lead to serious side effects. 
 
Corticosteroids exert their effect through the suppression of the immune system and the various 
inflammatory pathways. Hence they are used for the genetic auto inflammatory disorder TRAPS 
(Edwards, 2014). Currently, for the treatment of TRAPS, oral corticosteroids are preferred over 
topical corticosteroids, due to their high efficacy in the management of TRAPS. However, oral 
corticosteroids exhibit more serious side effects such as the suppression of the hypothalamic-
pituitary-adrenal axis and erratic absorption kinetics. Hence, in this research, a metal-drug 
complex with superior properties compared to conventional corticosteroids such as improved 
anti-oxidant/ant-inflammatory efficacy and permeation through the skinwas formulated.  
 
Metal-drug complexation involves the co-ordination of metal ions to a ligand (drug) and in this 
study Copper (II) (Cu2+) was complexed to prednisolone succinate (model drug). Cu2+ 
complexes are widely used in cancer treatment as therapeutic drugs (Gokhale et al., 2001; 
Malon et al., 2001; Singh et al., 2011; Chemik, 2013; Ng et al., 2014), and various observations 
have indicated that Cu2+ complexation enhances the anti-inflammatory effect of a number of 
drugs, resulting in more potent coordination compounds compared to the free ligands (Cini et 
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al., 1990; Sorenson, 1976). The therapeutic effects of Cu2+ complexes have been well studied 
and were found to be beneficial. One of its advantages is the ability to penetrate through the 
stratum corneum of the skin, reaching both the epidermis and dermis layers of the skin and 
becoming available for systemic and local effects (Hostynek et al., 2006; Szymanski et al., 
2012). Therefore, the copper complex may be an alternative ant-inflammatory bioactive via the 
transdermal route.  
 
Copper is depleted during inflammation and the body inevitably transports the copper to the 
inflamed tissue (Hostynek et al., 2011). The degradation and elimination of copper is managed 
by the body, as it is one of the essential micro-elements for human life and in contrary to other 
transition metals, like ruthenium it is considered less toxic (Szyman´ski et al., 2012; Chemik, 
2013). Although Cu compounds in therapeutic formulations are much higher than the normal 
daily requirements, it was established by Sorenson (1976) that patients with chronic 
inflammation require more than the normal requirements for the anti-inflammatory activity of the 
compounds, henceforth the risks of toxicity are minimized with the formulations (Sorenson, 
1976). Addition recent and historical data has shown that all forms of copper are safe for use in 
humans either in the form of metal, drug or complex (Roy et al., 2006; Hostynek et al., 2011; 
Stevenson et al., 2013). Hence the medicinal uses and applications of Cu complex are of 
increasing clinicalimportance.  
 
The objective of the current study was to employ the Cu(II) coordination strategy to link PS in 
the presence of a modulating glycylglycine (glygly) ligand to give a [Cu(glygly)(PS)] complex 
with improved anti-inflammatory/anti-oxidant activity relative to the free PS. The success of the 
coordination was confirmed using NMR, IR, mass spectrometry and UV–visible absorption 
spectroscopy. Furthermore additional studies were carried out, such as thermal analysis 
(TGA/DSC), X-ray diffraction, antioxidant activity assay, in vitro permeation studies, and a 
cytotoxicity assay.  
3.2. Materials and Methods 
3.2.1. Materials 
Copper (II) nitrate, glycylglycine (glygly), triethylamine, DPPH (1, 1-diphenyl-2-picrylhydrazyl), 
lipoxygenase enzyme linoleic acid,and prednisone succinate (PS) salt, deuterated methanol 
(CD3OD) were all purchased from Sigma-Aldrich (St. Louis, MO, USA). Buffering constituents: 
potassium chloride, potassium dihydrogen phosphate, disodium hydrogen phosphate, sodium 
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chloride, sodium hydroxide pellets, and hydrochloric acid, as well as D-methanol, dimethyl 
sulfoxide (DMSO), and boric acid were purchased from Merck (Wadeville). Deionised  water 
was obtained from a Milli-Q system (Milli-Q, Millipore, Johannesburg) and methanol from 
Rochelle Chemicals (Johannesburg, South Africa). The pig skin tissue was obtained from the 
University of the Witwatersrand animal unit (South Africa, Johannesburg). 
 
3.2.2. Synthesis of the [Copper(glycylglycine)(prednisolone succinate)]  complex 
The metal complex was prepared using methods adapted with modifications from Feng et al. 
(2014) and Sorenson (1976). PS salt (0.22mmol) in methanol was stirred continuously, adding a 
solution of glygly (0.22mmol) in deionised water. A drop of triethylamine was added to the 
reaction mixture, which was stirred for 30minutes before the addition of copper (II) nitrate 
(0.26mmol) (the reaction was done in a controlled pH of 7). The resulting blue solution was 
stirred for 2hours. Thereafter [Cu(glygly)PS] complex was precipitated using diethylether, 
filtered and washed with double deionised  waterthree times and dried in vacuo.  
 
Molecular simulation of the free PS drug and [Cu(glygly)(PS)] was performed using ChemBio3D 
Ultra 11.0 (CambridgeSoft Corporation, UK), where the structures of the PS and complex were 
visualised in their geometric preferences.  
 
3.2.3. Chemical structural analysis of the [Copper(glycylglycine)(prednisolone 
succinate)]  complex 
Fourier transform infrared (FTIR) spectrumwas generated on[Cu(glygly)(PS)] compared to the 
native PS. FT-IR Spectrometer (PerkinElmer Inc., Waltham, Massachusetts, USA) was used to 
assess the vibrational transitions in the chemical structures of these compounds. Samples were 
placed on a single bounce diamond crystal and processed by a universal attenuated total 
reflectance (ATR) polarization accessory, at a resolution of 4cm−1, with the spectrum ranging 
from 4000 to 650cm−1. 
 
3.2.4. Analysis of the chemical shifts of the [Copper(glycylglycine)(prednisolone 
succinate)]  complex 
The magnetic properties of the [Cu(glygly)(PS)] complex compared to the native PS was 
analysed using the nuclear magnetic resonance (NMR) spectroscopy (1H and 13C spectra) 
(Bruker BioSpin GmbH, Germany). All 1H NMR spectra were recorded on a Bruker Avance 
spectrometer operated at 300.13 MHz and all 13C NMR spectra were recorded on a Bruker 
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Avance spectrometer operation at 75.48 MHz. The samples were analysed by preparing 
15mg/mL of each sample in deuterated methanol (CD3OD). 
 
3.2.5. Analysis of the UV–visible absorption spectrometry of 
the[Copper(glycylglycine)(prednisolone succinate)] complex 
The UV–visible absorption of [Cu(glygly)(PS)] and PSwas determined using the double-beam 
UV-Vis spectrophotometer (PerkinElmer Spectrum 100, Llantrisant, Wales, UK) at room 
temperature. The spectrometric measurements were carried out over the UV–visible excitation 
wavelength range of 200-700nm for native PS and [Cu(glygly)(PS)]complex. 
 
3.2.6. Identification of the molecular fragmentations of the 
[Copper(glycylglycine)(prednisolone succinate)]  complex 
Molecular fragmentations of the PS and [Cu(glygly)(PS)] were identified using a quadrupole ion 
trap mass spectroscopy (Finnigan-MAT model LCQ, San Jose, CA, USA), equipped with 
electrospray ionization (ESI). Samples were dissolved in methanol (1mg/L) and introduced to 
the mass spectrometer at a flow rate of 3.0μL/min through the ESI. The major isotopic ions from 
PS and [Cu(glygly)(PS)] complex were mass selected with a 5m/z window and subjected to 
collision-induced dissociation (CID), to examine the fragmentation reactions of the isotopic ions. 
  
3.2.7. Evaluation of the degree of structural order of the the 
[Copper(glycylglycine)(prednisolone succinate)]  complex 
TheX-ray Diffraction (XRD) pattern of the [Cu(glygly)(PS)] complex compared to the the drug 
was investigated with the X-ray diffractometer (ULTIMA-III, Rigaku, Japan), using nickel-filtered 
Cu Kα radiation (a voltage of 40kV and a current of 30mA) for pure drug and formulated 
complex. The X-ray diffractograms were attained at the scanning rate of 5°/min with the 
scanning scope of 2θ from 5° to 90° at room temperature.  
 
3.2.8. Determination of thermal properties of the [Copper(glycylglycine)(prednisolone 
succinate)]  complex 
A differential scanning calorimeter (DSC) (Mettler Toledo, DSC1, STARe System, 
Swchwerzenback, Switzerland) was used to determine the thermal properties of the 
[Cu(glygly)(PS)] complex compared to the drug. The analysis was conducted using the basic 
DSC and alternating DSC (ADSC) at a temperature range of 25-350°C, ramped at 10°C/min 
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under a N2 atmosphere. All samples were weighed (10mg) on perforated 40μL aluminum 
crucibles. 
 
3.2.9. Determination of thermal properties of the [Copper(glycylglycine)(prednisolone 
succinate)]  complex 
Thermogravimetric analysis (TGA) was performed using a Toleda TC15 TA controller (Mettler). 
It was used to measure how the changes in the chemical and physical properties of the 
[Cu(glygly)(PS)] complex compared to the drug. Dried sample measurements of 5mg were 
analysed after tarring the empty crucibles. The analysis was carried out from 25 to 800°C, using 
a heating rate of 10°C/min under a constant nitrogen gas flow. The percentage weight losses 
incurred during the heating cycle were estimated using the associated software (STARe). 
 
3.2.10. Evaluation of the antioxidant/ antinflammatory activities of the 
Copper(glycylglycine)(prednisolone succinate)]  complex 
3.2.10.1. DPPH free radical scavenging assay 
TheDPPH free radical scavenging assays of [Cu(glygly)(PS)] complex compared to the free 
drug (PS) and ascorbic acid were determined by dissolving these samples in a methanolic 
solution (1mmol/L). Sample solutions were allowed to react for 30min with DPPH (1mmol/L) in 
the absence of light, thereafter the decrease in absorbance of these samples was measured at 
517nm using UV-Vis spectroscopy (PerkinElmer Spectrum 100, Llantrisant, Wales, UK). The 
percentage inhibition of radical scavenging activity was calculated using the following formula: 
%Inhibition = (
Ab−As
Ab
) × 100                                                                        Equation 3.1 
 
Where As is the absorbance of the sample after reacting with DPPH and Ab is the absorbance 
of the blank sample (DPPH in methanolic solution) (Awah et al., 2012; Hong and Yang, 2013; 
Jothy et al., 2011). 
 
3.2.10.2. 5-lipoxygenase inhibition assay 
The 5-lipoxygenase (5-Lox) inhibition assays of [Cu(glygly)(PS)] complex, free drug (PS) and 
ascorbic acid were determined. Each of the solutions used to measure the percentage 5-Lox 
inhibition assay was prepared using 0.05mL of the inhibitor (0.125mmol/L), 1.95mL of the 
enzyme (5-Lox) solution (10 000 units/mL) and 2mL of the substrate solution (0.125mmol/L), all 
of which were made in borate buffer (0.2M). The reaction solutions were left to react for 15min 
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at room temperature and subsequently the absorbance was measured using UV-Vis 
spectroscopy (PerkinElmer, Lambda 25 UV/Vis spectrometer, UK) at 234nm. A blank sample 
was prepared in a manner omitting the inhibitor from solution. The percentage inhibition of 
[Cu(glygly)(PS)] compared to the drug and ascorbic acid was determined using an equation 
adapted from Feng et al. (2014) as follows:  
%5 − Lox inhibition = (
A′
A0
) × 100                                                                                                     Equation 3.2 
 
Where A′ is the absorbance of the reaction mixture and A0 is the absorbance of the blank 
sample (Maiga et al., 2006 and Helle Wangensteen, Samuelsen,Malterud, 2004). 
 
3.2.11. In vitro permeation studies 
Full-thickness of a pig’s ear skin was separated from cartilage using a scalpel and dermis was 
wiped with isopropyl alcohol to remove any residual adhering fat. The skin was washed with 
deionised water, wrapped in aluminum foil and stored in a freezer at −20°C until required. Prior 
to the diffusion experiment the epidermis was thawed at room temperature and cut to a cross-
sectional area of 4cm2. 
 
The permeation studies were performed according to method adapted with modifications from 
Wissing and Muller (2002).These studies were carried out using the Franz diffusion cell with a 
diffusional area of 3.14cm2 and a receptor chamber with 12mL volume capacity. This chamber 
was filled with phosphate buffer saline (PBS) pH 7.4 and maintained at 37°C in order to ensure 
a surface skin temperature of 32°C. Weighed samples (5mg) of the drug and complex, which 
were dispersed in 3mL of PBS and evenly distributed on the surface of donor compartment. At 
hourly time intervals 0.2mL samples were taken from diffusion medium and the volume of the 
diffusion medium then replaced with PBS. Sampling was done every hour for the first 10h and at 
24h. The samples were diluted with 2.8mL of PBS before analysis and PBS was used as the 
reference. Absorbance was determined using the UV-Vis spectrophotometry (PerkinElmer 
Spectrum 100, Llantrisant, Wales, UK) at 248nm and 242nm for the PS and complex (Figure 
3.1) respectively. Calibration curves were constructed for concentration calculations. The flux 
and permeation coefficient (𝑃𝑘) were calculated using the following equations:  
Js =
Qs
AT
                                                                                                                          Equation 3.3 
Pk =
Js
Cdonor
                                                                                                                   Equation 3.4 
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Where 𝐽𝑠 is the flux (µg/cm2/hr), 𝑄𝑠 is the amount of drug (µg) and AT is the area (cm2) by time 
(hr). 𝐶𝑑𝑜𝑛𝑜𝑟 Concentration in the donor compartment. 
 
Figure 3.1: The calibration curve of (a) PS at 248nm and (b) [Cu(glygly)PS complex at 242nm. 
 
3.2.12. In vitro cytotoxicity analysis 
Human Dermal fibroblast adult (HDFa) cells (Cell Applications Inc. (CAI), San Diego, USA) 
wereseeded in culture flasks with complete media consisting of GIBCO®-Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 2mM glutamine and 
100U/ml penicillin/streptomycin (Sigma-Aldrich; St. Louise, MO, USA). The flasks used for the 
culturing were coated with poly-l-lysine (Sigma-Aldrich; St. Louise, MO, USA) 24h before cell 
culture was initiated. During cell culture the cells were then maintained in an incubator (RS 
Biotech Galaxy, Irvine, UK) with a humidified atmosphere of 5% CO2 at 37°C. 
  
Cultured HDFa cells were seeded at a concentration of 15000 cells/well. After culturing for 48h 
in complete media, PS, and [Cu(glygly)PS] were added at a concentration of 1, 2, 10, 20, 
100,and 200µg/ml  drug (PS) equivalent concentrations and the cells were further incubated for 
48h. At the end of the incubation the medium was removed and 100μL of MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution (diluted in a culture media with a 
final concentration of 0.5mg/mL) was added and incubated for another 4h. Following incubation 
the medium was removed through centrifuging (Optima® LE-80 K, Beckman, California, USA) 
at 3000rpm for 5 min. Next the remaining formazan crystals were dissolved by incubation for 30 
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min in 100μL of dimethyl sulfoxide (DMSO) and analysed with microplate reader (FilterMax™ F5 
Multi-Mode Microplate Reader, Molecular Devices, USA) 
 
The number of viable cells is directly proportional to the quantity of formazan product formed as 
quantified by absorbance at 570nm (Mohanty et al., 2012), using a microplate reader. Results 
are presented as %cell viability (CV) (mean ± standard deviation), the percentage of viable cells 
was calculated using the following equation:   
 
%CV =
absorbance read in treated cells
absorbance  read in control(untreated)cells
                                                                  Equation 3.5 
 
3.3. Results and Discussions 
3.3.1. Characterisation and evaluation of the formulations 
The [Cu(glygly)(PS)] complex was synthesised by the by reacting a PS with Cu (NO₃)₂ and 
glycylglycine as a ligand in a 1:1.2:1 ratio respectively. The resulting [Cu(glygly)(PS)] complex 
was obtained as a blue-green fine powder and percentage yield was 60- 69%. Shown in Figure 
3.2(a) are the 3D visualization models of the geometrical preferences of the PS and 
[Cu(glygly)(PS)] after molecular simulation, and in Figure 3.2(a) the reaction scheme for the 
preparation of the [Cu(glygly)PS] complex. 
 
 
 
 
 
 
 
 
 
 
 
a) 
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Figure 3.2: Visualization of geometrical preferences of (i) PS and (ii) [Cu(glygly)PS] complex 
after molecular simulation. Color codes: C (grey), O (red), N (white), H (pink) and Cu (blue), and 
b) reaction scheme for the preparation of the [Cu(glygly)PS] complex. 
 
The complex is expected to exert its anti-inflammatory effects through a number of pathways 
(Lewis, 1984). The different pathways of its anti-inflammatory effects are shown in Figure 3.3, 
most of the [Cu(glygly)PS]  complex is expected to dissociate once inside the body system. The 
drug and /or the [Cu(glygly)PS] complex may exert their own anti-inflammatory effects, while the 
Cu2+ binds to amino acids readily available in blood, or remain with the modulating ligand glygly 
(amino acid). The anti-inflammatory activity of the amino acid bound Cu2+ may be to the Cu-
amino acid complex or its metabolised residue.  
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Figure 3.3: The proposed anti-inflammatory effects caused by [Cu(glygly)(PS)] complex 
(Adapted with modifications from Lewis, 1984). 
 
3.3.2. Chemical structural evaluation of the the [Copper(glycylglycine)(prednisolone 
succinate)]  complex 
In order to investigate the coordination mode of PS to the metal in the complex, the FTIR 
spectrumof the parent ligand was evaluated in relation to the complex. The FTIR spectra of 
glycylglycine, PS and [Cu(glygly)(PS)] are shown in Figure 3.4 a,b and c, respectively. The 
absorption bands are discussed as marked in Figure 3.4 (inserted boxes). PS shows 
characteristic absorption bands in the region of 2929, 1719, 1654and 1571cm–1which were 
assigned to C-H (alkanes), C=O (alkyl ketone), C=O (ring ketone), and C=O (sodium 
hemisuccinate) vibrations, respectively. Most of the bands seen in PS are also present in the 
complex, with an important change in the shift of the asymCOO- upon complexation with copper. 
The absorption band at asymCOO 1572cm-1 and aymCOO 1370cm-1 in the ligand spectrum was 
shifted to 1590 and 1320cm–1 respectively. These shifts are a result of the withdrawal of electron 
density from the C-O bond due to coordination of the “O” donor to the copper ion. 
Relative to the spectrum of the free drug there are new molecular vibrations in the spectrum of 
the complex which infers the presence of the glygly dipeptide. Glycylglycine (glygly) contains 
three potential donors namely the N-amino, NH-peptido and O-carboxylate group. Additionally 
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glygly has a zwitterion ionic structure evident by the presence of the protonated N-amino and 
ionised O-carboxylate group (NH3+ and COO-) groups respectively. The νas(NH3+), and δ(NH3+) 
bands at 3015cm− in free glygly are red shifted to 3260 and 3249cm−1 in FTIR spectrum of the 
complex. This indicates that the NH3+ groups are deprotonated after coordination to the metal 
center.Notably the stretching band corresponding to 1134cm-1 for free glygly is shifted to 
ν(C4’−Namino) (~1132cm−1) in the spectrum of the complex. 
The (NH) peptide band at 3284cm-1 assigned to free glygly appeared at 3329cm−1in the 
spectrum of the complex and this implies that the NH-peptide remains protonated and possibly 
interacts as a donor to the copper metal center.The shift in the wavenumber of 1602 for 
ν(COO¯) asymmetric stretching O-carboxylate group of free glygly to higher wavenumber 
(∆vCOO- of 50cm-1) is indicative of coordination to the metal center (Mandal et al., 2015).  Both 
predicted and experimental results reported for copper (glygly) complexes give relative higher 
wavenumber of when coordination via the O-carboxylate group occurs. However the FTIR of the 
complex contained several overlapping bands in the regions of 1600-1500 cm−1 of which 
rendered it difficult to make an accurate characterisation. On closer evaluation of the FTIR 
spectrum there was a slight change to the symmetric (COO−) stretch at 1403 to 1393cm−1, 
which implies that copper may be coordinated to O-carboxylate donor of glygly.Therefore it may 
be established that in the copper (II) complex, the dipeptide acts as a tridentate ligand (N-
amino, NH-peptido donors and O-carboxylate) in the presence of PSA.  
 
 
 
Figure 3.4: The FTIR spectra of a) Glycylglycine, b) PS, c) [Cu(glygly)(PS)]. 
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With all these shifts and new bands appearing in the complex spectrum it may be established 
that the [Cu(glygly)(PS)] complex was successfully  formed.The nature of metal–ligand bonding 
is confirmed by the newly formed band at ~510 and ~ 440cm–1 in the spectra of the complex 
(Figure 3.5) which is tentatively assigned to Cu–N and Cu–N vibrations, a comparable band was 
observed in the studies of copper complexes by Baran (2005) and Zhang et al. (2010). 
 
 
Figure  3.5: The FTIR of the complex and drug at lower wavelengths, the red spectrum being 
the [Cu(glygly)(PS)] complex. 
 
3.3.3. Evaluation of the chemical shifts of the [Copper(glycylglycine)(prednisolone 
succinate)]  complex 
The comparative 1H NMR spectra of PS and [Cu(glygly)(PS)]  are shown in Figure 3.6a and b, 
respectively. To be noted were the broad 1H NMR bands of the [Cu(glygly)(PS)] complex, in 
comparison to the 1H NMR spectrum of free PS. The NMR spectrum of the Cu (II) complex 
shows a slightly upfield chemical shift (δ), relative to the free PS. For example 1H signals at 
δ2.49 and 2.68 were assigned to the methylene protons at C23 and 24 in the free ligand and 
these peaks appeared relatively up field values (2.33 and 2.61) indicative of metal coordination. 
It is possible that the copper complexation creates a shielding effect, as copper (II) is known to 
be paramagnetic, resulting in protons experiencing an overall lower effective magnetic 
environment, with these signals appearing upfield. Similar observations for copper (II) 
complexes have been reported (Tella and Obaleye, 2009). Overall the chemical shifts were 
relatively small, implying that delocalization of spin density from the metal into molecular orbitals 
of ligands was marginal (Ramadan et al., 2004).  
Similar slight upfield shifts are also noted in 13C NMR spectrum of PS and [Cu(glygly)(PS)]   
(Figure 3.7a and b, respectively). There is a significant shift for the C18 of adjacent carbon C17 
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hydroxy group undergoing some weak interactions after metal coordination. Additionally, C23 
and 24 show light movement to upfield values (24.84, 31.68 to 24.79 and 30.69).  
 
Figure 3.6: Comparison of 1H NMR for (a) PSA and (b) the [Cu(glygly)(PS)] complex in CD3OD. 
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Figure 3.7: Comparison of 13C NMR for (a) PSA and (b) the [Cu(glygly)(PS)] complex in CD3OD 
 
Based on the characterisation data it is indicated that the PS ligand is monodentate, glygly is 
tridentate and the binding sites are dipeptide nitrogen, amino and carboxylato oxygen atoms in 
the [Cu(glygly)(PS)] complex. The proposed structure of [Cu(glygly)(PS)] complex is shown 
along with the 1H NMR spectra (Figure 3.6b) with chemical formula of C29H37CuN2O11 and a 
molecular weight of 653.16m/z. 
 
3.3.4. Evaluation of the UV–visible absorption spectrometry of the 
[Copper(glycylglycine)(prednisolone succinate)]  complex 
The UV-VIS spectrum of the complex shows maximum absorption at 242nm (Figure 3.8a) which 
is lower than that seen in the free drug which is at 248nm and this is due to the charge transfer 
transitions that occur during the complexation which is indicative of metal complexation (Ahmed 
et al. 2012).  Since the [Cu (glygly)(PS)] complexis blue-green in color the expected absorption 
is at 650-750nm. This is evident by the observation of a very weak and broad band at ~700nm 
(Figure 3.8b) which is due to d-d transitions (metal-to-ligand charge transfer). This absorption 
band suggests that this complex may be tetrahedral in structure, as presented in the proposed 
structure (Ahmed et al. 2012). Moreover, these absorption band patterns are compatible with 
absorption spectra of reported copper complexes (Azzellini et al., 2010; Dias et al., 2010).  
 
 
 
 
Figure 3.8: The UV/Visible of complex at (a) 200-300nm and (b) 400-800nm in methanol. 
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3.3.5. Identification of the molecular fragmentations of the 
[Copper(glycylglycine)(prednisolone succinate)]  complex 
The mass analysis can play an important role in confirming the monomeric Cu(II) complex. In 
the free ligand [M+] loss of succinate to give prednisolone was assigned to m/z 383 for the 
fragment [M-succinate +Na+]. No [M+] ion was observed. Additional m/z for dimeric ions were 
observed at m/z 943 [2M+2succinate +Na+] and 949 [2M+2succinate +2Na+)].  
 
The molecular ion peak of [Cu(glygly)(PS)] was observed at m/z 690.7845 [M+K], with a 
fragment for the free prednisolone succinate ester observed at m/z 459.2015 [PS]+. Mass 
spectra the complex are well agreed with their proposed structures, with similar studies that 
undertaken by (Kowcun et al., 2012). Based on the characterisation data, it is indicated that the 
PS ligand is monodentate, glygly is tridentate and the binding sites are dipeptide nitrogen and 
carboxylato oxygen atoms, in the [Cu(glygly)(PS)] complex. The proposed structure of 
[Cu(glygly)(PS)] complex is shown along with the 1H NMR spectra (Figure 3.6b), with a chemical 
formula of C29H38CuN2O11 and a molecular weight of 691m/z was obtained via HR-ESI-MS. 
 
3.3.6. Evaluation of the degree of structural order of the 
[Copper(glycylglycine)(prednisolone succinate)]  complex 
The XRD analysis was performed to evaluate any changes in the crystalline nature of the 
complex compared to the free ligand. Figure 3.9a and b illustrates the XRD patterns for 
complex and free ligand PS. One sharp characteristic peaks is observed around 2θ = 18-22 for 
both samples and the intensity of the peak is reduced in the complex compared to the free drug. 
This peak is less pronounced in the complex, it is attributed to the PS structure. Both spectra 
show that the compounds are amorphous and this result are in alignment with the findings of 
Palanisamy and Khanam (2011) and Gup et al. (2015, where the XRD of prednisolone and 
Copper (II) complex have been studied, respectively. The amorphous state of the complex 
made the growing of a crystal for the complex impossible. These results confirm the interaction 
of PS and Cu during complexation, as seen in FTIR and NMR results. 
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Figure 3.9: The powder XRD of (a) pristine PS and (b) the [Cu(glygly)(PS)] complex is show. 
 
3.3.7. Evaluation of thermal properties of the [Copper(glycylglycine)(prednisolone 
succinate)]  complex 
The PSA trace indicatesendorthermic reaction peaks at 108°C and 170°C (melting process 
begins), and exothermic peak at 191°C (crystallization) specific to pure substances and an 
exothermic reaction >300°C attributed to the decomposition and combustion of PS organic 
structure (Figure 3.10a). 
 
Absence of dehydration peaks (100-125°C) supports the proposal of an anhydrous complex. 
The complex showed both an endothermic peaks at 380°C and exothermic peak at 385°C 
suggestive of melting and crystallization. The complex shows a two-stage decomposition at 
temperature >400C (Figure 3.10b). The first decomposition would result from loss of organic 
components and final decomposition would lead to CuO as seen in a study done by Joseyphus 
and Nair (2010). Overall this analysis implies greater thermal stability of complex relative to PS. 
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Figure 3.10: The DSC spectrometry of the (a) free PS and (b) [Cu(glygly)(PS)] complex. 
 
3.3.8. Evaluation of thermal properties of the [Copper(glycylglycine)(prednisolone 
succinate)]  complex 
Thermogravimetric (DT/TGA) analysis of the [Cu(glygly)(PS)] complex was employed to provide 
quantitative information on mass losses due to thermal decomposition as a function of 
temperature. The thermal analyses data of PS drug and Cu(glygly)(PS)] complex and PS drug 
were are shown in Figure 3.11a and b respectively. From DT/TGA curve shown in Figure 3.11a 
the decomposition of PS presented with the initial mass loss (12.3%) occuring at 90-97°Cwith 
Tpeak DTA = 95°C which may be the loss of the Na+ in the PS salt. The second step of 
decomposition is in the 211–720°C range (total mass loss) which is attributed to the loss of the 
organic compounds. There is no further mass loss beyond 720°C and a plateau is obtained. 
 
The thermogram (Figue 3.11b)for [Cu(glygly)(PS)] shows the presence of an anhydrous 
complex containing no water of crystallization, and no coordinated water molecules as evident 
by the plateau from 100 to 200°C. From DT/TGA curve, it is clear that thermal decomposition of 
the [Cu(glygly)(PS)] complex occurs in three major steps. The initial mass loss occurs within the 
temperature range 319–325°C, Tpeak DTA = 323.5°C with a mass loss of 14.5% possibly due to 
elimination of the glygly ligand. The second mass loss wasrepresented by two Tpeak DTA = at 
373 and 385°C occurring in the temperature range of 370-390°C (mass loss = ~15.5%), 
respectively, possibly due to initial loss of PS. The third step corresponds to the thermal 
decomposition and complete elimination of the remaining part of the PS drug molecule starting 
from 500°C on the thermogram of the complex with final mass loss ~83% at DTA = 740-760°C 
leaving the CuO residue. Comparable findings were obtained in a study done by Maravalli and 
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Goudar (1999) on thermal analysis of a copper complex.The findings of the DT/TG analysis 
were also in accordance with the above DSC and XRD results, providing evidence that the 
armophous structure of PS was re-organised into another amorphous state ([Cu(glygly)(PS)] 
complex), with strong interaction bonds, hence increased melting and decomposition 
temperatures are observed in the DT/TGA and DSC analysis.  
 
 
 
 
 
 
Figure 3.11:TG/DTGA) analysis of the (a) PS, and (b) [Cu(glygly)(PS)] complex. 
 
3.3.9. Antioxidant/anti-inflammatory activities of the 
[Copper(glycylglycine)(prednisolone succinate)] complex 
Compounds that may be useful in the treatment of TRAPS should have anti-inflammatory/ 
antioxidant activity exhibiting free radical scavenging activity (Psomas and Kessissoglou, 2013). 
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Hence DPPH is a stable free radical used for rapid screening of antioxidant activity and it is 
related to the ability of the compounds present in the extracts to donate electrons/hydrogen to 
free radicals, thus being used to determine the scavenging activity (Tolia et al., 2013). Anti-
inflammatory activity of copper complex has been shown to be effective by a number of 
researchers (Sorenson, 1976; Roy and Srivastava, 2006; Hostynek et al., 2011). Some of this 
research included various NSAIDS and steroidal complex (Dimiza et al., 2011, Psomas and 
Kessissoglou, 2013), with results demonstrating that copper complexes are more effective in the 
inhibition of inflammation compared to the free ligands (drugs). 
According to in vitro antioxidant activity evaluation of [Cu(glygly)(PS)] using DPPH, 
[Cu(glygly)(PS)] exhibited excellent antioxidant activities, which were comparable to the 
standard ascorbic acid with the a corresponding concentration. The DPPH scavenging activity 
of the [Cu(glygly)(PS)] complex was higher (60.13 ± 1.20%) than that of the corresponding free 
PS (4.41 ± 1.40%).  
Considering that lipoxygenase plays a role in regulating inflammation by producing pro-
inflammatory mediators (Wisastra and Dekker, 2014) the development of modulators targeting 
the Lox-5 pathway have the potential of providing a better approach in the treatment of TRAPS 
disorder. Lox-5 inhibitors have the ability to reduce the total oxidative stress resulting from the 
pathogenesis of inflammation. In this study it has been established that complexing the drug to 
the metal copper drastically improves the Lox-5 inhibition properties of free PS drug. The 
[Cu(glygly)(PS)] complex exhibit approximately 6 times (36.65 ± 1.30%) the percentage 
inhibition compared to the parent PS(6.14 ± 2.60%), wherethe overall antioxidant effect was 
compared to a standard ascorbic acid, which is known to be a highly effective antioxidant 
compound (Choy et al., 2000 and Barrita and Sanchez, 2013). 
 
According to the anti-radical activity and lipid peroxidation outcomes, as summarized in Table 
3.2 and shown in Figure 3.12, the synthesised complex showed increased antiradical activities 
in the DPPH radical scavenging assay and also improved lipid peroxidation in the presence of 
lipoxidase enzyme. It can be concluded that the complexation of the Cu2+ to PS 
significantlyimproves the anti-inflammatory and antioxidant efficacy of the PS. The results 
described here, show that copper complex may be an alternative ant-inflammatory bioactive in 
TRAPS. 
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Table 3.1: Antioxidant/anti-inflammatory activity 
Inhibitor 
DPPH assay % 
Inhibition 
5-Lox assay % 
Inhibition 
Ascorbic acid 94.73 ± 0.30 54.11 ± 0.50 
PS 4.41 ± 1.40 6.14 ± 2.60 
[Cu(glygly)(PS)] 60.13 ± 1.20 36.65 ± 1.30 
 
 
Figure 3.12:The percentage lipid peroxidation and antiradical activities of ascorbic acid (1) as 
the control, and the free PS drug (2), compared to [Cu(glygly)(PS)] complex (3) 
 
3.3.10. Ex vivo permeation studies 
The permeability of the drug and complexwas quantified in terms of cumulative amount of the 
drug that permeated per unit time and per unit area and the permeability was plotted against the 
time. The concentrations and flux values obtained from the permeability study are presented 
in Figure 3.13 and summarized in Table 3.2. According to the concentration in the donor 
compartment, the steady state was achieved after 7h for both formulations. The permeation rate 
of the complex through the skin is slightly elevated compared to the free drug and the peak 
concentrations were obtained after 24h. This is consistent with a study that was done by 
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Hostynek et al. (2011), where an increase in permeability of about 100-fold was found in a 
complete dermatomed skin with a copper (II) complex. Skin permeability coefficients (Pk) for the 
[Cu(glygly)PS] complex rang went up to 1.93 while the Pk value of PS was 1.60 and the overall 
flux value of PS was increased from 1.09µgcm2/h to 1.78µgcm2/h in the Cu complex form, which 
is slightly significant. These results suggest that the complex slightly improvesin vitro skin 
permeation compared to parent drug. 
 
 
Table 3.2: The ex vivo studies concentration and flux values (n=3) 
Time(h) 
PS Concentration 
(µg/ml) 
[Cu(glygly)(PS)] 
complexConcentration 
(µg/ml) 
1 4.09±1.10 4.92±2.10 
1 5.00±2.40 10.63±2.80 
2 6.44±1.90 8.55±0.80 
3 8.38±3.10 13.43±3.10 
4 11.35±3.60 16.86±2.90 
5 11.02±2.20 17.58±1.90 
6 11.94±1.90 18.41±4.00 
7 12.84±2.70 18.06±1.90 
8 14.36±4.10 23.54±4.50 
9 14.32±3.80 22.60±0.90 
10 18.87±0.90 20.64±2.00 
24 4.09±1.10 4.92±2.10 
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Figure 3.13: The permeability of the drug or/and Cu2+ was quantified in terms of cumulative 
amount permeated per unit time and per unit area and the permeability was plotted against the 
time. 
 
The results described here, show that a copper complex may be an alternative ant-inflammatory 
bioactive using the transdermal route as the Cu (II) ions complexed to a drug assist the 
hydrophilic drug across the stratum cornea. However, the permeation enhancement mechanism 
of this complex through skin still needs further discussion as it not fully understood.Also the skin 
permeation maybe further improved with the use of a nanocarrier system, which mayincludethe 
use of skin permeating polymers. 
 
3.3.11. Cytotoxic potential of the [Copper(glycylglycine)(prednisolone succinate)]  
complex 
Thepotential cytotoxicity of the PS, and [Cu(glygly)PS] were assessed by exposing cultured 
HDFa to different concentrations of these compounds, and by evaluating and comparing the 
change in the mitochondrial metabolic activity of those cells using the MTT assay. The results 
obtained from the MTT assays are presented in Figure 4. The results showed that 
[Cu(glygly)PS] complex did not significantly reduce the viability of HDFa when compared to the 
free drug (PS) and control (untreated cells). Hence it can be established that [Cu(glygly)PS] is 
non-toxic and the results confirm the findings of Roy et al. (2006); Hostynek et al. (2011) and 
Stevenson et al. (2013) suggesting that copper complexes have the potential for use without 
any toxicity concerns in humans. 
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Figure 3.14: The % Cell viability of the PS and complex with MTT assay 
 
3.4. Concluding Remarks 
In this study, it has been established that [Cu(glygly)PS] exhibited improved in vitro anti-
inflammatory/ anti-oxidant activity compared to the parent drug, and also its skin penetration 
efficacy was slightly improved in TDDS.Furthermore it appeared to be non-toxic in HDFa cells at 
a concentration equivalent to that of the parent drug. Based on these results, it can be 
concluded that the coordination of this corticosteroid drug to Cu2+has the potential of 
reactivating the drug into a more potent coordination compound with improved 
pharmacokinetics/dynamics that can be advantageous in the treatment of TRAPS through the 
transdermal route. Although this complex shows a positive outcome in TDDS, the unclear ligand 
exchange (change in oxidation state) of Cu2+during the diffusion through the skin and its less 
understood mechanism of action warrant further research directed towards this system. 
Furthermore the permeation of the complex could be improved by using specific polymeric drug 
delivery platforms, which have been prove to be highly effective in TDDS while utilizing the 
improved antioxidant effect of the complex at the site of action. 
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CHAPTER 4 
IN VITRO EVALUATION OF NOVEL REDOX/PH DUAL STIMULI-RESPONSIVE 
NANOLIPOSOMES LOADED WITH COPPER-LIGANDED BIOACTIVE COMPLEX 
 
 
4.1. Introduction 
Currently there is no ultimate treatment confirmed for prevention or cure for Tumor Necrosis 
Factor Receptor Associated Periodic Syndrome (TRAPS)disease (Ozen and Bilginer, 2014). 
This condition is modulated by oxidative stress and redox inflammatory process (Zhu et al., 
2012), therefore non-specific anti-inflammatory agents, including steroids are used to reduce the 
severity and duration of related symptoms.  Since the disease symptoms may be prolonged 
lasting from 1-3 weeks and normally beginning at an early childhood stage (Meiorin et al., 
2013). Long term steroidal therapy is a major concern, they become less effective over time, 
requiring increased dosages and serious side effects may result (Masson et al., 2004). 
Therefore in this study targeted dual stimuli responsive nanoliposomes (NLs) were formulated 
for the delivery of [Cu(glygly)(PS)] which have the potential to improve TRAPS symptom 
management even in prolonged therapy. Based on the vast studies highlighting the benefits of 
nanotechnologies, liposomes especially have been proven to reduce toxicity and improve the 
pharmacokinetics of a number of drugs (Kaiser et al., 2013). 
 
Among many kinds of nanocarriers, drug loaded NLs have been extensively studied as an 
effective type of drug delivery system due to their unique properties (Ozpolat et al., 2014). NLs 
possess the same physical and chemical properties as liposomes, except that they are 
presented in a nanoscale diameter range (Khosravi-Darani and Mozafari, 2010), hence allowing 
improved loading efficiency and their nanosize also allows for easy penetration through skin 
compared to ordinary liposomes. NLs can be designed to deliver drugs at specific and selective 
sites by modifying the carrier system, for instance conjugating carriers sensitive to different 
stimuli including redox and pH stimuli (Khosravi-Darani and Mozafari, 2010). Targeted 
nanocarriers have the potential to increase solubility, reduce toxicity, enhance bioavailability, 
improve time-controlled release and enable precision targeting of the entrapped bioactives to a 
greater extent due to increased surface area (Khosravi-Darani and Mozafari, 2010; Mura, 
Nicolas and Couvreur, 2013). 
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Liposomes were initially reported as skin penetration enhancers for transdermal drug delivery in 
1980. Since then, liposomes have been shown to be a promising drug-delivery system through 
the skin (Zhao et al., 2013). It has been determined that NLs up to 600nm in diameter penetrate 
through skin rather easily and more are retained in the stratum corneum, hence NLs may be 
significant for the TDD in TRAPS (Schramlova et al., 1997). TDDS provide a convenient route of 
drug administration for a variety of indications; diseases such as skin cancer, depression and 
post-menopausal bone loss already have drugs designed to suite TDDS (Patel et al., 2009). 
NLs delivering drugs through a TDDS can decrease systemic absorption and minimize collateral 
symptoms due to a reservoir effect and Phospholipid-containing liposomal formulations may act 
as penetration enhancers and facilitate dermal delivery (Pierre and Costa, 2011; Zhao et al., 
2013). In addition, liposomes are generally biodegradable, making them ideal candidates for the 
delivery of active agents to the body using different routes of administration including TDD 
(Bowey et al., 2014). 
 
Recently, there has been a growing interest in the development of improved intelligent 
polymeric drug nanocarrier systems. These systems may have the ability to respond to more 
than one stimuli, thus assuring controlled drug release under specific pathological conditions (Lu 
et al., 2014). As a result numerous studies on nanocarriers with dual or multi-sensitivities, such 
as pH/temperature, pH/redox, pH/glucose, pH/enzyme, dual enzyme, and enzyme/light (Ganta 
et al., 2008; Cheng et al., 2013; Mura,Nicolas and Couvreur, 2013),have been developed. Even 
though extensive work has been reported on dual stimuli sensitive nanocarriers, the full 
potential of these nanocarriers have not yet been reached, hence the aim of this study is to 
further explore the use of dual stimuli responsive in nanoliposomes and its application in TRAPS 
treatment.  
 
In the present work, a dual stimuli-responsive Eudragit® E100-cystamine (EuE100-cyst) 
polymer for pH and redox responsiveness was developed for anti-inflammatory drug delivery in 
patients with TRAPS. EuE100 is a cationic (pH dependent) polymer that has been widely 
exploited for its effects in tablet coating (Joshi, Kevadiya and Bajaj, 2010), taste masking 
(Shishu and Kapoor, 2009; Malik,Arora,and Singh, 2011) and few instances where it is used as 
an actual drug carrier system (Liu et al., 2007; Kalimuthu and Yadav, 2009; Guzmán, Manzo 
and Olivera, 2012) and in TDD (Hu et al., 2011). In the present work the EuE100 polymer was 
developed into a dual sensitive carrier system by coupling it with a sulphide containing agent 
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(cystamine dihydrochloride) into EuE100-Cyst, the amino groups representing the pH-sensitive 
component and redox-sensitivity represented by the disulfide bonds (Figure 4.1).  
 
The synthesised EuE100-Cyst polymer was prepared to target the oxidative stress areas of 
inflammation, as it is well established that the pathological consequences of TRAPS, have pro-
inflammatory effects (Touitou et al., 2013) leading to prolonged inflammation. During TRAPS 
disorder (inflammatory disorder), reactive oxygen species (ROS) are formed when oxygen 
undergoes a partial one-electron reduction to the super-oxide anion, and subsequently forms 
hydrogen peroxide and other oxidants causing an oxidative imbalance (stress) (Trachootham et 
al., 2009). ROS often induces redox adaptation in response to the continued oxidatives stress, 
leading to anup regulation of glutathione (GSH) and other antioxidant molecules (Zhu et al., 
2012). Hence the formulated NLs are triggered by both GSH increase (redox sensitivity) and low 
pH which are typically significant in inflamed tissues (Mahmoud et al., 2011). The underlying 
mechanism for redox sensitivity is based on the disulfide/GSH exchange reactions (Lopez-
Mirabal and Winther 2008). Figure 4.1 below shows the structure of the inflammatory sensitive 
EuE100-cyst and how it breaks down in the presence of GSH which is excessively increased in 
the intracellular matrix (ICM) of inflamed cells. 
 
 
Figure 4.1: Proposed chemical structure of EuE100-cyst and its ICM degradation through the 
disulfide link in the presence of a reducing agent (GSH). 
 
In this study, intellligent nanocarriers were formulated using EuE100-cyst, loaded with 
[Cu(glygly)(PS)] complex giving [Cu(glygly)(PS)]-loaded intelligent NLs. Firstly the EuE100 was 
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modified using cystamine hydrochloride and the formation of EuE100-cyst was confirmed using 
FTIR, COSY NMR and 1H NMR. Thereafter the [Cu(glygly)(PS)] complex was loaded into the 
prepared NLs and the loading was confirmed using FTIR, the complex entrapment efficacy was 
also measured. The formation of the NLs was confirmed using TEM and Zetasizer analysis, 
while the pH/redox sensitivity of the NLs was established by the change in particle size using 
the size analysis and drug release studies. Furthermore cytotoxicity studies were performed on 
both the loaded and non-loaded NLs. 
 
4.2. Materials and methods 
4.2.1. Materials 
Eudragit® E100 (EuE100) was purchased from Evonik Degussa Africa (Midrand, Gauteng, 
South Africa). Cystamine dihydrochloride (Cyst·2HCl), 1-Ethyl-3-(3dimethylaminopropyl) 
carbodiimide hydrochloride (EDC), N-hydroxysuccinimate (NHS, cystamine hydrochloride, and 
5, 5' dithiobis(nitrobenzoic acid) (Ellman’s agent, DTNB), phospholipids included L-α-
Phosphatidylcholine (PC),cholesterol (CHOL), and 1,2-distearoyl-sn-glycero-3-phosphatidyl-
ethanolamine (DSPE). Phosphate buffer saline (PBS) tablets, Prednisone Succinate (PS) salt, 
copper (II) nitrate were purchased from Sigma–Aldrich (St. Louise, MO, USA). Sodium 
hydroxide (NaOH) pellets and dimethylformamide (DMF), ammonium sulphate (NH4 (SO4)2), 
sodium acetate and glacial acetic acid were purchased from Merck (Wadeville). 
Dimethylsulfoxide (DMSO) was purchased from Saarchem (Pty) Ltd. (Brakpan, South Africa) 
and liquid nitrogen was obtained from Afrox (Pty) Ltd. (Industria West, Germiston, South Africa). 
Double deionised water (ddw) was obtained from a Milli-Q system (Milli-Q, Millipore, 
Johannesburg) and methanol from Rochelle Chemicals (Johannesburg, South Africa). All other 
solvents and reagents were of analytical grade and were used as received. 
 
4.2.2. Formulation of dual pH/redox responsive [Cu(glygly)PS]-loaded nanoliposomes 
4.2.2.1. Synthesis of the [Cu(glygly)(PS)]  complex 
[Cu(glygly)(PS)]  complex was prepared as previously detailed in Chapter 3, section 2.2. 
 
4.2.2.3. Coupling of the Eudragit® E100 
EuE100 (1mmol) was dissolved in ethanol, while excess NaOH (1.5mmol) was added, and the 
reaction mixture was left to stir at 60°C for 12h. The resulting brown-yellow solution was 
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dialyzed using a dialysis membrane of 12kDa against deionised water three times. The purified 
solution product was freeze-dried, resulting in a water soluble, light brown fine powder.  
  
The powdered dry product (0.5mmol) was dissolved in dimethylformamide(DMF) with EDC 
(0.6mmol) and NHS (0.6mmol) added immediately to the solution and left to stir for 30min. 
Cyst·2HCl (0.6mmol) was thereafter added to couple the polymer, carrying out the reaction at 
room temperature for 6h while stirring continuously. The resulting solution was dialyzed using a 
dialysis membrane of 12kDa against double deionised water three times, firstly time with 1%w/v 
NaCl2 to remove any unreacted cyst·2HCl (Li et al., 2011). Thereafter the purified solution was 
also freeze-dried to produce a water soluble caramel colored fine product (EuE100-Cyst). The 
thiol group on the side chain of E100-Cyst was determined using Ellman’s method.  
 
4.2.2.2. Determination of thiol groups 
The amount of thiol groups present on EuE100-Cyst was determined spectrophotometrically 
using ellmas reagent DTNB [5,5‘-dithiobis-(2-nitrobenzoic acid)], which is also known as the 
Ellman’s method. Briefly, 250µL of 5 mg EuE100-Cyst sample dissolved in 2.5mL PBS at pH 8, 
then 250µL of PBS at pH 8 and 500µL of 10 mM (4mg/mL) solution of DTNB. The mixture was 
incubated for 15min at room temperature. The absorbance was determined by the double-beam 
UV-Vis spectrophotometry (PerkinElmer Spectrum 100, Llantrisant, Wales, UK) at 415nm which 
is DTNB’s maximum absorption. The quantity of thiol was determined using a standard 
cystamine calibration curve of thiol concentration against absorbance (Robb et al., 2007 and 
Nguyen et al., 2011). 
 
4.2.2.3. Preparation of the nanoliposomes 
The [Cu(glygly)(PS)]-loaded NLs were prepared by adapting a method from Esfahani et al. 
(2014). In brief, 75:25:10 molar ratios of PC, cholesterol, and DSPE respectively were dissolved 
in a chloroform/methanol mixture (1:1% v/v) in a round bottom flask. Two phospholipid mixtures 
were formulated in different flasks. In one formulation the solution of [Cu(glygly)(PS)] complex 
was added in 0.2:1 ratio of complex  to phospholipid (Abraham et al., 2002) and stirred at room 
temperature for 2h. The mixtures were dried in vacuoovernight. The thin phospholid films 
remaining on the walls of both flasks were hydrated with 2mM suspension of EuE100-cyst in 
double deionised water. Final phospholipid concentrations (10mg/ml) (Castile and Taylor, 
1999)were subjected to probe sonication (Sonics VibraCell Inc. Danbury, CT, USA) in ice baths. 
Dual pH/redox responsive [Cu(glygly)(PS)]-loaded NLs and unloaded NLs were produced. In 
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the loaded NLs unencapsulated [Cu(glygly)(PS)], easily precipitated out of the double deionised  
water suspension, being easily separated from loaded NLs. The NLs were stored at 4C until 
further usage. 
 
4.2.3. Chemical structural analysis of EuE100, EuE100-Cyst, [Cu(glygly)(PS)]-loaded and 
unloaded NLs using Fourier transform infrared spectroscopy 
Fourier transform infrared (FTIR) spectra were performed on EuE100, EuE100-Cyst, 
[Cu(glygly)(PS)]-loaded and unloaded NLs. FT-IR Spectrometer (PerkinElmer Inc., Waltham, 
Massachusetts, USA) was used to assess the vibrational transitions in the chemical structures 
of these compounds, as described in chapter 3, section 3.2.3.  
 
4.2.4. Analysis of the chemical shifts of EuE100 and EuE100-cyst using Nuclear 
magnetic resonancespectroscopy 
The magnetic properties of EuE100 and EuE100-cyst were analysed using the nuclear 
magnetic resonance (NMR) spectroscopy (1H, 13C and correlated spectroscopy (COSY) 
spectra) operating at 500 MHz (Bruker Avance  BioSpin, Germany), as detailed in Chapter 3, 
section 3.2.4. 
 
4.2.5. X-ray diffraction Analysis of EuE100 and EuE100-cyst 
The XRD pattern of EuE100 and EuE100-cyst was investigated with the X-ray diffractometer 
(ULTIMA-III, Rigaku, Japan), as detailed in chapter 3, section 3.2.7. 
 
4.2.6. Determination of the thermal properties of EuE100 and EuE100-cyst 
4.2.6.1.Differential scanning calorimeter analysis 
A differential scanning calorimeter (DSC) (Mettler Toledo, DSC1, STARe System, 
Swchwerzenback, Switzerland) was used to determine the thermal properties of the EuE100 
and EuE100-cyst as detailed in chapter 3, section 3.2.9. 
 
4.2.6.2. Thermogravimetric analysis 
Thermal analysis was performed using thermogravimetric analysis (TGA) (Toleda TC15 TA 
controller, Mettler). It was used to measure the thermally induced changes in chemical and 
physical properties of EuE100 and EuE100-cyst as detailed in chapter 3, section 3.2.9. 
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4.2.7. Determination of particle size and zeta potential of[Cu(glygly)(PS)]-loaded 
intelligent nanoliposomes 
The zeta sizer was employed to determine the typical particle size and polydispersity index (PdI) 
of the NLs, also zeta potential analysis was performed to establish the surface charge and 
physical stability of the NLs. These procedures were carried out using a Zetasizer NanoZS 
(Malvern Instruments, Worcestershire, UK).  
 
4.2.8. Transmission electron microscopy of the [Cu(glygly)(PS)]-loaded intelligent 
nanoliposomes 
The structural morphology of the [Cu(glygly)(PS)]-loaded NLs was carried out using 
transmission electron microscopy (TEM) (Jeol 1200 EX, Japan). The NLs were suspended in 
double deionised water (0.5mg/mL) and a pipette was used to place a drop of the suspension 
on a 200 mesh thick formvar copper grid (TABB Laboratories Equipment, Berks, UK). The NLs 
were allowed to be adsorbed on the surface of the copper grid, thereafter a drop of 2%w/vuranyl 
acetate in double deionised water was added on the adsorbed NLs and left to dry for an hour at 
room temperature (Ruozi et al., 2011).  
 
4.2.9. Investigation of redox/pH Sensitivity of the [Cu(glygly)(PS)]- loaded intelligent 
nanoliposomes 
The significant concentration difference of GSH between the extracellular matrix (ECM) (~0.002 
to 0.02mM) and ICM (~10mM) environment has been widely utilized as an ideal trigger for the 
redox responsive delivery systems, as the disulphide bond is cleaved in the presence of GSH 
and drug release occurs (Lv et al., 2014; Ashwinkumar et al., 2014). Additionally during 
inflammatory diseases there is a significant decrease of pH in the ECM, hence the effect of pH 
is also used as a response mechanism for drug release. To mimic these responses the 
[Cu(glygly)(PS)]-loaded NLs were soaked in PBS (pH 7.4) and acetate buffer (pH 5), at room 
temperature with or without 10mM of GSH. The NLs were incubated for 30min ensuring that 
swelling equilibrium was reached (Aydın and Pulat, 2012). Particle size evaluation was 
undertaken after incubation of the NLs in different mediums, using a Zetasizer Nano Z (Malvern, 
UK). 
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4.2.10. Determination of entrapment efficiency of [Cu(glygly)(PS)]-loaded intelligent NLs 
Entrapment efficiency (EE) was calculated to account for the ratio of [Cu(glygly)(PS)] 
encapsulated in the NLs to that of the total [Cu(glygly)(PS)] in the NLs dispersion. To disrupt the 
structure of the NLs, the NLs were suspended in methanol (5mg/mL) and centrifuged at 
1000rpm for 20min to separate drug from phospholipids and polymer. The %EE was determined 
by measuring the absorbance of the supernatant using UV-Vis spectroscopy (PerkinElmer 
Spectrum 100, Llantrisant, Wales, UK) at wavelength 242nm. A concentration versus 
absorbance calibration curve was employed for the quantification of the [Cu(glygly)(PS)] 
entrapped. The %EE was calculated using the following equation: 
%EE = (
Amount of[Cu(glygly)(PS)] in liposomes 
Amount of total [Cu(glygly)(PS)]
) × 100                                                                      Equation 4.1 
 
4.2.11. In vitro drug release from the NLs 
In vitrodrug release from [Cu(glygly)(PS)]-loaded NLs was carried out in PBS (pH 7.4) and 
acetate buffer (pH 5) with and without GSH (10mM) at 37°C using dialysis membranes (MWCO: 
1.2kDa). The medium of pH 7.4 without GSH corresponds to the condition in which NLs will 
encounter during circulation after administration, while medium of pH 7.4 with 10mM GSH 
corresponds to the ICM condition. At pH 5 ECM conditions were mimicked with insignificant 
GSH (KC, Thapa,Xu, 2012). Equivalent amounts of [Cu(glygly)(PS)]-loaded NLs were placed in 
dialysis bags and immersed in 50mL of different buffer mediums. At predetermined time 
intervals (0.5, 1, 2, 4, 6 and 24h), 1mL of each buffer medium was removed for analysis and 
replaced with the same quantity of fresh buffer medium, to maintain sink conditions. Samples 
were kept at 8°C until they were analysed using the UV−vis spectroscopy at a wavelength of 
242nm using calibration curve as described in chapter 3, section 3.2.11. 
 
4.2.12. In vitro cytotoxicity studies 
In vitro cytotoxicity Studies of the [Cu(glygly)(PS)]-loaded and unloaded NLs were carried out 
usingHuman Dermal fibroblast adult (HDFa) cells (Cell Applications Inc. (CAI), San Diego, USA) 
as described in Chapter 3, section 3.2.12. 
 
4.2.13. Statistical analysis 
Results are presented as average ± SD of triplicate experiments unless otherwise mentioned.  
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4.3. Results and Discussion 
4.3.1. Synthesis and Characterisation of EuE100-Cyst 
The 3D structure of the EuE100 and EuE100-cyst in the visualization of geometrical preferences 
is shown in Figure 4.2(a), and b) reaction scheme for the preparation of the EuE100-cyst. 
  
 
 
Figure 4.2: Visualization of geometrical preferences of (i) EuE100 and (ii) EuE100-cyst after 
molecular simulation. Color codes: C (grey), O (red), N (white), H (pink) and S-S (yellow), and b) 
reaction scheme for the preparation of the EuE100-cyst. 
 
The dual pH/redox responsive NLs were loaded with [Cu(glygly)(PS)] complex. These NLs were 
prepared by conjugating a pH/redox responsive EuE100-cyst polymer with a phospholipid 
bilayer. The EuE100-cyst polymer was prepared by coupling a cationic EuE100 polymer with a 
cystamine compound producing a 20-28% cystamine (thiol) group substitution on the EuE100-
cyst. Due to the hydrophilicity of this polymer it is expected to attach itself on the outer 
a) 
b) 
i) 
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hydrophilic layer of the phospholipid bilayer while the hydrophobic [Cu(glygly)(PS)] complex is 
embedded within the bilayer. As a result of the EuE100-cyst conjugation, the NLs are predicted 
to degrade in a sequential manner (Figure 4.3). As the NLs penetrate through inflamed cells 
they will first encounter a low pH in the ECM where they will undergo an initial degradation 
(slight swelling). Upon reaching the ICM cytosol, the NLs will fully degrade in the presence of 
GSH and release the complex to the cell nucleus (site of action). This specific approach is 
expected to modify the release of the complex molecules under low pH values and high GSH 
concentrations, allowing the NLs molecules to move freely via normal diffusion and eventually 
be excreted if no inflammation occurs. 
 
Figure 4.3: The expected sequential degradation of the NLs in the inflamed tissue: 1. The initial 
degradation; as the NL passes through the extracellular matrix into the cell it encounters a 
reduced pH up to pH 5, and it swells. 2. The NL passes through the cell into the ICM (cytosol) 
where there is increased GSH concentration up to 10mM during inflammation, the NL 
undergoes full degradation. 3. The complex is finally released to the nucleus of the cell where it 
exert its improved ant-inflammatory effects. 
 
4.3.2. Chemical structural evaluation using Fourier transform infrared (FTIR) 
spectroscopy 
An FTIR spectrum is a unique technique that may be utilized in drug delivery to identify the 
presence or absence of certain chemical functional groups in molecules (Parida et al., 
2012).The vibrations of IR spectra may be used to characterize the possible interactions of the 
different molecules used to formulate the NLs. The FT-IR spectra of EuE100-cys and EuE100 
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are shown in Figure 4.4a, and b, respectively. Only the noteworthy absorption bands are 
discussed (inserted boxes). Figure 4.4a shows a new strong N-H stretch band at 3285cm−1, the 
one and two amide absorption bands are also seen at 1644 and 1555cm-1 respectively, and all 
these bands aredue to the coupling of the amino group from the cystamine to the COO- of the 
EuE100 resulting in -COONH-. It is also observed that the band at 1098cm−1, which is the ester 
stretch from RCOCH3 of the EuE100 is not seen in the EuE100-cyst spectra, hence thiolation of 
the polymer occurred.  
 
Furthermore other major absorption bands were noted to be present in both spectra for instance 
the alkyl carboxylic acid R-COO-R band at 1721cm-1, aliphatic C-H stretch absorption band at  
2949-59cm−1 , the methyl (-CH3) C-H stretch band at 1453cm-1 and isopropyl CH3 doublet at 
1370 and 1380cm-1. , thus the backbone of EuE100 was maintained. 
 
 
Figure 4.4: The FTIR spectra of EuE100 and its derivatives are shown. (a) EuE100-Cyst. (b) 
EuE100. 
 
FTIR spectra were used to validate the covalent conjugation of complex into the NLs. Figure 
4.5a, b and c shows a typical FTIR spectrogram of unloaded NLs, complex-loaded NLs the 
complex, respectively. The  FTIR  spectra  of  the complex loaded NLs and unloaded NLs 
indicate  that  characteristic  peaks of the unloaded NLs  were  not  altered  and had 
no  changes  in  their  positions after [Cu(glygly)(PS)] encapsulation. However there was one 
new significant C=O (aryl ketone) vibration which is the Cu(glygly)(PS)] characteristic peak 
at1653cm−1 and 1656cm−1 (inserted box in figure 4.6) for [Cu(glygly)(PS)] and [Cu(glygly)(PS)]-
b
b
b 
 
a
) 
b) 
 
 
72 
 
loaded NLs, respectively, indicating complex loading was achieved. The novel [Cu(glygly)(PS)]- 
loaded NLs were thus successfully formulated. 
 
Figure 4.5: FTIR spectroscopic analysis of (a) [Cu(glygly)(PS)]- loaded NLs, (b) unloaded NLs 
and (c)complex. 
 
4.3.3. Evaluation of the magnetic properties using Nuclear magnetic 
resonancespectroscopy 
The 1H NMR comparative spectra of EuE100 and EuE100-cyst indicate that the polymer 
(EuE100) and cystamine successfully coupled into EuE100-cyst (Figure 4.6). It can be found 
that the peak at 7.99ppm is associated with the amide bond (-CONH-) where the cystamine 
interacts with the EuE100 in coupling reaction. The rest of the peaks from 0.92-4.18ppm in the 
EuE100-cyst are corresponding to the EuE100 peaks from 0.92-4.14. The only difference being 
the shifting of the peak at from 4.13 in EuE100 to 4.18 in EuE100-cyst which shows the bonding 
of the COO- to the amide instead of the carbon (methyl group). This also demonstrates that the 
backbone of the EuE100 chain is maintained. 
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Figure 4.6: Comparative1H NMR in MeOD. 
 
AdditionallyCOSYis important in structure elucidation as it shows the correlation or coupling 
between two adjacent protons. From the COSY spectrum (Figure 4.7), the coupling between 
protons at [1] and [4] (blue dotted line) and [2] and [7] (red dotted line) is observed. When 
compared to the EUD cyst similar interactions are observed and there are some new CH2-CH2 
interactions as well (green dotted line) coming from the cyst moiety. These new interactions 
confirm the coupling reaction. 
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Figure 4.7: Comparative COSY NMR in MeOD. 
 
4.3.4.Evaluation of the thermal properties of EuE100 and EuE100-Cystusing differential 
scanning calorimeter analysis 
Figure 4.8 shows the DSC thermograms of EuE100and EuE100-Cyst. All the graphs represent 
endothermic melting peaks, Figure 4.8a shows EuE100 with the onset at: 260.03°C, maximum 
peak at: 301.13°C, and recovery (endset) at: 333.13°C, Figure 4.8b shows EuE100-Cyst with 
the onset at: 210.28°C, maximum peak at: 254.23°C, recovery (endset) at: 288.32°C. 
Additionally there is a small peak at ~272°C on the EuE100-cytgraph which may be attributed to 
the decomposition of the cystamine group on the EuE100. 
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Figure 4.8: The DSC graphs, a) EuE100, b) EuE100-cyst. 
 
4.3.5. Evaluation of the thermal properties usingthermogravimetric analysis (TGA) 
The simultaneous TG/DTA thermal analysis of EuE100 and EuE100-Cyst are observed in 
Figure 4.9a and b. The graphs show that the weight losses from EuE100 and EuE100-Cyst in 
the temperature range of 300–400°C are approximately 46-74% and 46-76%, respectively. The 
total weight loss occurred at 425°C and 470°C for EuE100 and EuE100-Cyst, respectively, 
which shows the decomposition of the compounds. The shift to a higher temperature in the 
thermal degradation of the thiolated EuE100 indicated an increase in the organization of the 
compound mostly due to the interaction between the cyst and EuE100 during the coupling 
resulting into EuE100-cyst. Additionally there is a small peak between 350°C and 400°C in the 
TG/DTA graph which may be attributed to the decomposition of the Cystamine group on the 
EuE100.  This also agrees with the DSC results where the EuE100 has a higher melting point 
compared to the EuE100-cyst. 
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Figure 4.9: (a) TG/DTA of the EuE100 and (b) TG/DTA of EuE100-cyst. 
 
4.3.6. Assessment of the degree of structural order using X-ray Diffraction 
 The powder X-ray diffraction patterns for the pure EuE100 and functionalized EuE100 
(EuE100-cyst) are given in Figure 4.10. In the XRD profiles of the powder, EuE100 is in a 
crystalline state with the main diffraction peaks observed at 2θ = 9.3 and 19.1, whereas in the 
EuE100-cyst these two corresponding amorphous peaks still exist, but their intensities are 
reduced. These results demonstrate that the functionalization of EuE100 by coupling with cyst 
destroyed the original amorphous state of the EuE100. In addition these results confirm the 
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interaction of the EuE100 carbonyl group and amino group of the cyst, which then resulted in an 
amorphous structure of the polymer complex (EuE100). According to Prabaharan and Gong 
(2008) the amorphous nature of the thiolated EuE100, may be attributed to the improved 
biodegradability and mucoadhesive properties of the EuE100-cyst. The findings of the XRD 
analysis were also in accordance with the above DSC and TGA results, providing evidence that 
the crystalline structure of EuE100 was converted to an amorphous state (EuE100-cyst). 
 
Figure 4.10: The X-ray diffraction of the (a) EuE100-Cyst powder and (b) EuE100. 
 
4.3.7. Determination of particle size in functionalised nanoliposomes 
The size distribution and average of three different batches of nanoliposome suspensions were 
analysed using the Zeta sizer. The size distribution profile of all the batches was narrow (PdI 
0.199± 0.148) with a particle range of 100 ± 47nm (Figure 4.11). The zeta potential analysis 
(Figure 4.12), show that the [Cu(gly)(PS)]-loaded NLs had a charge of +17mV which is 
significantly more positive compared to the surface charge of the non-loaded NLs which is 
+5mV. The strong positive charge on [Cu(gly)(PS)]-loaded NLs may be due to the complex 
which is on the lipid bilayer of the NLs. 
 
a) 
b) 
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Figure 4.11: Size distribution of the [Cu(gly)(PS)]-loaded intelligent NLs is shown. 
 
 
Figure 4.12: Surface charge (zeta potential) of the [Cu(gly)(PS)]-loaded intelligent NLs 
 
4.3.8. Transmission electron microscopy of the [Cu(gly)(PS)]-loaded intelligent 
nanoliposomes 
The morphology and presence of the NLs were confirmed by TEM which established the 
existence of predominantly spherical-shaped unilaminar vesicles with a size range less than 
200nm (Figure 4.13). The NLs existed homogenously dispersedly in the system, in a non-
aggregated form. The sizes of the NLs observed in the TEM micrographs were typically of a 
similar size as the results obtained by the measurement of the particle size. 
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Figure 4.13: The TEM micrographs of [Cu(gly)(PS)]-loaded intelligent nanoliposomes in  uranyl 
acetate (negative stain). 
 
4.3.9. Investigation of redox/pH sensitivity of nanoliposomes 
As the EuE100-cyst network contains a pH-ionizable group, and a disulphide bond that is 
broken in the presence of GSH/pH, soaking the NLs in a medium with GSH, low pH or both 
mimics the inflamed environment conditions thus elicits the swelling behavior. Therefore the 
change in mean size of the pH/redox sensitive EuE100 NLs was determined. According to the 
graphs in Figure 4.14, particle size sharply increased when pH was reduced from 7.4 to 5 and in 
the presence of GSH;the GSH has a major impact on the particle size, hence as swelling and 
drug release, as confirmed by a sharp increase in its presence compared to low pH. This GSH-
responsive behavior could be ascribed to cleavage of the disulphide bonds in the ICM 
environment of inflamed cells, but firstly NL penetrates through the cell from ECM to the ICM 
where the complex is partially released in the low pH and once in the cytosol complete drug 
release occurs in the presence of GSH (Aydın and Pulat, 2012). This will ensure a controlled 
release of the complex. 
 
These results concluded that particle size of the NLs is very sensitive to the changing pH/redox 
values of the aqueous environment they are in. The particle size is increased from 100nm up to 
357nm at low pH 5 and 900nm in the presence of GSH. In this study, the swelling and shrinking 
mechanism with regard to swinging pH values has been investigated in terms of smart 
responsive nanoparticle systems for localised drug delivery. 
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Figure 4.14: The particle size of NLs: (a) at pH 5 with 10mM GSH, (b) at pH 5 without any GSH, 
(c) at pH 7.4 with 10mM GSH and (d) at pH 7.4 without any GSH. 
 
4.3.10. Entrapment efficiency and in vitro [Cu(glygly)PS] release studies 
An ultimate stimuli responsive nanocarrier system should have properties of slow drug release 
during circulation while it targets the affected cells and release the drug rapidly in the affected 
cells. This ensures fewer side effects from the drug, as less drug molecules are expected to be 
present in blood circulation. The %EE was 85±8% and the percentage in vitro release was 
calculated using the established %EE values. In vitro complex release from the dual pH/redox 
sensitive NLs was assessed and the results are summarized in Figure 4.15.As anticipated, the 
release rate of [Cu(glygly)(PS)] in pH 5 was faster than that in pH 7.4, 65.2±4.9 and 78.9±3.7 of 
the complex was released within 6h in pH 7.4 and 5 respectively, with 10mM of GSH. The % 
release in pH 5 and 7.4 without GSH was 65.6±4.2 and 27.6±5.4%, respectively. The slow 
release of [Cu(glygly)(PS)]in PBS pH 7.4 without GSH indicates that the functionalized NLs are 
mostly stable at physiological environments, hence minimising side effects in the unaffected 
tissues and cells. It should be noted that the effects of the GSH are more pronounced compared 
to the acidic pH effects in the swelling, degradation and release of the drug; this could be due to 
the direct coupling of the disulphide bond on the EuE100 polymer (high percentage of 
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substitution). This concludes that the incorporation of the redox/pH polymer controls the 
degradation and the release of [Cu(glygly)(PS)]. This finding is also consistent with the swelling 
of the NLs in Figure 4.14 with NLs incubated in GHS at both PBS (pH 7.4) and acetate buffer 
(pH 5), with and without 10mM GSH. This concludes that the incorporation of the redox/pH 
polymer controls the degradation and the release of the complex. These results agree with the 
findings established by number investigators(Remant et al., 2012; Lu et al., 2014; Kang et al., 
2015). 
 
 
Figure 4.15: Drug-release profile of [Cu(glygly)(PS)] from pH/redox sensitive NLs at pH 7.4 and 
5, with and without 10mM GSH. 
 
4.3.11. Evaluation of in vitro cytotoxicity 
Thepotential cytotoxicity of the [Cu(glygly)PS]-loaded and unloaded NLs were assessed by 
exposing cultured HDFa to different concentrations of these compounds. The CV observed 
(Figure 4.16) was consistent throughout all the concentrations and slightly dependent on the 
concentration, the CV was increased with an increase in both the loaded and unloaded NLs 
concentration. These results show no significant difference in CV of the HDFa cells when 
compared to the the control (untreated cells).  According to Sharma et al. (2012) a cell viability 
of 80% or greater shows a good cytotoxicity compatibility of the tested formulations, hence 
establishing that these formulations have the potential for use without toxicity concerns. 
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Figure 4.16:The % Cell viability of the [Cu(glygly)(PS)]-loaded and unloded NLs with MTT 
assay. 
 
4.4. Concluding Remarks 
In conclusion, a nanoliposome vehicle for controlled [Cu(glygly)(PS)] delivery in TRAPS which is 
based on dual pH/redox responsive NLs were successfully formulated. The NLs are responsive 
to inflammatory mediators due to the hydrophilic redox/ pH sensitive layer of EuE100-cyst 
coating the phospholipids. The dual responsive [Cu(glygly)(PS)] release from the NLs have 
been successfully demonstrated. Further, an MTT assay was performed to observe the cell 
viability using HDFa cells in the presence of the unloaded and [Cu(glygly)(PS)] loaded NLs. The 
good biocompatibility and efficient drug release of these functionalized NLs establish a 
promising future pharmaceutical/biomedical application. To be noted is that the combination of 
the use of metal-drug complex as a bioactive and the targeting pH/redox-triggered quick drug 
release system could significantly increase the intracellular bioactive concentration and 
efficiently during inflammation inhibition with reduced drug (steroids) side effects. However in 
vivo studies are necessary to support the establishedin vitro findings. 
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CHAPTER 5 
 
APPLICATION OF BOX-BEHNKEN DESIGN IN THE FORMULATION AND OPTIMISATION 
OF DUAL RESPONSIVE [COPPER-GLYCYLGLYCINE-PREDNISOLONE SUCCINATE] 
LOADED NANOLIPOSOMAL SLUDGE FOR TRANSDERMAL DRUG DELIVERY 
 
 
5.1. Introduction 
Management of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) using 
corticosteroids is mainly limited by long-term side effects from oral drug delivery (Aróstegui, 
2011) mainly due to high systemic drug exposure. This may result in poor bioavailability of 
drugs at the site of action, which may be circumvented by using an intelligent metal-drug 
complex loaded nanocarrier design for transdermal drug delivery system (TDDS). Even though 
the TDDS have many advantages over other drug administration routes, the stratum corneum 
forms a strong barrier to most topically applied formulations (Prausnitz and Langer, 2008). 
However by combining the advantages of both a liposomal nanocarrier and a gel-based vehicle, 
a liposomal nanogel with superior properties is formulated. A liposomal nanogel may be 
described as a lipid-coated drug loaded nanoparticulates dispersed in a gel matrix (Kermany, 
2010; Murphy et al., 2011), the gel matrix further enhances the overall drug delivery outcome of 
the design. 
 
In the development of a gel system hydroxypropyl methylcellulose (HPMC) was used due to its 
gel forming, hydration (Karavas et al., 2006) and skin permeating properties (Batheja et al., 
2011) and poly(N-vinylpyrrolydone) (PVP)  was added to promote the bio-adhesiveness 
(Karavas et al., 2006) and the stability (Qiu and Bae, 2006) of the nanogel as previously 
assessed (Fang et al., 1999; Darwhekar et al., 2011). The main aim of the study was to 
formulate a liposomal nanogel termed a nanoliposomal sludge with optimal mechanical 
properties, good bioadhesion and acceptable viscosity which may attribute to increased patient 
compliance and clinical efficacy of the formulation. Previously a gel matrix based on a blend of 
HPMC and PVP has been designed for enhanced transdermal drug delivery (Fang et al., 1999; 
Darwhekar et al., 2011) and it was established that combining the chemical bonds between 
these two polymers may be an ideal TDDS design for TRAPS management. 
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In the present study, a dual pH/redox responsive cationic polymer Eudragit E100-cystamine 
(EuE100-cyst) and phospholipids were conjugated into pH/redox responsive nanoliposomes 
(NLs). NLs have previously been investigated as promising drug delivery systems for various 
applications in TDDS (El-Nabarawi et al., 2013; Ghanbarzadeh and Arami, 2013; Sun et al., 
2015). Herein the NLs were loaded with the previously formulated [Copper-glycylglycine-
prednisolone succinate] complex (Chapter 3) and optimised using the design of experiments by 
employing a 3-factor, 3-level Box-Behnken statistical design method. Independent variables 
studied were the different ratios of lipids, cholesterol and sonication time. The dependent 
variables studied were the Z-Average size, Polydispersity Index (pdi), zeta potential, entrapment 
efficiency (%EE) and % drug loading (%DL). Response surface plots were drawn, statistical 
validity of the polynomials was established, and an optimised formulation was selected by 
feasibility and grid search. The optimsed formulation was characterized using FTIR, DSC and 
SEM. Lastly the optimized formulation was dispersed in a blend of HPMC/PVA gel resulting into 
a ([Cu(glygly)(PS)]) loaded nanoliposomal sludge with desired viscosity for TDDS. Furthermore 
the sludge was characterized using ex vivo permeation and in vitro release studies compared to 
the conventional and marketed prednisolone formulations. 
 
5.2. Materials and methods 
5.2.1. Materials 
Eudragit E100-cystamine (EuE100-cyst) was synthesised as described in Chapter 4.  
Phospholipids included L-α-Phosphatidylcholine (PC), cholesterol, and 1,2-distearoyl-sn-
glycero-3-phosphatidyl-ethanolamine (DSPE) which were purchased from Sigma–Aldrich (St. 
Louise, MO, USA). Phosphate buffer saline (PBS) tablets, Prednisone Succinate (PS) salt and 
copper (II) nitrate, were also purchased from Sigma–Aldrich (St. Louise, MO, USA). Sodium 
hydroxide (NaOH) pellets and dimethylformamide (DMF), ammonium sulphate (NH4 (SO4)2), 
sodium acetate and glacial acetate acid were purchased from Merck (Wadeville). 
Dimethylsulfoxide (DMSO) was purchased from Saarchem (Pty) Ltd. (Brakpan, South Africa) 
and liquid nitrogen was obtained from Afrox (Pty) Ltd. (Industria West, Germiston, South Africa). 
Double deionised water (ddw) was obtained from a Milli-Q system (Milli-Q, Millipore, 
Johannesburg) and methanol from Rochelle Chemicals (Johannesburg, South Africa). 
Prednisolone tablets and syrup were commercially available. All other solvents and reagents 
were of analytical grade and were used as received. 
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5.2.2. Preparation of dual pH/redox [Cu(glygly)(PS)]-loaded nanoliposomes 
5.2.2.1. Optimisation using a Box–Behnken design 
A three-factor, three-level BB design was applied for the optimization procedure with the 
independent factors and the dependent variables used in this design listed in Table 5.1. The 
amounts of PC, cholesterol, DSPE and sonication time used to prepare each of the 27 
formulations are given in Table 5.2. These high, middle, and low levels were selected from the 
preliminary experimentation.  
 
Table 5.1: The Box–Behnken design independent and dependent variables are shown 
Independent variables Low Middle High 
X1: L-α-Phosphatidylcholine (PC) 50 87.5 125 
X2: Cholesterol (CHOL) 0 37.5 75 
X3: 1,2-distearoyl-sn-glycero-3-
phosphatidyl-ethanolamine (DSPE) 
0 25 50 
X4: Sonication Time 5 17.5 30 
Dependent variables Goal 
Y1: Z-Average size (nm) Minimise 
Y2: Polydispersity Index (pdi) Minimise 
Y3: Zeta potential (Mv) In range 
Y4: % drug loading (%DL) Maximise 
Y5: % Entrapment Efficiency  (%EE) Maximise 
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Table 5.2: The BB design formulations 
Formulation X1 (mg) X2 (mg) X3 (mg) X4 (min) 
1 50 37.5 0 17.5 
2 50 37.5 25 30 
3 87.5 0 25 5 
4 87.5 37.5 25 17.5 
5 87.5 37.5 0 5 
6 125 37.5 50 17.5 
7 125 0 25 17.5 
8 87.5 75 50 17.5 
9 87.5 0 25 30 
10 50 0 25 17.5 
11 50 37.5 50 17.5 
12 87.5 0 0 17.5 
13 125 37.5 0 17.5 
14 125 75 25 17.5 
15 87.5 37.5 50 5 
16 87.5 75 25 30 
17 50 75 25 17.5 
18 87.5 37.5 25 17.5 
19 87.5 37.5 0 30 
20 87.5 37.5 50 30 
21 87.5 75 25 5 
22 87.5 37.5 25 17.5 
23 87.5 75 0 17.5 
24 125 37.5 25 5 
25 50 37.5 25 5 
26 125 37.5 25 30 
27 87.5 0 50 17.5 
 
 
 
5.2.2.2. Formulation of the [Cu(glygly)(PS)]-loaded nanoliposomes 
NLs were prepared as described in chapter 4 (Section 4.2.2.3). The NLs were frozen at -80oC 
for 2h and then lyophillised for 24h to maintain the stability for longer storage (Chen et al., 2010; 
Wieberet al., 2012) and to prevent them from aggregation. Sucrose (1%w/v) was used as a 
cyroprotectant (Zhoua et al., 2013). 
 
5.2.3. Dermal sludge preparation 
The dermal sludgeformulation was composed of 76%w/v[Cu(glygly)(PS)]-loaded NLs 
(equivalent to 1%w/vPS), 4%w/vHPMC/PVA (1:1 ratio), 10%v/vglycerol and 76%v/vdouble 
*X1: L-α-Phosphatidylcholine (PC); X2: Cholesterol (CHOL); X3: 1,2-distearoyl-
sn-glycero-3-phosphatidyl-ethanolamine (DSPE) and X4: Sonication Time. 
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deionised  water. For the preparation of the sludge, deionised water and glycerol were mixed 
using magnetic stirrer, HPMC and PVA were added slowly until a clear gel was formed. The gel 
was left for 24h to form while stirring. Subsequently, [Cu(glygly)(PS)]-loaded NLs were added to 
the vortex of agitated gel, the NLs were not soluble in the formulation, they remained suspended 
and the dermal sludge was formed. The dermal nanoliposomal sludge was stored at 4°C until 
further usage (Prasad and Kishore, 2012; Darwhekar et al., 2011 and Shah et al., 2012).  
 
 
5.2.4. Preparation of Conventional prednisolone Gel 
Conventional prednisolone gel was as per the method described by Shakeel et al. (2007) with 
modifications where 1g of the Carbopol® 940 was dispersed in a sufficient quantity of deionised 
water. The carbopol 940 solution was left in the dark while stirring overnight for complete 
settling of the gel. Thereafter 1g of prednisolone was dissolved in deionised water. This solution 
of drug was added slowly to the aqueous dispersion of Carbopol® 940. Subsequently additional 
ingredients like isopropyl alcohol 10%w/w, propylene glycol 10%w/w, and triethanolamine 
0.5%w/w were added to obtain a homogeneous neutral gel. 
 
5.2.5. Determination of entrapment efficiency and drug loading of the nanoliposomes 
 For the quantitative determination of [Cu(glygly)(PS)] within the NLs, the loading and 
encapsulation efficacy of the NLs was determined. Drug loading capacity (DL) was calculated 
as [Cu(glygly)(PS)] complex analysed and determined as detailed in chapter 4, section 
4.2.9.The % entrapment efficiency (%EE) of [Cu(glygly)(PS)] in NLs was determined, being the 
ratio between actual and theoretical loading, using the following equation: 
 %EE =
[Cu(glygly)(PS)] added in NLs 
 total [Cu(glygly)(PS)] added
∗ 100Equation 5.1 
 
The %DL and EE were both determined using the UV/Vis spectrometry (PerkinElmer Spectrum 
100, Llantrisant, Wales, UK), the detection wavelength was 242nm. 
 
5.2.6. Chemical structural analysis of [Cu(glygly)(PS)] complex, optimised 
[Cu(glygly)(PS)]-loaded and unloaded NLs using Fourier transform infrared (FTIR) 
spectroscopy 
Fourier-transform infrared (FTIR) spectroscopy was generated using A Perkin Elmer Spectrum 
2000 FTIR spectrometer with a MIRTGS detector, (PerkinElmer Spectrum 100, Llantrisant, 
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Wales, UK). FTIR analysis was performed on the dried [Cu(glygly)(PS)] complex, optimised 
[Cu(glygly)(PS)]-loaded and unloaded NLs, NLs loaded nanoliposomal sludge and unloaded 
HPMC/PVP gel as described in chapter 3, section 3.2.3. 
 
5.2.7. Determination of the thermal properties of the [Cu(glygly)(PS)] complex, optimised 
[Cu(glygly)(PS)]-loaded and unloaded NLs 
5.2.7.1. Differential scanning calorimeter analysis 
The differential scanning calorimeter (DSC) analysis of the dried [Cu(glygly)(PS)] complex, 
optimised [Cu(glygly)(PS)]-loaded and unloaded NLs was perfomed as detailed in Chapter 3, 
section 3.2.8. 
 
5.2.7.2. Thermogravimetric analysis 
Thermal analysis was performed using thermogravimetric analysis (TGA) (Toleda TC15 TA 
controller, Mettler). It was used to measure how the changes in chemical and physical 
properties of the [Cu(glygly)(PS)], optimised[Cu(glygly)(PS)]-loaded and unloaded NLs, as 
detailed in chapter 3, section 3.2.9. 
 
5.2.8. Determination of the size and zeta potential of the nanoliposomes 
The particle size was analysed to determine the typical diameter and PdI of the NLs, also zeta 
potential analysis was performed to establish the surface charge and physical stability of the 
NLs. These procedures were carried out using a Zetasizer NanoZS (Malvern Instruments, 
Worcestershire, UK).  
 
5.2.9. Analysis of the surface and structure morphology of the optimised dual pH/redox 
responsive nanolipoosmes 
5.2.9.1. Scanning electron microscopy 
The surface morphology of the cryo-protected [Cu(glygly)(PS)]-loaded NLs were analysed using 
a scanning electron microscopy (SEM) (Jeol JSM-120, Tokyo, Japan) . A small quantity of the 
cryo-protected lyophilized NLs, was sputter coated using gold isotope while being mounted on 
an aluminum spud, with an EPI coater (SPI Module TM sputter-coater and control unit, Chester, 
PA, USA). After coating the NLs for 60s, under constant nitrogen gas conditions, the sample 
was analysed using a FEI Quanta 400F (FEITM, Hillsboro, OR, USA) electron microscope. To 
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produce high image resolution of the particles an electron acceleration charge of 20kV was 
used. 
 
5.2.9.2. Transmission electron microscopy 
The structural morphology of the [Cu(glygly)(PS)]-loaded NLs was determined using a 
transmission electron microscopy (TEM) (Jeol 1200 EX, Japan), as described in chapter 4, 
section 4.2.7. 
 
5.2.10. Analysis of the rheological behaviour of the nanoliposomal sludge 
The storage modulus (G′), loss modulus (G′′) and dynamic viscosity (η) of the sludge were 
determined using a Haake Modular Advanced Rheometer (Thermo Electron Corp., Karlsruhe, 
Germany). These rheological tests were determined over a frequency of 1Hz. In the oscillatory 
mode, a parallel plate of 40mm diameter, the geometry measuring system was employed, and 
the gap was set to 1mm. The G′ and G′′ was employed to determine the viscoelasticity of the 
sludge, applying a small oscillatory stress and measuring the resulting strain. This was used to 
determine the deformation energy and flow, while the η was used to analyse the flow properties 
of the sludge. The G′, G′′ and η tests were all undertaken at 37°C, recorded and each test was 
run in triplicate (Kantaria, Rees and Lawrence, 1999). 
 
5.2.11. Analysis of the textural properties of the optimizednanoliposomal sludge 
A Texture Analyser (TA.XT plus. Textureanalyser, Stable Microsystems®, Surrey, UK) was 
used to determine the textural properties of the optimizednanoliposomal sludge. The textural 
properties of the sludge were performed using a Force (N)-Time (Sec) profile, as a measure of 
the sludge hardness, cohesiveness and adhesiveness after a compressive stress was applied 
by the textural probe. Three replicate analyses were performed at room temperature for the 
sludge and the parameter employed for the textural properties are shown in Table 5.3. 
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Table 5.3: Textural analysis parameter settings for determining the nanoliposomal sludge 
textural properties. 
 
Parameter Setting 
Test Mode Compression 
Pre-Test Speed 1.0mm/sec 
Test Speed 1.5mm/sec 
Post-Speed 1.5mm/sec 
Target Mode Force 
Force 4N 
Trigger Type Auto Force 
Trigger Force 0.05N 
Probe type 10mm cylinder 
 
5.2.12. In vitro drug release studies of the PS, [Cu(glygly)(PS)]-loaded NLs and 
[Cu(glygly)(PS)]- loaded nanoliposomal sludge 
In vitrodrug release from conventional oral PS, [Cu(glygly)(PS)]-loaded NLs and 
[Cu(glygly)(PS)]- loaded nanoliposomal sludge was performed in buffers (PBS pH 7.4 and 
acetate buffer at pH 5) with and without GSH (10mM) at 37°C using dialysis membranes 
(MWCO: 1.2kDa). It has been reported that the concentration of GSH in ECM fluid is less than 
0.01mM, while ICM GSH is significantly higher, in the range of ~10mM.The medium of pH 7.4 
without GSH corresponds to the condition in which NLs will encounter during circulation after 
administration, while the medium of pH 7.4 with 10mM GSH corresponds to the ICM condition, 
and pH 5 mimics the ECM condition which has insignificant GSH (RB KC, B Thapa, P Xu, 
2012).These three formulations were placed in  dialysis bags and immersed into 30mL buffer 
solutions in the different media. At a predetermined time (0.5, 1, 2, 4, 6, 8 and 24h) 1.0mL of the 
buffer was taken out and the same amount of fresh buffer was added to make up the constant 
volume of the release medium. 
 
Absorbance using the UV-Vis spectrophotometry (PerkinElmer Spectrum 100, Llantrisant, 
Wales, UK) at 248nm and 242nm for the PS and complex was used to quantify the release, 
concentration versus absorbance calibration curves were employed as shown in chapter 3, 
section 3.3. 
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5.2.13. Ex vivo permeation studies of the [Cu(glygly)(PS)]-loaded nanoliposomal sludge 
compared to conventional formulations 
The full-thickness of a pig’s ear skin was separated from cartilage using a scalpel and dermis 
was wiped with isopropyl alcohol to remove any residual adhering fat. The skin was washed 
with deionised water, wrapped in aluminum foil and stored in a freezer at −20°C, and was used 
within a month. Prior to the diffusion experiment the epidermis was thawed at room temperature 
and cut to appropriate size (2 by 2cm). The ex vivo studies were performed on prednisolone 
cream, conventional prednisolone gel, [Cu(glygly)(PS)]-loaded HPMC/PVP gel, and 
[Cu(glygly)(PS)]-loaded nanoliposomal sludge in PBS pH 7.4. These studies were performed 
according to method adapted from Wissing and Muller (2002), as detailed in chapter 3, section 
3.2.11. 
 
Furthermore, the skin membrane integrity was evaluated before and after each exposure to the 
different formulations being tested by measuring the skin surface electrical conductivity 
according to a method described by Klimova et al. (2012) with modifications. A simple dual 
pH/conductivity meter (Mettler-Toledo, Zürich, Switzerland) was used to measure the 
conductivity in order to determine if the skin remained intact while in contact with the 
formulations. 
 
5.2.13.1. Determination of complex and drug retention in the Skin 
At the end of the permeation experiments, the skin was carefully removed from the Franz cell 
and the skin surface was swabbed and washed twice with PBS pH 7.4 ensuring that no traces 
of formulation were left on the skin surface. The permeation area of the skin was excised and 
cut into small pieces to extract the drug/complex content present in the skin with methanol. The 
resulting solutions were centrifuged at 5000rpm for 30min using and drug/complex retained was 
expressed as percent of the initially applied formulation (Ghanbarzadehand Arami, 2013). 
 
5.3.Results and discussions 
5.3.1.1. The results of optimization using the Box–Behnken design 
All 27 formulations from the design template produced NLs of variable z-average size, zeta 
potential, drug loading, and entrapment efficacy (Table 5.4). The results showed that the DEE 
ranged from 86.0 to 98.2% and DL ranged from 16 to 21%. The maximum DEE value (98.2%) 
was found in conditions of X1 = 87.5mg, X2 = 37.5mg, X3 = 50mg and X4 = 30min. The 
measured z-average size for the different formulations showed wide variation, the particles 
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ranged from 88 to 933nm. The minimum particle size was found in conditions X1 = 87.5mg, X2 
= 37.5mg, X3 = 50mg and X4 = 17.5min, which are the same conditions as the formulation with 
highest DEE, the only difference being the sonication time. It was also seen that the highest 
DL% is attributed to formulations in which the ratio of PC is the highest.  
 
These results clearly indicate that the responses values are strongly affected by the variables 
selected for the study. Further it was established that there was a correlation between particle 
size and amount of drug incorporated, the smaller the particle size the more drug was loaded 
mainly because of the increase in surface area with the reduction in particle size. Additional with 
the wide lipid compositions used there was significant influence of the lipid on the particle size 
as well amount of drug incorporated. Increasing the ratio of the cholesterol in comparison with 
the other lipid constituents significantly increased the particle size, which resulted in reduced % 
DEE and DL as observed by Patel et al. (2012) as well. This may be due to increased rigidity 
and packing density caused by the cholesterol/phospholipid molecules assembled into bilayer 
vesicles, which reduces the encapsulation of the drug on the hydrophobic [Cu(glygly)(PS)] by 
the lipid bilayer (Semple et al., 1996). 
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Table 5.4:Responses measured for the Box–Behnken design 
Formulation Y1 (nm) Y2 (Pdl) Y3 (Mv) Y4 (%) Y5 (%) 
1 394± 0 0.428±0.008 22.4±5.6 17.86 89.3±3.2 
2 252±18 0.44±0.002 12.6±5.2 20.1 95.4±2.1 
3 132± 2 0.363±0.004 27.5±0.5 17.56 87.8±6.1 
4 249±76 0.403±0.084 15.8±1.2 18.14 90.7±2.9 
5 181±24 0.319±0.009 8.89±5.14 17.2 86.0±1.8 
6 256±23 0.408±0.06 23.9±4.03 19.9 96.2±2.7 
7 257±22 0.380±0.09 5.6±0.9 18.82 94.1±3.3 
8 88±43 0.295±0.120 17.9±2.1 19.1 95.5+1.2 
9 275±80 0.295±0.09 18.8±6.2 18.98 94.9±2.0 
10 178±46 0.340±0.05 26.4±1.4 18.76 93.8±0.9 
11 315±40 0.245±0.01 6.61±25 16.7 83.5±3.9 
12 119±51 0.240±0.075 26±8 18.84 94.2+2.2 
13 131±53 0.288±0.088 15.5±7 17.8 89+3.8 
14 176±90 0.399±0.099 0.625±0.6 18.82 94.1±0.8 
15 609±29 0.375±0.022 22.6±4.5 17.6 88±3.1 
16 160±29 0.423±0.003 4.1±2.2 19.3 96.5±2.8 
17 617±50 0.529±0.023 19.9±5 17.42 87.1±3.0 
18 249±76 0.403±0.084 15.8±1.2 18.14 90.7±2.9 
19 383±11 0.519±0.031 24.5±1.6 17.98 89.9±2.6 
20 342±20 0.361±0.012 20.7±2.4 20.64 98.2±0.8 
21 880±36 0.188±0.006 4.86±0.9 17.84 89.2±4.1 
22 249±76 0.403±0.084 15.8±1.2 18.14 90.7±2.9 
23 772±46 0.459±0.099 14.6±5.71 17.62 88.1±3.3 
24 933±23 0.487±0.007 22.1±6 18.94 94.7±1.6 
25 250±47 0.482±0.004 21±4.1 17.86 89.3±2.0 
26 241±44 0.342±0.034 4.72±1.1 21.02 95.1±0.7 
27 252±24 0.424±0.022 31.5±1.5 17.68 88.4±3.9 
 
 
The obtained results were inputted into the MINITAB®(V14, State College, Pennsylvania, 
USA)software to yield four possible optimized formulations and the most appropriate optimized 
formulation had a composite desirability (D) of 1.000. The optimal formulation had independent 
* Y1: Z-Average size (nm); Y2: Polydispersity Index (pdi); Y3: Zeta potential 
(Mv); Y4: % drug loading (%DL) and Y5: % Entrapment Efficiency (%EE). 
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parameters as follows; sonication time of 30min and PC: Chol: DSPE ratio of 50: 75: 50 which 
gave predicted NLs responses of; z-average size 52.1667nm (Y1), % DL of 19.6967 (Y4) and 
%EE of 95.650 (Y5) (Figure 5.1). The independent and dependent variables relationship 
generated using MINITAB® is also described in a study done by Ailiesei et al. (2014) and Lu et 
al. (2014), where the size of the NLs increases with increase in cholesterol ratio compared to 
PC, while the sonication time also plays a major role in reducing the particle size. 
 
 
Figure 5.1: The resulted generated using MINITAB® for the optimizedformulation, the desirable 
results are also shown. 
 
5.3.1.2. Statistical validity of the optimized formulation 
The suitability of the model was assessed byadditional experimental data that was derived using 
the optimized formulation. The predicted values were approximately a size of 52.2nm, %DL of 
19.7% and %EE of 95.7% and in the experimental the data it was 138±32.34nm, 21.2±0.5% 
and 93.8±0.8% for Y1, Y4 and Y5, respectively (Table 5.5). Although the particle size of the 
optimized NLs was not within the same range as the predicted value the generated model was 
considered to be adequately valid. According to Lu et al. (2014) it was stated that the bulky 
nature of lipids may not be suitable for smaller particle range especially in cases where the 
cholesterol ratio is high compared to the rest of the lipids, and also a particle size below 200nm 
is considered sufficient for penetration through the dermis and hair follicles for a TDDS (Tomoda 
et al., 2012; Gomes et al., 2014). 
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Table 5.5:The predicted responses versus the actual responses from the optimized formulation. 
Responses Y1 (nm) Y4 (%) Y5 (%) 
Predicted 52.2 19.70 95.7 
Actual  138±18 21.2±0.5 93.8±0.8 
 
5.3.1.3. Dermal sludge formulation 
The optimized Cu(glygly)(PS)]-loaded NLs were intended for a TDDS, therefore an adequate 
permeation efficacy, skin adhesiveness and rheology was achieved by preparing a 
nanoliposomal sludge of desired properties. The sludge would be applied dermally and degrade 
in an inflammatory-responsive manner as described previously described in chapter 4 (section 
4.3.1) and shown in Figure 5.2. 
 
Figure 5.2: (a) The expected penetration of the nanoliposomal sludge through theskin and (b) 
thereafter its sequential degradation of the inflamed site occuras described in Chapter 3, Figure 
4.3. 
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5.3.2. Structural characterisation of the optimized nanoliposomes and sludge 
The FTIR spectra of the complex loaded-NLs and unloaded NLs 
indicate that characteristic peaks of the unloaded NLs were not altered and had no changes 
in their positions after [Cu(glygly)(PS)] encapsulation, as detailed in chapter 3 section 3.3.2. The 
similarities and differences are seen in Figure 5.3 where the spectra are superimposed. From 
these results it can be established that complex encapsulation within the optimised NLs was 
achieved. 
 
Figure 5.3:Superimposed FTIR spectra of[Cu(glygly)(PS)],  [Cu(glygly)(PS)]-loaded NLs and 
unloaded NLs 
Figure 5.4 shows the FTIR spectroscopic analysis of the unloaded gel compared to 
nanoliposomal sludge which also showed no remarkable chemical interaction occurring 
between the complex and the polymers used to formulate the gel. Notably the nanoliposome 
characteristic peak is seen (box in figure 5) at 1729.29cm−1 and 1728.9cm−1 for [Cu(glygly)(PS)]-
loaded NLs and nanoliposomal sludge. These FTIR spectra shows that the [Cu(glygly)(PS)]-
loaded NLs were successfully adsorbed into the HPMC/PVP gel matrix. FTIR spectroscopy is 
one of the most powerful chemical analytical techniques used for analyzing, vibration, and 
characteristics of chemical functional groups of phospholipids, similar results were 
demonstrated by Mufamadi et al. (2013) and Jin et al. (2014). Overall the absence of significant 
chemical interaction within the loaded NLs and nanoliposomal gel has an added advantage 
since the respective phospholipids and polymeric functions of the NLs and gel are retained, 
hence the site-specific function of the NLs is not altered by the loading within the gel. 
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Figure 5.4: The comparative FTIR spectroscopic analysis of the placebo gel and loaded NLs 
compared to the nanolipoosomal sludge which is the combination of the two. 
 
5.3.3. Evaluation of the thermal properties of the optimized nanoliposomes and sludge 
The DSC tracings for [Cu(glygly)(PS)], unloaded NLs and [Cu(glygly)(PS)]-loaded NLs are 
presented in Figure 5.5. The complex showed an endothermic peaks at 380°C and an 
exothermic peak at 385°C, which corresponds to its melting and glass transition temparature. 
The endothermic peaks for unloaded NLs are observed at 194.3and 280°C indicating glass 
transition and melting temperatures, respectively.The endothermic peaks for the 
[Cu(glygly)(PS)]-loaded NLs were observed at 185.3, 237.3, 285 and 358.7°C in which the 
temperatures have relatively shifted with an additional peak at 358.7°C compared to the 
unloaded NLs. These changes in the endothermic peaks may be attributed to the physical and 
morphological changes of NLs after [Cu(glygly)(PS)] loading. Additionally the absence of the 
significant [Cu(glygly)(PS)] peaks and shifting of the lipid bilayer components endotherm 
suggested significant interaction of [Cu(glygly)(PS)] with the bilayers. Similar findings were 
previously noted by Hathout et al. (2007).  
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Figure 5.5: DSC analysis of [Cu(glygly)(PS)] complex, (b) unloaded NLs and (c) 
[Cu(glygly)(PS)]-loaded NLs 
 
Thermogravimetric (TG/DTG) analysis of the [Cu(glygly)(PS)] complex was employed to provide 
quantitative information on mass losses due to thermal decomposition as a function of 
temperature. The thermal analyses data of [Cu(glygly)(PS)], [Cu(glygly)(PS)]-loaded and 
unloaded NLs are shown in figure 5.6a, b and c respectively.The thermogram (Figure 5.6a) for 
[Cu(glygly)(PS)] shows the presence of an anhydrous complex containing no water of 
crystallization, and no coordinated water molecules as evident by the plateau from 100 to 
200°C. From the DTG/TGA curve, it is clear that the thermal decomposition of the 
Cu(glygly)(PS)] complex occurs in three steps. The initial mass loss occurs within the 
temperature range of 319–325°C, Tpeak DTG of 323.5°C, with a mass loss of 14.5% possibly 
due to elimination of the glygly ligand.  The second mass loss has a split peak with the Tpeak 
DTG of 373 and 385°C occurring in the temperature range of 370-390°C (mass loss = ~15.5%, 
respectively) possibly due to initial loss of PS. The third step corresponds to the thermal 
decomposition and complete elimination of the remaining part of the PS drug molecule staring 
from 500°C on the thermogram of the complex with final mass loss of ~83% at DTG between 
740-760°Cfor the leaving CuO residue. Comparable findings were obtained in a study done by 
Maravalli and Goudar (1999) on thermal analysis of copper complexes.  
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Figure 5.6: TG/DTG) analysis of the (a) [Cu(glygly)(PS)], (b) [Cu(glygly)(PS)]-loaded and (b) 
unloaded NLs 
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5.3.4. Particle size and zeta potential of the optimised nanoliposomes 
The size distribution is generally used as a characterisation tool to evaluate the stability of NLs, 
and vesicle size is a relevant characteristic regarding both the organ distribution and 
encapsulation or adsorption efficiency of liposomal drug carriers. Polydispersity is an indicator of 
particle diameter distribution in colloidal systems. The smaller the value of polydispersity index 
(PdI), the more likely the particle diameter distribution is narrower, and thus particles show 
better uniformity in diameter (Ding et al., 2011). The ideal nanoliposome particle size ws 
obtained using the sonication procedure, the average particle size of the unloaded NLs was 
99.14±48.7nm with a PdI of 0.24 (Figure 5.7a). The particle size was slightly increased after 
[Cu(glygly)(PS)] was loaded into the NLs to 138.0±32.34nm with PDI of 0.20 (Figure 5.7c). The 
particle size doesnot match the predicted size (52.1667nm) according to the BB design due to 
the bulky nanture of the lipids, complex and EuE100-cyst combined. However it has been 
reported that a mean particle size of 200nm or less is sufficient for penetrating through the 
dermis and hair follicles (Tomoda et al., 2012; Gomes et al., 2014), hence these nanoliposomes 
are considered appropriate for TDDS. 
 
 
 
 
 
Figure 5.7: The size (a+c) and zeta potential (b+d) distribution of the unloaded (a+b) and 
loaded (b+d) NLs 
 
The zeta potential of NLs was 28.0±3.81mV and 21.9±6.47mV before and after [Cu(glygly)(PS)]  
loading, respectively. Figure 5.7b and d shows the zeta potential for the unloaded and loaded 
NLs, respectively. The NLs showed a positive zeta potential, in agreement with the observations 
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of previous studies where chitosan, which is also a cationic polymer, was used to coat 
liposomes (Mady et al., 2010). This potential can be attributed to the cationic EuE100-Cyst 
adsorbed to the liposomal surface. Since the [Cu(glygly)(PS)] complex has a neutral charge and 
is hydrophobic it is adsorbed on the surface of the NLs (Xu et al., 2007); the adsorption of  the 
[Cu(glygly)(PS)] appears to have reduced the density of positive charge in the loaded NLs. The 
magnitude of the zeta potential indicates the potential stability of the colloidal system, as zeta 
potential increases the colloidal stability also increases (Mady et al., 2010). As a rule of 
thumbdescribed by Honary et al. (2013), zetapotential values of around 20mV or higher and 
lower than -20mV can provide sufficient stabilization, therefore the nanoliposome zeta potential 
in this study is desirable. 
 
5.3.5. The electron micrographs of the optimized [Cu(glygly)(PS)]-Loaded nanoliposomes 
The physical morphology of the Cu(glygly)(PS)]-Loaded NLs was evaluated using TEM. Figure 
5.8a reveals that the NLs have a mean particle size of 100–200 nm, and most of them appeared 
spherical in shape. The particles existed dispersedly on the copper grid, and they were not 
agglomerated. Further seen in the inserted figure is that the NLs were unilaminar and these 
results agree with previous studies (Mufamadi et al., 2012; Fonte et al., 2014 and Mohan et al., 
2014). 
 
The surface morphology of the cyroprotected NLs was assessed using SEM (Figure 5.8b). The 
powder obtained by lyophilization of the NLs containing 1% sucrose cryoprotectant indicates 
that fusion of the phospholipid nanoparticulates did not occur. The lyophilized NLs are visible in 
the micrographs as spherical structures and they are clearly incorporated into the excess mass 
of sucrose. According to Yokota, Moraes and Pinho (2012) the addition of cryoprotectants 
prevents leakage or fusion and plays an essential role in cake formation by creating an 
amorphous matrix in and around the phospholipid vesicles. Similar studies were undertaken by 
Moretton et al. (2011) and Zhoua et al. (2013) where the addition of a cryoprotectant enhanced 
the separation of nanoparticulates without altering the size and morphology of the phospholipid 
nanoparticulates. 
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Figure 5.8:a) The TEM analysis of the [Cu(glygly)(PS)]- Loaded NLs in a negative stain (uranyl 
acetate) and  b) SEM evaluation of the cryoprocted freeze dried NLs at 1260X 
 
 
5.3.6. Rheological evaluation of the optimized nanoliposomal sludge 
The nanoliposmal sludge was monitored by the dynamic small-amplitude oscillatory shear 
measurements using the time sweep mode at 1 rad s/1 of angular frequency and 1 strain. The 
storage modulus (G′) and loss modulus (G″) were presented as functions of time as shown in 
Figure 5.9. In general, it can be seen that the behavior of the sludge can be divided into three 
zones. First, there was a short period where viscosity and elasticity were alternatively seen, of 
which when stress was applied there is an increase in G′ (decrease in G″) resulting in increase 
in viscosity. While when stress was removed there was an increase in G″ (decrease in G′) 
resulting in the gel retaining it elasticity. At the end of the first zone the frequency dropped to 
almost zero as G′ increased rapidly while G″ decreased rapidly as well when the transition stage 
was reached. During the final zone the sludge reached its fluidity zone, as the G′ increased and 
G″ decreased reaching their final equilibrium value. Additionally η* decreased with an increase 
in applied frequency, similar results are seen where solid lipid nanoparticles gel were formulated 
(Khurana et al., 2013). These results show that the sludge possess shear-thinning properties 
(pseudoplastic behavior) as it has the ability to thin during application (shear stress application) 
(Batheja et al., 2011) and reform following application of shear stress (Kumar et al., 2005). 
Therefore it was established that the sludge had desirable properties for topical application with 
ideal cohesiveness, adhesiveness and spreadibility.  
(a) (b) 
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Figure 5.9: The rheological analysis of the nanoliposomal sludge 
 
5.3.7. Determination of the texture properties of the optimized nanoliposomal sludge 
Textural analyses properties i.e. hardness, compressibility, cohesiveness and adhesiveness 
aredirectly correlated with in vivo sensory parameters. Therefore, they are valuable in designing 
an optimal transdermal formulation with desirable characteristics that contribute to patient 
acceptability and compliance (Hurler et al., 2012 and Gratieri et al., 2010). Figure 5.10 shows 
the texture analysis profile of the nanoliposomal sludge, where the maximum compressing 
force, cohesiveness, adhesiveness and minimum retracting forces are displayed.  
The maximum compressing force hereby present the hardness of the nanoliposomal sludge, 
which is related to the maximum work required to spread the product over a certain skin surface 
area. After the sludge has been applied on the skin it is desirable for the sludge to form a 
homogeneous layer on the skin surface. An idealnanoliposomal sludge, particularly in relation to 
prolonged retention time on the skin, for the treatment of inflammatory disorders, a balance 
between the sludge adhesiveness and cohesiveness should be maintained. Cohesiveness 
relates to the work required to spread the sludge over a certain skin surface (Hurler et al., 
2010), while adhesiveness relates to the work necessary to overcome the attractive forces 
between the surface of the sludge and the surface of the skin (Gratier et al., 2012). A 
formulation designed for transdermal use should present with good spreadability on the skin 
surface and adhere to the mucous layer without disintegrating, in order to prolong retention 
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time. A higher adhesiveness value imply greater adhesion at the skin surface and increase the 
retention time and based on the results presented (Figure 5.10), the nanoliposomal sludge 
confers these desirable properties, and they are in agreement with its storage modulus values. 
Similar findings were observed by Tamburic and Craig (1997). 
 
Figure 5.10: Typical force versus time plot of the nanoliposomal sludge. 
 
5.3.8. Drug release analysis of PS, [Cu(glygly)(PS)]-loaded NLs and [Cu(glygly)(PS)]- 
loaded nanoliposomal sludge 
The drug release profile of the [Cu(glygly)(PS)]-loaded nanoliposomal sludge, PS conventional 
gel, PS tablet and PS syrup upon acid and redox gradient was assessed in phosphate-buffered 
saline (PBS, pH 7.4) and acetate buffer (pH 5) with and without GSH (10mM) at 37°C. The 
nanoliposomal sludge results are summarized in Figure 5.11a. As expected, the release rate of 
[Cu(glygly)(PS)]  in PBS pH 7.4 was much slower than that in acetate buffer pH 5.0,  about 
21.9±1.1% and 40.4±2.1% of [Cu(glygly)(PS)]  was released respectively in the first 8h. 
However the amount of [Cu(glygly)(PS)] released from the NLs was promptly increased when it 
was incubated in the medium complemented with 10mM GSH. At pH 7.4 and 5.0 with GSH a 
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release of 67.5±1.5% and 70.1±0.9% was achieved respectively, over the same time period. It 
is worth noting that even though the release of the [Cu(glygly)(PS)]  is low at pH  7.4 but with 
the supplementation of GSH the released is notably enhanced such that more [Cu(glygly)(PS)]  
was release compared to pH 5, indicating the superiority of the redox-sensitivity of the 
nanoliposomal sludge, which could be attributed to the direct incorporation of disulfide bonds to 
the polymeric backbone of the EuE100 used in the nanocarrier preparation, the cleavage of 
which highly promoted drug release (Lu et al., 2014). Similar finding are observed in studies are 
observed in cancer targeted drug delivery which is also characterized as an inflammatory 
disease (Pan et al., 2012; Lu et al., 2014; Lv et al., 2014).The nanolipsomal sludge slowed 
down the release rate of the [Cu(glygly)(PS)] complex as compared to the release  from the NLs 
described in (Chapter 4, section 4.3.10), this delay is advantageous to the system as it has to 
first penetrate through the skin before reaching the site of release. The nanolipsomal sludge is 
expected to effectively enhance the penetration of the NLs through the skin, while the NLs will 
deliver the [Cu(glygly)(PS)] complex, reducing the undesired drug loss during blood circulation 
and hence reducing the drug-related side effect and preferentially release the drugs under the 
inflammatory-relevant conditions. Further there is improved anti-inflammatory/antioxidant 
properties of the complex compared to parent, which will altogether lead to the enhanced anti-
inflammatory efficacy in TRAPS. 
 
Comparative in vitro skin release  studies were performed to compare the release of drug from  
[Cu(glygly)(PS)] loaded nanoliposomal sludge, [Cu(glygly)(PS)] loaded gel , PS conventional 
gel, PS cream, tablet and syrup, all having the same quantity (1% w/w) of PS in the medium of 
pH 7.4 with 10mM GSH corresponds to the ICM condition. The release was highest from the PS 
tablet and syrup (Figures 5.11b), however to be noted is that the release of both these 
formulations is not controlled (Figure 5.11c and d for tablet and syrup, respectively) as their 
release remain constant at about 90±5% at 8h all the drug is released within the first 6h in both 
formulations at all mediums. The sludge showed improved release compared to the 
conventional gel which also releases the drug in a non-controlled manner (Figure 5.11e), where 
approximately 30±6% is release at 8h in all the media. The complex loaded gel showed an 
intermediate release profile (Figure 5.11f) of approximately 30±5% of the complex in all media. 
The cream had the lowest % release profile (Figure 11g). Overall the [Cu(glygly)(PS)]-loaded 
nanolipsomal sludge significantly improved the in vitro % release profile of the [Cu(glygly)(PS)] 
complexby delaying the release rate of the [Cu(glygly)(PS)] complex, this is mainly due to gel 
matrix.  
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Figure 5.11: (a) The % [Cu(glygly)(PS)]  release from the nanolipoosomal sludge treated with 
GSH (10 mM) in acid (pH 5.0) and normal pH 7.4  at 37 °C. (b) The comparative combined data 
of all the marketed PS formulations (cream, tablet and syrup), conventional gel and novel 
[Cu(glygly)(PS)]  loaded nanolipsomal sludge formulation. (c) The % PS  release from the tablet 
treated with GSH (10 mM) in acid (pH 5.0) and normal pH 7.4 at 37 °C. (d) The % PS  release 
from the syrup treated with GSH (10 mM) in acid (pH 5.0) and normal pH 7.4 at 37 °C. (e) The 
PS  release from the conventional gel treated with GSH (10 mM) in acid (pH 5.0) and normal pH 
7.4 at 37 °C. (f) The [Cu(glygly)(PS)] release from the PVP/HPMC gel treated with GSH (10 
mM) in acid (pH 5.0) and normal pH 7.4  at 37 °C.  (g) The PS  release from the cream treated 
with GSH (10 mM) in acid (pH 5.0) and normal pH 7.4 at 37 °C. (Data represent mean ±S.D. 
(n=3)). 
 
5.3.9. Skin Permeation evaluation 
Transdermal cumulative flux for the marketed formulation (cream), conventional gel, 
[Cu(glygly)(PS)]  loaded PVP/HPMC gel and [Cu(glygly)(PS)] loaded nanoliposomal sludge 
across the excised pig skin was 10.9± 0.9, 11.3 ± 1.6, 18.9±2.2 and 26.6 ± 1.2µg/cm3/h, 
respectively after 8h  in PBS pH 7.4 at 37°C (Figure 5.12) .  
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Figure 5.12: Comparative permeation studies throught the pig skin in PBS pH7.4 at 37 °C. 
 
The flux from the nanoliposomal sludge was significantly higher (approximately 2.1±0.6-fold 
higher) than that obtained after application of either the conventional gel or cream in PBS pH 
7.4 and approximately 0.4± 0.5-fold higher than the HPMC/PVP gel in PBS pH 7.4. The data 
indicates that the transdermal flux of [Cu(glygly)(PS)]  was enhanced and this may be attributed 
to the vesicle size (138.0±52.34nm) as it has been established that particle size <200nm results 
into an improved permeation (Mavuso et al., 2015). Furthermore, better permeation of 
[Cu(glygly)(PS)]  from the sludge compared to either the [Cu(glygly)(PS)] complex (Chapter 3, 
section 3.3.3) and HPMC/PVP gel alone suggested some kind of synergistic mechanism 
between nanoliposmal vesicles, the gel matrix, and skin lipids.  Results also revealed that, some 
of the drug and complex were retained in the skin layers, the amount of drug or/and complex 
retained was 4.2±1.1, 4.5±0.9, 5.8±0.5 and 11.5±0.7µg/cm3 for the cream, conventional gel, 
HPMC/PVP gel and sludge, respectively. Compared to the rest of the formulation, incorporation 
of the vesicular formulation into the HPMC/PVP gel preparation significantly increased flux. It 
can be concluded from the results that the nanoliposomal sludge could penetrate and deposit 
the bioactive 2-3 times more than the conventional and other formulations. High deposition 
percent indicated that the sludge could provide a drug reservoir in skin to prolong the effect of 
bioactive and for its local effects. Similar findings were also recorded in other studies 
(Ghanbarzadeh and Arami, 2013). Moreover the skin integrity was maintained (Table 5.6) as 
there is only a slight change in conductivity from before and 24h after formulation application, 
and this was considered insignificant. Hence it was concluded that the permeation was not 
altered by the skin’s integrity.  
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Table 5.6: Comparative skin conductivity values before and after ex vivo studies. 
Formulation Conductivity (mV) 
Before exposure After exposure 
Cream 141.7±1.2 142.8±1.6 
Conventional gel 141.8±0.9 142.1±1.3 
HPMC/PVP gel 145.2±2.0 146.0±0.8 
Nnaoliposomal sludge 145.0±2.7 145.9±1.1 
 
5.4 . Concluding Remarks 
The dual pH/redox responsive [Cu(glygly)(PS)]-loaded NLs were successfully formulated and 
the design of the NLs was optimised using the Box-Behnken experimental design. The 
dependent responses were the Z-Average size, %DL and %DEE, and, for diverse combinations 
of independent variables, which were the different ratios of lipids, cholesterol and sonication 
time. The quantitative effect of independent variables at different levels on the dependent 
response was investigated by using polynomial equations generated by the model. This study 
revealed that the relative ratios of the phospholipids significantly influenced the size of the NLs, 
which alters the %DL and %DEE. On the basis of desirable constraints, the point predication 
technique of Box-Behnken design proposed an optimized formulation combination. The optimal 
formulation had independent parameters of sonication time of 30min and PC: Chol: DSPE ratio 
of 50: 75: 50 which gave predicted NLs responses of; z-average size 52.167nm (Y1), % DL of 
19.697 (Y4) and %EE of 95.650 (Y5). It can be concluded that [Cu(glygly)(PS)]-loaded NLs 
were successfully optimized and developed using the Box-Behnken design. 
 
The [Cu(glygly)(PS)]-loaded NLs showed a dual pH/redox responsive release pattern with a 
promptly increased release in an environment mimicking inflammation while a sustained release 
was achieved in a normal physiological environment. Further the flux from the nanoliposmal 
sludge was significantly higher (about 2.1±0.6-fold higher) than that obtained after application of 
either the conventional gel or cream. Moreover, more [Cu(glygly)(PS)] was retained in the skin 
layers compared to other formulations and the integrity of the skin was maintained throughout 
the ex vivo studies. In conclusion this platform has shown the potential for use in the 
management of TRAPS inflammatory disorder, however further in vivo evaluation studies are 
necessary to confirm the superiority of this design. 
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CHAPTER 6 
IN VIVO EVALUATION OF A [COPPER(GLYCYLGLYCINE)(PREDNISOLONE 
SUCCINATE)]- LOADED NANOLIPOSOMAL SLUDGE IN SPRAGUE-DAWLEY RATS FOR 
TRANSDERMAL DRUG DELIVERY 
 
 
6.1. Introduction 
Numerous transdermal drug delivery system (TDDS) containing drugs such as nitroglycerin, 
scopoloamine, clonidine, fentanyl, oxybutynin, nicotine and estradiol are already available in the 
market (Wokovich et al., 2006). However, the use of TDDS is limited due to a number of 
reasons such as tremendously low drug release rate from the matrix and the low permeability of 
the drug through the skin (Im et al., 2010). Generally, specific regulations over the quantity of 
the drug and its rate of release are necessary in optimizing the overall drug therapy. The main 
hypothesis of this study was to optimize the overall drug therapy in TNF receptor associated 
periodic syndrome (TRAPS) which is a genetic auto-inflammatory disorder through TDDS. This 
may be attained by designing a drug nanocarrier system that responds to internal or external 
cues and releases the drug-metal complex in a predictable fashion.  
 
A dual stimuli responsive nanoliposomal sludge loaded with a Copper (II) liganded bioactive 
complex which is the [Copper(glycylglycine)(prednisolone)] ([Cu(glyg)(PS)]) complex that has 
been established to have improved in vitro anti-inflammatory/anti-oxidant activities (Chapter 3, 
section 3.3.10). Herein the objective is to show that these properties are enhanced as 
suggested by the in vitro studies. Additionally the nanoliposomal sludge was intended to 
achieve both systemic and local effects via skin application for TDD, as nanoliposomes (NLs) 
are believed to improve the complex deposition within the skin at the site of action where the 
goal is to reduce systemic absorption and thus minimize side effects (El Maghraby  et al., 2008). 
Hence the efficacy of the NLs as carrier systems woul be evaluated for both local and systemic 
effects. 
 
In the present study the delivery of the [Cu(glyg)(PS)] complex from  the nanoliposomal sludge 
for TDD was tested over  a period of 24 hours in the rat model. The rat model has been selected 
as the ideal model as it share physiological and anatomical similarity to humans which makes 
them the ideal models for conduction of in vivo testing (Spanagel, 2000).Various studies of 
nanocarriers in TDD and its effects have been carried out in rat models (Akhter et al., 2008; Nal 
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et al., 2008; Pillai and Panchagnula, 2003). Additionally the size of rats allows for great 
manipulation and Sprague-Dawley rats are particularly docile and easy to handle (Suckow et al., 
2006). In vivo studies using the rats were aimed at providing information on the preclinical 
efficacy of the nanoliposomal sludge and the ant-inflammatory/ antioxidant activity of the 
complex in vivofor correlation with in vitro studies. Additionallythe kinetics of drug release was 
evaluatedto determine PS concnentrationin the blood so that it can be established that the dual 
stimuli responsive delivery device increases the anti-inflammatory efficacy of the PS at the site 
of action, while it reduces the systemic availability of the drug, hence less steroidal side effects.  
 
The amount of [Cu(glyg)(PS)] complex released was analysed using Ultra Performance Liquid 
Chromatography (UPLC), as depicted in Chapter 3, section 3.3.1 (Figure 3.3). After the complex 
is released, the drug and metal coordination is broken (Lewis, 1984), as a result free PS may be 
detected in blood serum. A similar quantification procudure was carried out previously in a study 
done by Martins et al., 2015, where the release of a copper–naproxen metallodrug was done 
using High Performance Liquid Chromatography (HPLC). The molar concentration of PS is 
expected to be equivalent to that of Cu2+ as proposed in chapter 3. 
 
6.2. Materials and methods 
6.2.1. Materials 
The Sprague Dawley rats utilized in this study were obtained according to the Central Animal 
Services (CAS) protocols at the University of the Witwatersrand. Prednisolone succinate, 
dexamethasone and copper (II) nitrate and glycylglycine were purchased from Sigma Aldrich 
(St. Louis, MO, USA). Double de-ionized water was obtained from a Milli-Q system, (Milli- Q, 
Millipore, Johannesburg). Acetonitrile, prednisolone syrup and tables were commercially 
available. All solvents utilized for UPLC-UV detection were of UPLC grade and all other 
reagents were of analytical grade. The preparation of the optimized nanoliposomal sludge was 
discussed earlier in this dissertation in Chapter 5, Section 5.2.2. 
 
6.2.2. Nanoliposomal sludge sterilization and lyophillisation 
A suspension (10mg/ml) of NLs was diluted to a concentration of 10mg/5mL with water and 
sterilized by filtration through sterile disposable syringe filters (0.20μm Millipore filter) into 5mL 
glass vials (Darole et al., 2008). All glasswares were sterilized by autoclaving and the entire 
procedure was performed in a laminar flow hood (Esco. Singapore). The NLs were then frozen 
at −80°C for overnight, for long term stability the NLs were lyophillised in the presence of a 
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cryoprotectant (1% sucrose) and the samples were kept at −20°C (Chaudhury et al., 2012). The 
gel was sterilized under UV light overnight (Karunakaran et al., 2011; Luo et al., 2008) and NLs 
were then dispersed into it under the laminar flow hood unit. The sterility of the gel was 
validated by incubating the sludge in an agar plate at 37°C for 24h. 
 
6.2.3. Experimental design 
Sprague Dawley rats weighing 250 to 300g were housed in a room that was automatically 
maintained on a 12h light/dark cycle at 25°C and properly humidified. Animals were handled in 
accordance with the University of the Witwatersrand CAS guidelines. The 110 rats (5 for pilot 
and 105 for main study) were housed singly at the CAS and were allowed one week to adjust to 
the surroundings. They were fed with standard rodent pellet and supplied with water ad-libitum 
under strict hygienic conditions. The rats receiving an oral administration of the prednisolone 
were fasted from solid food for 12h before the experiments but habituated with a diet of jelly for 
sustenance and to ensuring that their energy levels were upheld (Pang et al., 2008). Prior to the 
main study a  pilot study was conducted using five additional rats with the aim of assessing 
inflammation induction using carrageenan and to test the efficacy of the open glass chamber to 
hold the formulation in place, Figure 6.1 shows the flow diagram of the procedure. 
 
Rats were assigned in groups of five (n=5/group, except at 0h where n=1/group), one rat was 
euthanized at each specific time point per group and all studies were done in triplicate. Each 
group underwent administration of the relevant formulation as well as blood sampling. To 
ensure that formulations remained in place, treated rats were covered with a layer of Tegaderm 
(3 M, St. Paul, MN), a layer of dry non-adherent gauze (Telfa, Kendall Company, Manfield, MA), 
and an elastic bandage was wrapped around the dorsum and abdomen of the rats. Prior to the 
application of all the formulations the rats were anesthetized with xylazine (5mg/kg) and 
ketamine (100mg/kg).  
 
This was an interventional study where 105 rats with an initial mass of 250g-300g were 
randomly assigned to 5 groups (21 rats per group) (refer to Flow diagram, Figure 6.2), the steps 
of the procedure are also summarised (Figure 6.3). 
 
Group 1: This was the placebo group where inflammatory challenged rats received a dermal 
application of placebo nanoliposomal sludge that was applied evenly on the dorsal portion 
(3.14cm2) of the rats.  
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Group 2: This was the test group where inflammatory challenged rats received a dermal 
application of [Cu(glyg)(PS)]-loaded nanoliposomal sludge that was applied evenly on the dorsal 
portion (3.14cm2)  of the rats.  
 
Group 3: This was the comparison group where inflammatory challenged rats received an oral 
formulation of the PS drug  
 
Group 4: This was the comparison group where inflammatory challenged rats received the 
model drug, a dermal application of prednisolone, which was applied on the dorsal portion 
(3.14cm2) of the rats. 
 
Group 5: This was the comparison group where healthy rats received a dermal application of 
[Cu(glyg)(PS)]-loaded nanoliposomal sludge, which was applied evenly on the dorsal portion 
(3.14cm2) of the rats.  
 
Group 2 is the experimental group and groups 1, 3, 4 and 5 are the control groups. In all groups 
inflammation was induced except group 5.  
 
At the end of both the pilot and main study the rats were euthanized through the cardiac 
puncture and sodium pentobarbital (200mg/kg). This was done in order to determine the 
concentration of the drug/ complex in the system of the animals a large volume of blood was 
needed (Parasuraman et al., 2010) and due to the small size of the animal, the animals were 
sacrificed in order to obtain the blood volume of 5mL (Beeton et al., 2007). Additionally 
histopathological skin samples were required in order to grade the induced inflammation.  
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Figure 6.1: The flow diagram showing the steps involved in the pilot of the in vivo studies using 
sprague–dawley rats. 
 
. 
 
Animals was euthanized with sodium pentobarbital after blood sampling. 
 
 
The treated skin area was excised for all the rats assigned to the different time points and cut into half 
for histological examination and the determination of retained complex in skin. 
Test 
5 rats: 1%w/w prednisolone equivalent (1000μL sludge) for topical application. 
Procedures were undertaken to ensure a general state of well-being in all rats 1 week prior to 
experimentation, CAS score sheets were used to observe the animals. Group 4 were fasted from 
solid food 12 hours before experimentation. 
At 0 hours, xylazine (5mg/kg) and ketamine (100mg/kg) anaesthesia was administered to all rats, 
all rats were shaved on their dorsum using an electric shaver (an area of ~16cm2). Control and test 
formulations were applied evenly on the rats’ dorsum (3.14cm2) in the all groups, except group 4 
where gavage was performed. 
 
At 0.50 hours the rats were challenged by a subcutaneous injection of 100μL 1% w/v solution of 
carrageenan in saline water into the plantar side of the left hind paw. The carrageenan was used to 
induce inflammation so that the efficacy of the formulations to inhibit inflammation could be 
determined.  
. 
 
Blood samples were collected from all rats and centrifuged to collect the plasma. The samples were 
kept at 8°C until they were characterized using the inductively coupled plasma atomic emission 
spectroscopy (ICP-AES) and ultra-performance liquid chromatography (UPLC) which were used to 
quantify the Cu2+ ions released in complex and free PS drug respectively. 
 
Group 2 
5 Sprague–Dawley rats 
Blood samples were collected through the 
intracardiac puncture and conducted at pre-
determined time intervals: 0, 2, 4, 8 and 24 hours 
post administration of all formulations. Five rats will 
be assigned to these time points, for each sample 
group. 
Anaesthetization with intramuscular 
Anaket® (Ketamine, 100mg/kg) and 
Chanazine® (Xylazine, 5mg/kg) 3-4 
minutes before blood sampling. 
Pilot study 
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Figure 6.2: The flow diagram showing the steps involved in the main in vivo studies using 
sprague–dawley rats. 
Group 1 
 
Group 3 Group 4  Group 2 Group 5  
Animals was euthanized with sodium pentobarbital after blood sampling. 
 
 
The treated skin area was excised for all the rats assigned to the different time points and cut into 
half for histological examination and the determination of retained complex in skin.  
Main study 
Placebo 
21 rats:  1000μL 
placebo sludge 
for topical 
application. 
Test 
21 rats: 1%w/w 
prednisolone 
equivalent(1000μ
L sludge) for 
topical 
application. 
Comparison 1 
21 rats: 660μL 
(2.2ml/kg of 
1mg/ml 
prednisolone) 
oral solution. 
Comparison 2 
21 rats: 1%w/w 
prednisolone 
(1000μL gel)for 
topical application. 
Procedures were undertaken to ensure a general state of well-being in all rats 1 week prior to 
experimentation, CAS score sheets were used to observe the animals. Group 4 were fasted from solid food 
12 hours before experimentation.  
At 0 hours, xylazine (5mg/kg) and ketamine (100mg/kg) anaesthesia was administered to all rats, all rats 
were shaved on their dorsum using an electric shaver (an area of ~16cm2). Control and test formulations 
were applied evenly on the rats’ dorsum (3.14cm2) in the all groups, except group 4 where gavage was 
performed. 
 
At 0.50 hours the rats were challenged by a subcutaneous injection of 100μL 1% w/v solution 
of carrageenan in saline water into the plantar side of the left hind paw. The carrageenan was 
used to induce inflammation so that the efficacy of the formulations to inhibit inflammation 
could be determined.  
. 
 
Blood samples were collected from all rats and centrifuged to collect the plasma. The samples 
were kept at 8°C until they were characterized using the inductively coupled plasma atomic 
emission spectroscopy (ICP-AES) and ultra-performance liquid chromatography (UPLC) which 
were used to quantify the Cu2+ ions released in complex and free PS drug respectively. 
 
105 Sprague–Dawley rats 
Comparison 3 
21 rats: 1%w/w 
prednisolone 
equivalent 
(1000μL sludge) 
for topical 
application. 
Blood samples were collected through the intracardiac 
puncture and conducted at pre-determined time intervals: 
0, 2, 4, 8 and 24 hours post administration of all 
formulations. Five rats will be assigned to these time 
points, for each sample group. 
Anaesthetization with 
intramuscular Anaket® (Ketamine, 
100mg/kg) and Chanazine® 
(Xylazine, 5mg/kg) 3-4 minutes 
before blood sampling. 
116 
 
 
 
 
 
Figure 6.3: The photographic procedure of the in vivo studies using rats. Wherein (i) An 
anesthesia was administered to all rats, (ii) all rats were shaved on their dorsum and shaved 
area wiped with water, (iii) at 0h different gels were applied on an area of 1.44cm2 of the shaved 
portion, while group 3 rats were gavaged, (iv) all rats except group 5 rats received an SC 
injection at 0.5h after gel application, (v) all rats were bandaged to keep the formulations in 
place, (vi) blood was collected through cardiac puncture, (vii) and rats were euthanized 
immediately after blood collection and skin was excised. 
 
6.2.4. Histological assessment 
For histological assessment, immediately after the rats were euthanized the treated skin area 
was excised for all the rats assigned to the different time points and stored in 10% formalin. A 
skin section of 5μm thickness was cut from each sample and stained with hematoxylin–eosin for 
microscopic examination (Pillai and Panchagnula, 2003). The treated skin sections were 
observed under a light microscope and a scoring system was used to assess the changes in the 
skin. The intensity of the inflammatory response was graded from 0 to 3, where: 0, represents 
the absence of any inflammatory cells (no infiltration); 1, represents the presence of less than 
10% of inflammatory cells (mild infiltration); 2, represents the presence of 10 to 50% of 
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inflammatory cells (moderate infiltration); and 3, represents the presence of more than 50% of 
inflammatory cells (severe infiltration) within the total population cells (Riella et al., 2012). All 
histological assessments were performed in triplicate. 
6.2.5. Determination of retained complex in skin 
Complex/drug retained in the skin were determined according to a method described by Lei et 
al. (2013). The skin layers were separated by removing the stratum corneum using a tape 
stripping and 10 strips were collected. The remained skin was frozen at -80°C and separated 
into epidermis and dermis horizontally. The parts of skin layers were chopped and extracted in 
methanol with homogenization. The samples were kept refrigerated for 12h and then 
centrifuged to obtain a supernatant for analysis of complex content using UPLC. 
 
6.2.6. Prednisolone analysis using Ultra-performance liquid chromatography (UPLC) 
6.2.6.1. The chromatographic system 
The PS released was analysed using an ultra-performance liquid chromatography (UPLC) 
system after an appropriate extraction procedure. UPLC chromatographic separations were 
performed with an ACQUITY UPLC®BEH Shield RP 18 column (1.7μm, 100mm × 2.1mm) 
(Waters, Milford, MA, USA), equipped with array detector(PDA), Empower®  Pro software 
(Waters, Milford, MA, USA), autosampler and 515 dual pumps. The mobile phase was pumped 
at a flow rate of 0.05mL/min and consisted of the combination water: Acetonitrile 40:60% v/v. 
Detection was by UV absorption at 248nm at room temperature. The prepared mobile phase 
was filtered through a 0.22μm Millipore filter before use. The injection volume for all UPLC 
analyses was 10µL. 
6.2.6.2. Internal standard 
The internal standard used was dexamethasone where 25μg/mL (25μl) concentration of the 
drug in methanol was added to the plasma for generation of calibration standards and samples 
from rats.  
 
6.2.6.3. Calibration curve standards 
Standard solutions of PS (50μg/ml) and dexamethasone (0.025μg/μL) in ethanol were prepared. 
From these solutions, calibration standards were prepared in 150μLof blood plasma so that 
each contained 25, 50, 75, 100, 125 or 150μL of PS (0.050μg/μL) and 150μL of dexamethasone 
(0.025μg/μL) as the internal standard. The mixtures were sonicated for 5min before the 
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extraction procedure. A standard calibration was constructed with the area under the curve 
(AUC) of the standard solutions and internal standard using the following equation:  
y =
AUC of standard solution
AUC of internal standard
                                                                                            Equation 6.1 
  
6.2.6.4. Liquid-liquid extraction procedure 
Plasma (150µL) was extracted by shaking on a vortex mixer for 5min with 1mL ethyl acetate in a 
2.5mL centrifuge tube and then centrifuging for 10min at 5000rpm. The supernatant organic 
phase was transferred to a glass vial and evaporated in a vacuum oven to dryness underinert 
conditions at 60°C. The residue was reconstituted with 1mL of mobile phase and vortex mixed 
for 2min. The solution was filtered through a 0.22µm millipore filter (Morrison et al., 1977) before 
being injected into UPLC column. The total percentage of PS extracted was determined using 
the AUC of the plasma and standard solution as follows:  
Percentage yield =
AUC plasma
AUC standard
                                   Equation 6.2 
 
6.2.6.5. Plasma sample handling and preparation from rats 
Rats’ blood samples were collected into glass tubes and centrifuged at 3000rpm for 15 min and 
the plasma separated. The plasma was kept frozen at −80°C until analysis. In all the plasma 
samples (1mL) 50μL of methanol and 50μL of naproxen sodium in methanol (1mg/mL) were 
added and extracted as described above.  
 
6.2.6.6. Method validation 
Method validity was assessed as validated by AbuRuz et al. (2003) and Kurakula et al. (2011) 
using the linearity, accuracy and precision. The linearity was investigated from the squared 
correlation coefficient (R2value). Five calibrators were included in the curve and were required to 
meet all qualitative identification and quantification criteria. The quantitative accuracy required 
was within 20% of target. Linearity was achieved with a minimal R2valueof 0.99. Accuracy was 
expressed as percent recovery after analyzing drug-spiked serum and comparing this to the 
added amounts; precision was expressed as the relative standard deviations (RSDs) of the 
determined concentrations.  
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6.3. Results and Discussion 
6.3.1. Validity of the sterility procedure 
The incubated plate with a streak of the sterilized sludge revealed that there was no bacterial 
growth from the sludge, hence it was established that the sludge was sterile before its 
application in the in vivo studies, Figure 6.4 demonstrates the plate with no bacterial growth. 
 
Figure 6.4: the agar plate streaked with sludge, after it has been incubated for 24h at 37°C 
 
6.3.2. Pilot study using five rats from group B 
The pilot study was performed as shown in Figure 6.1, where each rat was euthanized 0, 2, 4, 8 
and 24h. According to the histopathology results (Figure 6.5), inflammation was successfully 
induced with inflammatory cells comprising of neutrophils and lymphocytes. Figure 6.5 shows 
the inflammatory cells of the subcutaneous and dermis regions, at 2h with moderate (grade 2) to 
mild inflammation at 4h (grade 1). There was an immediate slight increase of edema and 
erythema due to inflammation, similar observations were also reported previously (Tsuji et al., 
1998; Mei et al., 2003; Fouad et al., 2013). Worth noting is a study done by Khurana et al. 
(2013) where there was no obvious skin erythema and edema observed in the animals, yet the 
histology of the animals skin proved that inflammation occurred after inflammation was induced 
using carrageenan, thus the slight edema observed in this pilot study may be justified. As the 
pilot study was carried out, it was established that the Teflon rings were not necessary as the 
gel was viscous enough to stick on the designated area, henceforth they were not used in the 
main study.  
 
 
 
 
 
The agar plate 
with no growth 
The agar 
plate lid 
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Figure 6.5: The light microscope images of the H&E stained slides showing the pilot study 
images (a) the subcutaneus region at 2h, (b) the subcuneus region at 4h, (c) the dermis region 
at 2h, and (d) the dermis region at 4h. 
 
6.3.3. In vivo evaluation of the anti-inflammatory/anti-oxidant activity of the [Cu(glyg)(PS)] 
delivered from the sludge 
The anti-inflammatory/anti-oxidant activity of the [Cu(glyg)(PS)] delivered from the sludge 
was evaluated and compared to other formulations using histopathology, results are 
summarizedin table 6.1 and discussed as follows: 
Group 1 
The histopathology results showed that mild inflammation was observed at 2h and moderate 
inflammation was observed at 4h which subsied to mild inflamation at 8 and 24h post-exposure. 
The inflammatmy challenged rats showed constant inflammation with no discernible effect of the 
placebo nanoliposomal sludge, detailed results are described as follows:  
(a) (b) 
(c) (d) 
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(i) At 2h: A focus of mild dermal oedema was noted along with very mild mononuclear 
infiltration in the subcutis below the cutaneous skeletal muscle. The epidermis, 
subcutis and cutaneous skeletal muscle were within normal limits.  
(ii) At 4h: Moderate perivascular to interstitial neutrophilic infiltration was noted in the 
subcutis below the cutaneous skeletal muscle and was associated with mild 
haemorrhage. Scattered lymphocytes, plasma cells and macrophages were also 
present. The epidermis, dermis and cutaneous skeletal muscle appear within normal 
limits.   
(iii) At 8h: Mild dermal oedema was noted along with a mild increase in interstitial 
leukocytes which included a few neutrophils as well as mononuclear cells. Mild 
subcutaneous fibroplasia was noted along with mild oedema and a very mild 
increase in neutrophils and spindle cells below the cutaneous skeletal muscle. The 
epidermis and cutaneous skeletal muscle appear within normal limits.  
(iv) At 24h: Mild increase in interstitial leukocytes, mostly mononuclear cells with a few 
scattered lymphocytes and were noted in the subcutis below the cutaneous skeletal 
muscle. Mild acanthosis was observed in the epidermis. The dermis and cutaneous 
skeletal muscle appear within normal limits.  
Group 2 
The histopathology results showed that no inflammation was observed at 2h which increased to 
very mild inflammation at 4 and 8h with reduction to no inflammation at 24h. This would suggest 
that the test substance may have an anti-inflammatory effect, detailed results are described as 
follows: 
(i) At 2h: The epidermis, dermis, follicles, subcutis and cutaneous skeletal muscle were 
all within nonnal limits. No inflammatory cells were observed.   
(ii) At 4h:  Very mild eosinophilic and mononuclear infiltration was observed in the 
subcutis below the cutaneous skeletal muscle. The epidermis, dermis and cutaneous 
skeletal muscle appear normal limits. 
(iii) At 8h:  Very mild scattered neutrophilic and eosinophilic infltration along with a few 
lymphocytes and plasma cells were noted in the suhcutis below the cutaneuos 
skeletal muscle. The epidermis, dermis and cutaneous skeletal muscle appear within 
normal. 
(iv) At 24h: The epidermis, dermis, follicles, subcutis and cutaneous skeletal muscle 
were all within normal limits. No inflammatory cells were observed.  
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Group 3 
The histopathology results showed that no inflammation was observed at 2h but mild 
inflammation was observed at 4h. This was reduced to very mild inflammation at 8 and 24h. The 
anti-inflammatory was comparatively more notably in group 2 animals as the inflammatory grade 
of 2 was not reached. This would indicate that oral prednisolone treatment may have had some 
anti-inflammatory effect, detailed results are described as follows: 
(i) At 2h: One hair follicle showed only mild intramural mononuclear infiltration. Very 
mild oedema and scattered mononuclear cells were observed in the subcutis below 
the cutaneous skektal muscle. The remaining epidermis, dermis and cutaneous 
skeletal muscle were within normal limits.  
(ii) At 4h: A mild increase in the number of neutrophils and lesser numbers of eosinopils 
was observed in the subcutis below the cutaneous skeletal muscle along with mild 
focal haemorrhage, oedema and an increase in spindle cells. The epidermis, dermis 
and cutaneous skeletal muscle appear within normal limits  
(iii) At 8h: Mild dermal oedema was observed along with very mild, scattered 
lymphocytes and plasma cells in the subcutis below the cutaneous skeletal muscle 
as well as mild oedema. The epidermis showed focal areas of mild aeanthosis. The 
cutaneous skeletal muscle appears within normal limits. 
(iv) At 24h: Mild dennal oedema was noted and one sample also showed very mild 
scattered mononuclear cell infiltration in the dermis. Very mild, scattered eosinophilic 
and mononuclear infiltration was present in the subcutis below the cutaneous 
skeletal muscle along witJ1 mild oedema. The cutaneous skeletal muscle appears 
within normal limits.  
Group 4 
The histopathology results showed that very mild inflammation was observed at 2h while mild 
inflammation was observed at 4h which subsided to very mild inflammation at 8h and again 
increased at 24h. This would indicate the epicutaneous application of prednisolone may have 
had some anti-inflammatory effect, detailed results are described as follows: 
(i) At 2h: Mild haemorrhage was noted in the subcutis below the cutaneous skeletal 
muscle and this was associated with mild oedema and very mild, scattered 
mononuclear infiltration with a few neutrophils and eosinophils. Mild acanthosis was 
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noted in the epidermis. The dermis and cutaneous skeletal muscle appear within 
normal limits. No inflammatory cells were observed.  
(ii) At 4h: Mild dermal oedema with just a few scattered interstitial neutrophils were 
observed, primarily in the superficial dermis. One section did show a mild 
accumulation of non-degenerate heterophils in the subcutis just below the cutaneous 
skeletal muscle. The epidermis and cutaneous skeletal muscle appear within normal 
limits. 
(iii) At 8h: Very mild, scattered mononuclear cells were observed in the subcutis below 
the level of the cutaneous skeletal muscle along with mild oedema. The epidermis, 
dermis and cutaneous skeletal muscle appear within nonual limits.  
(iv) At 24h: A single focus of mild infiltration with non-degenerate neutrophils, 
eosinophils as well as lymphocytes and plasma cells and the occasional Mott cell 
were noted in the subcutis below thecutaneous skeletal muscle. A few segments of 
skeletal muscle degeneration with mild interstitial neutrophilic and 
lymphoplasmacytic infiltration was observed just adjacent to the area of inflammation 
in the subcutis. The epidermis and dermis appear within normal limits.  
Group 5 
The histopathology results showed that very mild inflammation was observed at 2 and 4hwith no 
inflammation at 8h and 24h. This would suggest that the [Copper(glycylglycine)(prednisolone)]-
loaded nanoliposomal had an anti-inflammatory effect. It was noted that the cutaneous skeletal 
muscle showed degeneration in association with the inflammation and may represent an 
injection tract injury, detailed results are described as follows: 
(i) At 2h: Very mild, scattered eosinophilic as well as mononuclear infiltration was noted 
in the subcutis below the cutaneous skeletal muscle along with mild oedema. The 
epidermis, dermis and cutaneous skeletal muscle appear within normal limits.  
(ii) At 4h:  Very mild perivascular to interstitial neutrophilic infiltration was noted in the 
subcutis below the cutaneous skeletal muscle and was associated with very mild 
haemorrhage. Scattered lymphocytes, plasma cells and macrophages were also 
present. The epidermis, dermis and cutaneous skeletal muscle appear within normal 
limits. 
(iii) At 8h: The epidermis, dermis, follicles, subcutis and cutaneous skeletal muscle were 
all within normal limits. No inflammatory cells were observed.  
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(iv) At 24h: The epidermis, dermis, follicles, subcutis and cutaneous skeletal muscle 
were all within normal limits. No inflammatory cells were observed. 
Table 6.1: Grading of the anti-inflammatory effects of the formulations applied on the different 
groups of rats. 
Time (h) INFLAMMATION GRADING 
 Group 1 Group 2 Group 3 Group 4 Group 5 
0 0 0 0 0 0 
2 1 0 0 1 1 
4 3 1 2 2 1 
8 2 1 1 1 0 
24 2 0 1 2 0 
*Where 0 is no infiltration, 1 is mild infiltration, 2 is moderate infiltration, and 3 is severe 
infiltration.  
 
 
Figure 6.6: The light microscope images of the H&E stained slides showing some of the main 
study images (a) the subcutaneus region with no infiltartion (grade 0), (b) the subcutaneus 
region with mild infiltration (grade 1), (c) the subcuneus region with moderate infliltration (grade 
2), and (d) the subcuneus region with severe infiltration (grade 3). 
 
(a) 
(c) 
(b)
a) 
 (a) 
(d) 
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Examples of the hislopathology grading are shown in Figure 6.6, where grade 0 and 1 were the 
skin samples from group 2 rats, grade 2 and grade 3 were the skin samples from group 3 and 1, 
respectively. The [Copper(glycylglycine)(prednisolone)]-loaded nanoliposomal sludge appeared 
to have an anti-inflammatory effect comparable to oral prednisolone but this will have to be 
proven with appropriate statistical testing as the lesions are mostly mild to begin with. These 
samples have no relation to timing of exposure and may likely indicate chronic trauma or injury 
in these sections.  
6.3.4. In vivo evaluation of the [Cu(glyg)(PS)] complex delivery from the sludge 
6.3.4.1. Validation of the extraction procedure 
The liquid-liquid extraction method was considered to be valid as the recovery and purity of PS 
were optimum. Average recoveries were calculated for four plasma analytes concentrations of 
1.25-7.5µg/µL (n=3) as summarized in Table 6.2, the recovery percentage ranged from ~87 to 
95%.  
Table 6.2:Average and relative standard deviations (RSDs) of PS recoveries from spiked 
plasma blanks. 
 
PS concentration (µg/µL) 1.25  2.5  6.25 7.5 
 
Recovery (%)  
 
87.3  
 
94.7 
 
94.5  
 
90.5 
RSDs (%)  4.4 12.1 9.6  8.9 
 
6.3.4.2. Chromatographic separation and validation assay 
Figure 6.7 shows calibration curve properties for the PS analytical method in the mobile phase 
(a) and blood serum (b). The PS and dexamethasone (internal standard) spiked in the analytes 
were effectively eluted within 10min, with an observed PS retention time (Rt) of 4.496 and 
4.137min, and dexamethasone Rtof 6.150 and 5.977min in mobile phase and blood serum, 
respectively. The calibration curve was found to be linear in the range of 1.25-7.5µg/µL, with five 
calibrators and R2 = 0.945. The acceptance criteria to fulfill the requirements for therapeutic drug 
monitoring were: ±10% for accuracy and RSD≤10%; for the lowest concentration on the 
calibration curve the RSD was ≤20%, which is in accordance with US Food and Drug 
Administration (FDA) and ICH requirements (Frahnert et al., 2003).  
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Figure 6.7: The UPLC PS and dexamethasone (internal standard,(a) in themobile phase and 
(b) blood serum 
 
6.3.4.3. Determination of the [Cu(glyg)(PS)] concentrations in the rats blood plasma 
To complement the anti-inflammatory effects that indirectly assess the ability of the dermal 
sludge to deliver [Cu(glygly)(PS)] the across skin, the plasma PS concentrations were directly 
measured using UPLC. The plasma PS concentration versus time profiles following the 
application of the different formulations are shown in Figure 6.8. The time to reach maximum 
serum concentration (Cmax) of PS released was different for all formulations, however it was 
noted that the PS released from the formulation in group B rats was significantly higher and 
released in a controlled manner compared to the rest of the groups. The pharmacokinetic 
parameters of PS after the oral administration were significantly different from the parameters 
obtained after the transdermal application of sludge formulation. After the oral administration of 
PS, the Cmax of PS was reached within 4h, and a sharp decay was observed afterwards as 
shown in the graph (Figure 6.8). The AUC of PS after the application of dermal sludge was 
increased immediately after application of formulation in group 2, which indicates the improved 
bioavailability of PS through the TDD route. The bioavailability of PS with reference to orally 
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administered PS was found to increase by 2.4 times within 2h when the sludge formulation was 
applied in inflammatory challenged rats. Greater PS plasma levels were achieved immediately 
and were maintained till the last sample, where a Cmax of 3.611±0.405µg/mL was achieved at 
24h. With this type of release the anti-inflammatory activity of the sludge formulation is expected 
to be maintained for longer period of time as the drug is released in a sustained manner and this 
was attributed to the NLs presence in gel structure and the surface-active properties of the gel. 
Additionally the release of the PS from the sludge in group 2 is maintained within the minimum 
and maximum therapeutic range (0.5-2mg/kg). 
According to the AUC of PS from the sludge in Group 2 and 5 it is observed that the NLs 
circulated in the blood for a long period of time in Group 5 where inflammation was not induced 
compared to Group 2. In Group 5 there is a slight increase of the PS release as the sludge was 
applied on the skin, the release was maintained at 0.959, 1.695 and 1.397µg/mL at 2, 4 and 8h, 
and eventually the PS release was abruptly reduced to 0.409µg/mL at 24h. Comparing the 
release in Group 2 and 5, this mechanism of release is attributed to the inflammatory responsive 
release system that was designed in this study. The AUC of PS retained in the skin of the Group 
5 rats was significantly higher compared to inflammatory challenged rats (Group 2) as shown in 
Figure 6.9, hence it was established that less NLs degrade in an inflammatory free environment 
while more NLs are retained within the skin resulting in low bioavailability and reduced 
cytotoxicity as the NLs slowly degrade. Further it was noted that the sludge relased the drug in a 
single steady peak rather than fluctuating peaks which may be observed from repeated oral 
(Group 3) administration of PS, hence the sludge may have less side effects associated with 
drug compared to conventional oral formulation. 
In the conventional gel formulation (Group 4 rats) a PS Cmax of 1.153µg/mL was achieved at 
8h which is below the minimum therapeutic effective dose of 0.5mg/kg (~125-150µg in each rat 
considering their weight), therefore this gel was not as effective as the sludge. Also be noted 
was the low amount of drug retained in the skin with this gel compared to the sludge (Figure 
6.9).The AUC decreased in the following order Group 5 > 2 > 4 for skin retained PS. In the 
present studies, the skin of the rats after a 24h application of the formulations in the different 
groups did not show any visible skin reaction. 
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Figure 6.8: The plasma levels of PS in Sprague-Dawley rats after the application of the different 
formulations in all the groups (standard deviations (n=3)). 
 
 
Figure 6.9: The AUC of the formulations applied on the different groups of rats at various time 
intervals with the standard deviations (n=3). 
 
Considering the in vivo release studies in this chapter and in vitro release studies covered in 
chapter 5 of the PS from the dermal sludge, it is indicated that even though the release rates 
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were higher in the in vitro studies there is still some correlation in the release pattern. In the 
literature, in vivo-in vitro correlations have been performed for other drugs and the correlation 
between in vitro and in vivo studies were generally poor, in vitro studies gave higher rates than 
in vivo results (Kararli et al., 1995). Therefore the correlation perceived in this study was 
considered significant, as the relationship observed between the in vivo and in vitro studies 
indicate a consistency between in vitro study and in vivo study. 
6.4. Concluding Remarks 
In conclusion, in vitro and in vivo studies indicated that the management of the inflammatory 
symptoms during TRAPS could be enhanced by the novel nanoliposomal dermal sludge. 
According to the in vivo studies the [Copper(glycylglycine)(prednisolone)]-loaded nanoliposomal 
sludge showed anti-inflammatory effects comparable to the oral prednisolone and this 
formulation is capable of overcoming the shortcomings of the oral administration of PS, such as 
high first pass metabolism, while maintaining the required therapeutic dose of the drug. 
Therefore, it was established that the dermal sludge may be a promising system to be used in 
the treatment of inflammation in TRAPS.  
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CHAPTER 7 
CONCLUSIONS AND RECOMMENDATIONS
 
7.1. Conclusions 
Tumour necrosis factor receptor (TNFR) associated periodic syndrome (TRAPS) is found 
worldwide, and is a key representative of Genetic auto-inflammatory inflammatory skin disorders 
(GAISDs)(Stojanov and McDermott, 2005). The clinical presentation is typically associated with 
recurrent fever episodes and systemic inflammation involving skin and serosal linings (Yaoet al., 
2012). The use of this novel transdermal drug delivery system (TDDS) may be beneficial in the 
management of these symptoms. This system may have an advantage over the currently used 
oral corticosteroids as it has the ability to reduce side effects associated with corticosteroids 
while increasing the efficacy of the drug.  
In this study, it has been established that a novel copper-liganded bioactive complex with 
prednisolone succinate as the corticosteroid drugexhibited improved in vitro anti-inflammatory/ 
anti-oxidant activity, in comparison to the parent drug, and also its skin penetration efficacy was 
slightly improved in TDDS. The complex appeared to be non-toxic in human dermal fibroblast 
adult (HDFa) cells in a concentration equivalent to that of parent drug. Based on these results, it 
can be concluded that the coordination of this corticosteroid drug to copper (II)has the potential 
of reactivating the drug into a more potent coordination compound with improved 
pharmacokinetics/dynamics that can be advantageous in the treatment of TRAPS through the 
transdermal route.  
 
To further enhance the TDDS of the copper-liganded bioactive complex, the complex was 
successfully loaded into a dual pH/redox responsive nanoliposomal system, allowing the 
complex to be released in an inflammatory responsive manner. The complex loaded 
nanoliposomes (NLs) were optimized and developed successfully using the Box-Behnken 
design. The overall designed system displayed the synergistic effects of the metal-drug complex 
as a bioactive, dual pH/redox-responsive NLs as the complex nanocarrier and gel matrix which 
promoted the skin penetration of the complex loaded NLs. The combined gel-based vehicle 
resulted in a liposomal nanogel with an ideal TDDS design for TRAPS management which was 
termed the nanoliposomal dermal sludge. According to the in vitro, ex vivo, and in vivo results, 
which were collected in this study it was concluded that this system could significantly increase 
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the intracellular bioactive concentration and efficiencyfor TRAPS inflammation inhibition, with 
reduced drug (steroids) side effects through the transdermal route of delivery. 
 
7.2. Recommendations 
TRAPS may result from consequences of the abnormally retained TRAPS mutant TNFR1 
(Lobito et al., 2006).The TRAPS therapy proposed in this dissertation indirectly treat the 
inflammatory symptoms without correcting the underlying molecular abnormality. Therefore 
further research is required for therapies directed at inhibiting expression or aiding the 
correction of the folded mutant receptors, which may be additional targets for therapy in TRAPS.  
The novel copper-liganded bioactive complex conceptualised in this study shows a tremendous 
inflammation inhibitory outcome, however it remains unclear how the ligand exchange (change 
in oxidation state) of Cu2+occurs during diffusion after its application. Its mechanism of action is 
still not entirely understood, and this warrant further research towards this system. Various 
studies have prove that metal complexes may have properties other than their anti-inflammatory 
effects, such as anti-malaria, antimicrobial and anticancer effects (Chohan et al., 2004; Chohan 
et al., 2005; Bruijnincx and Sadler, 2008; Salas, Herrmann and Orvig, 2013), these 
advantageous properties associated with complexes may create unique research expansion in 
pharmaceutical science research with the use of the copper-liganded bioactive complex. 
 
The sludge in this study could be upgrading to allow for a longer duration as it was observed 
that the maximum drug release was achieved at 24h. The increase in duration may be achieved 
by means of using a more sustainable system that would release the bioactive at a slower rate; 
such a system that may be considered may be an implant, which would also offer better patient 
compliance as well. With the use of nanocarriers responsive to inflammatory cues and their 
designing as an implant, it may result in an improved system with enhanced efficacy and 
increased device functional duration in comparison to the sludge.  
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APPENDIX D: Abstract for the Academic Pharmaceutical Society, Sandton, September 
2015 research conference first poster presentation
 
A novel copper(II) mixed-ligand complex of model anti-inflammatory drug : Synthesis, 
characterization and biological evaluations 
Abstract 
Purpose: The objective of the study was to employ metal coordination as a strategy to link the 
model drug in presence of a modulating ligand to give a complex with improved anti-
inflammatory/anti-oxidant activity relative to the free drug. The overall aim was to develop a 
metal-liganded formulation that could enhance the permeation of the drug and increase the 
efficacy of the parent drug for the management of inflammatory diseases. 
Methods: A novel mixed-ligand copper complex, was prepared by the interaction of Cu(II) with 
the anti-inflammatory model drug, and a safe modulating ligand. Characterization of the 
prepared coordination compound via spectroscopic, physicochemical, and thermal techniques 
was carried out to unequivocally confirm transition metal coordination. The antioxidant and anti-
inflammatory activities were evaluated in terms of 5-lipoxygenase inhibition assay and 1,1-
diphenyl-2-picrylhydrazyl (DPPH) free radical scavenging assay, respectively. Ex vivo 
permeation studies were assessed across pig ear skin of full thickness. Moreover cytotoxicity 
studies were performed using MTT Assay on Human Dermal fibroblast (HDF) cells. The 
pharmacodynamics of the parent drug was compared to those of the complex.  
Results: The copper complex has been structurally characterized by spectral (IR, UV–Vis and 
NMR) data. The observed spectral changes in the 1H NMR spectroscopy coupled with shifts in 
molecular vibrations of coordinating donors and absorption bands support the formation of the 
complex. Relative to the free drug the complex exhibited a higher free radical-scavenging 
activity of 60.1±1.2% and lipoxygenase (LOX-5) inhibitory activity of 36.7±1.3% compared to 
4.4±1.4% and 6.1±2.6% respectively. This high inhibitory activity of the copper complex 
indicates the superiority of the complex to the free model drug as an anti-inflammatory and 
antioxidant agent. Furthermore, the skin permeation of model was improved by 19.5±1.3% after 
complexation and the complex showed no significant toxicity effects on the HDF cells.  
Conclusions: It has been shown that metal coordination has the potential of reactivating the 
model drug into a more potent bioactive with improved pharmacodynamics. 
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2015 research conference second poster presentation
 
In vitro evaluation of novel redox/pH dual stimuli-responsive nanoliposomes loaded with 
Copper-liganded bioactive 
Abstract 
Purpose: To develop an advanced drug delivery carrier for the controlled and specific delivery 
of an anti-inflammatory model drug.  
Methods: Novel redox/pH dual stimuli-responsive copper-liganded bioactive-loaded 
nanoliposomes were designed by conjugation of the chemically modified methacrylic acid 
copolymer to phospholipids via the lipid film hydration method, using a sonicator for sizing. 
Characterization of the functionalised methacrylic acid copolymer and nanoliposomes was done 
using spectroscopic and physicochemical techniques to confirm the formation of redox/pH dual 
stimuli-responsive copper-liganded bioactive-loaded nanoliposomes. Furthermore MTT assay 
cytotoxicity studies were performed on both the loaded and non-loaded nanoliposomes using 
Human Dermal fibroblast (HDF) cells.  
Results: The functionalised methacrylic acid copolymer, complex and nanoliposomes have 
been structurally characterized by FTIR and NMR spectral data. The morphology and size of the 
nanoliposomes was confirmed using TEM and Zetasizer NanoZS, respectively, showing 
predominantly spherical-shaped unilaminar vesicles with an average particle size of 100±25 nm. 
The nanoliposomes easily swelled and were degraded into discrete short chains in the presence 
of 10 mM glutathione (GSH) and/or pH 5, hence the pH/redox sensitivity of the nanoliposomes 
was established by the change in particle size and drug release studies in the presence of pH 7 
and 5, with and without GSH 10 mM. The particles increased from 100±25 nm to 1050±50 nm in 
the presence of low pH and GSH (10 mM) and up to 154± 21 nm at pH 7.4 without any GSH. 
The percentage release profile of the copper-liganded bioactive -loaded nanoliposomes showed 
a low level of drug release ( ~20w/w% in 24 h) at pH 7.4, and was significantly accelerated at a 
lower pH (5.0) and reducing environment (~ 88w/w% in 8 h), demonstrating an obvious 
pH/redox dual-responsive controlled drug release capability. Furthermore the cytotoxicity of the 
copper-liganded bioactive complex encapsulated dual-sensitive NLs and non-encapsulated NLs 
showed no significant toxicity effects on the HDF cells.  
Conclusions: These dual stimuli sensitive copper-liganded bioactive -loaded nanoliposomes 
have showed specific and controlled release of the bioactive demonstrating its great potential 
for use as a novel advanced drug delivery carrier. 
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APPENDIX F: Abstract for a review paper published from this dissertation
 
A review of polymeric colloidal nanogels in transdermal drug delivery 
Abstract 
Nanogel nanoparticles loaded with active compounds are referred to as Drug-loaded polymeric 
colloidal nanogels (DPCNs). These nanogels are emerging as promising carriers for 
transdermal drug delivery applications. Much interest has been directed towards the potential 
use of DPCNs to deliver a variety of drugs for either controlled or sustained drug delivery 
systems. Transdermal drug delivery systems (TDDS) have shown a number of beneficial 
properties such as improving patients compliance as they are conveniently dosed compared to 
intravenous and oral therapy. The use of TDDS depends on the effectiveness of the drug 
formulation to accumulate in sufficient concentrations at the specific targeted sites, hence the 
therapeutic significance of DPCNs in TDDS. Nanogels have a high drug loading capacity, 
biodegradability and biocompatibility, which are the key points in designing an efficient TDDS. 
The advanced development of DPCN has led to stimuli responsive drug delivery systems that 
release the entrapped drug under variable environmental incentives. The development of these 
drug delivery systems has created room for further research to characterize the physical and 
chemical properties of theses nanogels as well as their in vitro and in vivo behavior. Therefore 
this review presents an insight on the basic fabrication methods, advanced developments, 
limitations and therapeutic significance of the DPCN in TDDS as well as forthcoming potential 
applications. Despite these numerous positive scientific findings, efficient TDDS remains a 
challenge for pharmaceutical scientists and significant amount of research is still directed 
toward the development of superior TDDS. 
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APPENDIX G: Abstract for a research paper published from this dissertation
 
 
Dual pH/redox responsive nanolipsomes for the delivery of a Copper-liganded bioactive 
complex in inflammation 
Abstract 
Novel dual pH/redox responsive polymeric nanoliposomes (NLs) loaded with copper-liganded 
bioactive complex were prepared and designed as a controlled delivery system for the 
management of inflammation. The NLs were synthesised after preparation of the copper-
glycylglycine-prednisolone succinate] ([(Cu(glygly)(PS)]) complex, and the dual pH/redox 
responsive biopolymer respectively.The methodology undertaken for the development of drug 
delivery system involved coordination of the bioactive to Copper (II), preparation of dual 
pH/redox responsive biopolymer, and the synthesis of dual pH/redox nanoliposomes 
Characterisations of the prepared copper-liganded bioactive [Copper-glycylglycine-prednisolone 
succinate] ([(Cu(glygly)(PS)]) complex, dual pH/redox responsive biopolymer (Eudragit E100-
cystamine) and [(Cu(glygly)(PS)]-loaded NLs were carried out using spectroscopic and 
physicochemical techniques. Results indicated a high inflammatory/oxidant inhibitory activity of 
[Cu(glygly)(PS)] in comparison to the free PS drug. The [Cu(glygly)(PS)] complex exhibited a 
significant free radical-scavenging activity (60.1±1.2%) and lipoxygenase (LOX-5) inhibitory 
activity (36.6±1.3%) in comparison to PS which gave activity of  4.4±1.4% and inhibition of 
6.1±2.6% respectively. The [Cu(glygly)(PS)] loaded NLs showed a low level of [Cu(glygly)(PS)] 
release of 22.9±5.4% in 6h at pH 7.4, in comparison to a significant accelerated release at pH 5 
in a reducing environment of 75.9±3.7%in 6 h. The results suggest that the novel copper-
liganded bioactive delivery system with controlled drug release mechanism could serve as an 
potential drug delivery system candidate in the management of inflammation. 
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APPENDIX H: IDEXX laboratory histopathological report  
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